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Chapter 1: General introduction 
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Probiotics  
The definitions given to the term probiotic are numerous. The FAO (Food and Agriculture 
Organization) and WHO (World Health Organization) define probiotics living organisms which, 
when administered in adequate amounts, bring benefits to the health of the host. The term 
probiotic is therefore closely related to the term health: the human intestinal bacterial flora can 
in fact be easily weakened by different factors such as administration of drugs and stress 
situations and for this reason it’s important to consider a way to support and strengthen the 
same. Here come into play foods containing probiotics, in line with the definition given above, 
they are in fact able to optimize the intestinal flora in order to achieve the well-being and a 
good health. 
 
The International Scientific Association for Probiotics and Prebiotics (ISAPP) organized on 23 
October 2013 a meeting of experts on probiotics to revise the definition of the term “probiotic” 
and to develop clear guidelines for a more conscious use of the term. After the meeting, 
individual panelists have written a summary document that was approved by all the members 
before submission called precisely “consensus statements”. The panelists established that the 
FAO/WHO definition of the term “probiotic” remains relevant to validate a new probiotic strain 
with one modification. A specific strain can be considered as probiotic even if randomized 
controlled trials are not conducted on it, if the strain belongs to species for which exists a 
scientific evidence about their beneficial effects on human health. Furthermore, the panel did 
not agree with the fact of require investigational new drug applications for probiotics food 
because this activity would increase the costs of research and it is very difficult for products 
that do not respect pharmaceutical standards. Finally, the panel considers that a strong 
evidence about the beneficial effect of the probiotic is necessary both at strain-specific or 
group level and stresses the need to improve communication to the public on the beneficial 
effects of probiotics. 
 
Our digestive system contains hundreds of viable organisms. There are more than 400 species 
bacteria that live in the gastrointestinal tract, constituting a real ecosystem. The health of the 
gastrointestinal flora is not only essential for the correct functioning of the bowel, but it is also 
important to increment the body's natural defenses against invading bacteria and pathogens. 
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So food containing probiotics, or friendly bacteria, help to sustain the vitality of our natural 
defenses. 
 
Human microbiota 
The human body is inhabited by a large number of bacteria, viruses and other unicellular 
eukaryotic organisms. The set of micro-organisms that live in peaceful coexistence with their 
human host is defined "microbiota" or "normal microflora". The human microbiota consists of a 
biomass really huge, there are not less than 10^14 bacterial cells. 
The microbiota is an intestinal ecosystem formed by a large number of ecological niches, which 
are the house of the bacterial population consisting of numerous species and high number of 
strains. It is closely related with the intestinal mucosa, or with the epithelial interface, that it is, 
after the respiratory, the largest surface of the body, being approximately 250 - 400 m^2. 
Microbial colonization is a process that begins at birth, when the baby comes into contact with 
bacteria from the urogenital tract of the mother. Subsequently there is the development of 
many other microbial species, leading to the establishment of complex interactions between 
the bacteria themselves and between the latter and the human organism. The microbiota is 
influenced by many factors such as the composition of the diet of the subject, the body 
temperature, the use of drugs, the quantity of ingested food and other physiological 
characteristics; accordingly, it is subject to variations in relation to the changes that occur in the 
life of an individual.  
 
Man born germ-free. During the first year the intestinal stretch of the baby passes by a 
condition of sterility to a colonization very dense. Breast milk is an important source of bacteria 
that influences the development of the intestinal microbiota of the infant. Lactic acid bacteria, 
bifidobacteria, streptococci and staphylococci are the main groups represented and, between 
these, the first two are those that  will operate positively in different periods of human life. A 
two-years life of the new born intestinal microflora is almost stabilized. 
 
Any portion of the gastrointestinal tract is colonized by specific bacteria that adapt to local 
conditions. 
The oral cavity due to its characteristics of temperature, pH and nutrient availability is a 
favorable environment for the growth of microorganisms. The main bacterial genera present in 
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the oral cavity are Streptococcus and Lactobacillus and also Actinomyces are quite abundant in 
this cavity; however, there is a considerable variation of the microflora in the case of plate or of 
oral infections. 
In the mouth, in addition to the bacteria, are also commonly present Archea, yeasts, especially 
of the genus Candida, and other microorganisms such as mycoplasma and protozoa. 
The environment of the stomach has a low pH (less than three), which makes difficult the 
survival and growth of microorganisms. The gastric flora is quantitatively very poor, so it is 
possible to define the content of the stomach almost sterile. Only some bacteria are able to 
multiply in this section of the digestive system; they are acid tolerant and they consist mainly of 
lactobacilli (Lactobacillus acidophilus and L. plantarum) and streptococci. 
 
The number of bacterial cells present in the gastrointestinal tract of a mammal shows a 
continuum increasing, varying from 10^3 bacteria/g in the stomach and duodenum, to 10^4-
10^7 in jejunum and ileum, to over 10^12 cells/g in the cecum and in the colon (Figure 1). The 
acid environment of the stomach has a negative impact on the most bacteria that pass through 
it, so this is the first defensive barrier to contamination from the outside. Most of the bacteria 
resides in the lower part of the digestive system, especially in the large intestine, also because 
in the most proximal tract bile and pancreatic secretions are toxic or not favorable for the 
growth of the most microorganisms. 
 
 
       Figure 1: Distribution of intestinal microflora (Customprobiotics.com) 
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This microflora normally is not pathogenic and helps to maintain the state of health of the host, 
facilitating the absorption of nutrients, degrading substances potentially harmful or allergenic 
proteins and generating immune responses such as to prevent inflammation in the intestine 
(Chin et al., 2000).  
 
It was seen that among the components of the gut flora, lactic acid bacteria, such as 
bifidobacteria and lactobacilli, are able to exert benefits for the health of the host. Lactobacilli 
are ubiquitous inhabitants of our body being found in numerous districts: gastric, intestinal, 
oral, urogenital, etc. They are also an important component of the intestinal microbiota, not so 
much in quantitatively terms but mainly from the functional point of view, and because they 
are used in probiotic applications. The intake of lactobacilli as probiotics is aimed to maintain 
the intestinal microbial flora constantly in balance in order to avoid situations of intestinal 
dysbiosis, characterized by an alteration of the same with the predominance of pathogenic 
bacteria. 
 
Lactic acid bacteria 
Lactic acid bacteria constitute a large and diverse family of microorganisms that, from the 
fermentation of sugars, mainly produce lactic acid. These bacteria, essentially ubiquitous, are 
normally present in food products and are widely used at industrial level because they 
intervene in many fermentation processes. In particular, they are found in foods and beverages 
made with plant materials such as sauerkraut, pickles, silage, fodder and beer; they are also 
agents of the cheese ripening and, together with yeast, are involved in the leavening of bakery 
products. Some are part of the normal microbiota of the animals and can be ingested by 
humans as well as probiotics. These microorganisms may have the form of coco or rod, are 
Gram positive, catalase negative, unable to move, they don’t produce spores, and anaerobic-
microaerophilic, in fact they well multiply at low oxygen concentrations. In addition to not 
possess the catalase they don’t even have the enzymes nitrate reductase and cytochrome 
oxidase; in fact, they don’t have a respiratory chain but they have a fermentative metabolism. 
They are heterotrophic microorganisms, adapted to live on complex substrates and which, as a 
source of energy, require not only carbohydrates but also vitamins, nucleotides, mineral 
elements such as manganese and magnesium (used as cofactors of metabolism) and amino 
5 
 
acids. They are in fact very demanding from the nutritional point of view and they require 
particular regards for nitrogen and vitamin sources while they are being diversified for the 
carbonaceous sources. Among lactic acid bacteria there are mesophilic and thermophilic 
species; the optimum pH for growth varies from 7 to 5, otherwise  they well tolerate high 
acidity, some species are in fact able to grow at pH values very low, approximately  of three 
units. This taxa, belonging to the phylum Firmicutes, class Bacilli and order Lactobacillales, 
includes a variety of genus such as Abiotrophia, Aerococcus, Carnobacterium, Enterococcus 
Lactobacillus, Lactococcus, Leuconostoc, Oenococcus, Pediococcus, Streptococcus, 
Tetragenococcus, Vagococcus and Weissella. 
Among them the genus Lactococcus, Streptococcus and Lactobacillus are particularly important 
(Makarova and Koonin, 2007). 
 
Genus Lactobacillus 
Lactobacillus is a genus of Gram positive and rod-shape bacteria belonging to the family of 
Lactobacillaceae. The genus Lactobacillus is widely distributed in nature (there are over 100 
species) although, like all lactic acid bacteria, it has high nutritional requirements. Lactobacilli 
can grow in a temperature range between 5°C and 53°C with optimal values of 30 - 40°C. They 
have an optimum pH for growth of 5.5 to 5.8 but they can still grow even at pH less than 5. 
These bacteria produce mainly lactic acid by fermentation of sugars but also acetic acid, 
ethanol, carbon dioxide and other secondary compounds. The production of lactic acid leads to 
a reduction of the pH of the medium in which they grow, and this acidification of the 
environment is able to inhibit the growth of certain pathogenic microorganisms. On the basis of 
how they use glucose during fermentation process they may be divided into homofermentative 
(if they produce more than 85% of lactic acid from glucose) and heterofermentative, 
responsible in this case of heterolactic fermentation that products for about 50% lactic acid and 
for about 50% other substances (they produce lactic acid, carbon dioxide, ethanol and / or 
acetic acid in equimolar amounts). In relation to the metabolism, the species of Lactobacillus 
can be divided into three groups: 
• Obliged homofermentative: include microorganisms that ferment hexoses carbohydrates with 
production of only lactic acid, they are not able to ferment pentose and they don’t produce gas. 
They are part of this group the species L. delbrueckii, L. acidophilus, L. helveticus and L. 
salivarius. 
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• Facultative heterofermentative: include lactobacilli which produce lactic acid by fermentation 
of hexoses but some species, in certain conditions, also produce acetic acid, formic acid and / or 
ethanol. In addition, they also ferment pentoses with the production of lactic acid and acetic 
acid. This group includes the species L. casei, L. curvatus, L. plantarum, L. sakei. 
• Obliged heterofermentative: they ferment hexoses with formation of lactic acid, carbon 
dioxide, acetic acid and / or ethyl alcohol. They are also able to ferment pentose producing 
lactic acid and acetic acid. They are included in this group the species L. fermentum, L. brevis, L. 
collenoides, L. hilgardii, L. fructivorans. 
 
Lactobacilli are present in different habitats, in addition to the digestive and urogenital human 
system other habitats are represented by silage, soil, water, cereals and fermented foods (milk, 
meat and vegetables). 
The different species of lactobacilli have adapted differently: they have developed different 
characteristics associated with the environment in which they live. The broad ecological 
distribution of lactobacilli makes them an interesting subject of research on genome evolution 
and lifestyle adaptation. To explore evolutionary mechanisms that determine genomic diversity 
of different species of lactobacilli, nowadays it is used the comparative analysis of genomes. 
The analysis of the genome have contributed to a more complete understanding of their 
phylogenetic position and revealed important details about their specialized adaptation to a 
specific environment. Van de Guchte et al., 2006, through genome sequencing, have 
demonstrated the adaptation of L. bulgaricus to the milk environment through the 
protocooperation with Streptococcus thermophilus and these species are in fact the species 
most used for yogurt production. Also Cremonesi et al., 2013 through the genomic analysis 
explained the widespread use of L. helveticus in cheese technology. About that it has revealed 
genes responsible for key metabolic functions such as proteolysis, lipolysis, and cell lysis and 
these genes can facilitate the production of cheese and cheese derivatives. These studies 
provide insights about mechanisms for genome evolution and lifestyle adaptation of these 
ecologically flexible and industrially important lactic acid bacteria.  
 
Genus Bifidobacterium 
Microorganisms of the genus Bifidobacterium are non spore-forming, non motile and they can 
show various shapes, which the most typical ones are slightly bifurcated club-shaped or 
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spatulated extremities. They are strictly anaerobic, although some species can tolerate low 
oxygen concentrations and they have a fermentative metabolism. Tissier described these 
bacteria at the beginning of the twentieth century (Tissier, 1900). They were first included 
among the family Lactobacillaceae, but in 1924 the species L. bifidum was reclassified into the 
new genus Bifidobacterium. 
The species of the genus Bifidobacterium form a coherent phylogenetic group and show over 
93% similarity to the 16S rRNA sequences among them (Satokari et al., 2003). This genus is 
included in the phylum Actinobacteria, class Actinobacteria, subclass Actinobacteridae, order 
Bifidobacteriales, family Bifidobacteriaceae, and it includes Gram-positive bacteria with high 
content of G+C. 
All the currently known Bifidobacterium isolates are from a very limited number of habitats, 
that is human and animal GITs, food, insect intestine, and sewage (Felis and Dellaglio, 2007; 
Ventura et al., 2004). Strains most commonly found in human intestines and feces are those 
belonging to the species Bifidobacterium catenulatum, B. pseudocatenulatum, B. adolescentis, 
B. longum, B. breve, B. angulatum, B. bifidum and B. dentium, and the typical species isolated 
from functional foods is B. animalis subsp. lactis (Masco et al., 2005). Often in commercial 
products are present species other than those typical of the human gut. An example is given by 
B. lactis, a species widely used in commercial products thanks to its greater capacity for survival 
and resistance to stress. 
The genome structure of this group of microorganisms remains largely unexplored; Milani et 
al., 2014 sequenced the genomes of 42 subspecies belonging to the genus Bifidobacterium and 
they used this information to explore the genetic picture of this bacterial group. They suggest 
that the evolution of this genus was substantially influenced by genetic adaptations to obtain 
access to glycans, indicating in this way that this mechanism represents a strong evolutionary 
force in shaping bifidobacterial genomes. 
Another application of the analysis of the genome revealed the genetic elements responsible 
for the use of carbohydrates by bifidobacteria of the intestinal microbiota. Particularly, Milani 
et al., 2015 have performed the analysis of the genome of 47 strains of bifidobacteria showing 
that, in this bacterial genus, the genes for the catabolism and degradation of carbohydrates are 
better represented compared to those found in other bacteria of the intestinal microbiota and 
this ability to degrade glycans reflects the availability of carbon sources of the human gut. 
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“Non-conventional” probiotics 
In recent years new species of bacteria with probiotic properties have been discovered. Among 
them there is the species Faecalibacterium prausnitzii, an important commensal bacterium of 
the human gut flora. In healthy adults, the species F. prausnitzii represents more than 5% of the 
bacteria in the intestine, making it one of the most common gut bacteria. In the last few years 
an increasing number of studies have described the importance of this commensal bacterium 
as a component of the healthy human microbiota demonstrating that lower than usual levels of 
F. prausnitzii in the human gut have been associated to dysbiosis in several human disorders 
(Miquel et al., 2013). Particularly, it was shown that a decrease in the levels of this bacterial 
species is closely related to Crohn's Disease as demonstrated by Wright et al., 2015. They 
studied the taxonomic shifts in patients with this inflammatory bowel disease revealing 
significant changes in microbial composition: the abundance of Bacteroidetes is increased and 
Firmicutes decreased in Crohn's disease compared with healthy controls. Enterobacteriaceae, 
specifically Escherichia coli, is enriched while F. prausnitzii is found at lower abundance.           
In order to develop a novel probiotic, several strains of this bacterial species were isolated and 
characterized by Foditsch et al., 2014 showing that the concentrations of the short chain fatty 
acids acetate, butyrate, propionate and isobutyrate in the culture media change in the 
presence of bacterial growth. They observed a significative reduction in the concentration of 
acetate followed by a concomitant increase in the concentration of butyrate, suggesting that 
the isolates are able to consume acetate present in the media and producing butyrate. This is a 
positive effect because butyrate has many benefits to the colonic epithelial cells and so the 
selection of strains that produce higher amounts of butyrate is extremely important for the 
development of a new potential probiotic. 
Another “non-conventional” probiotic is represented by the species Akkermansia muciniphila, a 
species of the new genus, Akkermansia, proposed in 2004 by Derrien et al. A. muciniphila is 
a Gram-negative, strictly anaerobic, non-motile, non-spore-forming and oval-shaped. It is able 
to use mucin as its sole source of carbon and nitrogen, and able to colonize the gastrointestinal 
tracts of human. Extensive research is being undertaken to understand its association 
particularly with inflammation (Everard et al., 2013). Infact, A. muciniphila is believed to have 
anti-inflammatory effects in humans, and studies have shown inverse relationships between A. 
muciniphila colonization and inflammatory conditions such as appendicitis or irritable bowel 
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syndrome. In one study, reduced levels of A. muciniphila are correlated with increased severity 
of appendicitis. In a separate study, patients with irritable bowel syndrome were found to have 
lower levels of A. muciniphila in their intestinal tract than individuals without this syndrome 
(van Passel et al., 2011). 
 
Probiotics: guidelines for use in foods and food supplements 
In order to protect the health of consumers, foods containing probiotics are subject of 
attention, as confirmed by the elaboration of international guidelines aimed to safeguard the 
quality of the products. 
Ministerial guidelines (revision of 2013) define first the requirements required to use 
microorganisms as probiotics. They must in fact be sure to use in humans and to be alive and 
vital in such quantity as to allow multiplication and their activity in the intestine (for reasons that 
are explained after).  
 
Amount of microorganisms 
Ministerial guidelines specify that the minimum quantity of microorganisms able to temporarily 
colonize the intestine is 10^9 living cells for strain and for day. The recommended daily dose of 
the product must therefore possess a charge in viable cells equal to 10^9 for at least one of the 
strains present in the product. This is a topic of much debate because despite regulatory 
orientation is the one just mentioned, some leaders of the sector say that in a mixed product all 
species must have a charge of at least 10^9. 
 
Safety of probiotics 
To ensure the safety of the microorganism used, it’s necessary an identification of the same on 
the strain level. First of all, for safety and efficacy reasons it is important that each strain under 
study is clearly identified, in fact different bacterial strains belonging to the same species may 
play different beneficial actions in the host. The species can be identified by determination and 
analysis of the DNA sequence coding for the 16S rRNA or through the hybridization of nucleic 
acids, the strain can be characterized by PFGE (Pulse Field Gel Electrophoresis). Some of these 
methods are technically obsolete, however, they are still required from regulatory point of 
10 
 
view. Some of these techniques are no longer used because they are time-consuming and not 
cost efficient but they are highly reliable because they allow to obtain highly reproducible 
profiles unlike other new methods. 
 
The clear identification of strains and their amount in the products are nowadays subject to 
careful regulation given the frequent cases of misidentification and mislabeling that occurring. 
An example is shown by the control made by Aureli et al., 2010 who tested 72 of probiotic food 
supplements produced and distributed on the Italian market during 2005-2006. They have 
shown that 87% of the products analyzed do not comply with the guidelines and the differences 
were both quantitative and qualitative (number, types and viability of microorganisms). 
Moreover, even though most labelled supplements indicate the presence of Bifidobacterium 
bifidum, this organism was detected only rarely and always as dead cells. This study is a clear 
demonstration that on the Italian market, there are commercial probiotic products that do not 
correspond to what is written on the label and consequently to what the Italian guidelines 
suggest. 
 
In order to consider safe a bacterial strain is necessary a reliable taxonomical identification as 
described above, and the evaluation of the sensitivity to antibiotics. As is known, in fact, the 
phenomenon of bacterial resistance to antibiotics is often based on the presence in the 
bacterial cells of mobile genetic elements, such as plasmids and transposons, which can be 
transmitted from one organism to another promoting the horizontal spread of resistance. 
Particularly the intrinsic resistance to antibiotics is not a problem, the problem arises when the 
resistance determinants may be transferred to other bacterial strains; evaluation of antibiotic 
sensitivity is necessary to ensure the absence of acquired or potentially transmissible 
resistances. For the evaluation of the bacterial safety EFSA (European Food Safety Authority) 
has introduced the concept of QPS ("Qualified Presumption of Safety"), in practice it was 
developed a list of bacterial groups suitable for QPS assessment: for them it is not necessary 
safety assessment but only the determination of sensitivity to antibiotics (EFSA, 2013). 
 
It is on the basis of this regulation and the international community on probiotics that 
researchers should be directed to develop products really useful to the consumer, taking into 
account that different types of consumers need different probiotics: probiotics are in fact 
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influenced by various factors such as age of the host, his physiological / pathological conditions 
and his diet. It is also necessary to increase the effectiveness of products containing probiotics 
and, for that, it is important to pay attention in each phase of the production: from the 
selection of bacterial strains to the classification and identification of the same and then 
proceed to the safety assessment and the determination of the functional characteristics of the 
strains. 
 
Selection and characterization of Lactobacillus and Bifidobacterium strains: 
“conventional screening” 
A pool of bacterial strains is initially characterized from the taxonomical point of view and for 
safety for use in human (“conventional screening”) and then only bacterial strains that possess 
these features of safety were subjected to a more specific screening, depending on the 
application to which they will be destined (targeted screening application-focused). 
 They will therefore be intended to a process of "selection funnel" aimed at the realization of a 
series of in vitro tests to assess their applicability as probiotics for the promotion of human 
health. 
 
The most common bacteria used as probiotics belong to the genus Lactobacillus and 
Bifidobacterium. The selection process of a strain to be used as a probiotic is based on a multi-
step approach:  
According to FAO/WHO guidelines it is necessary to identify the microorganism to 
species/strain level because probiotic effects are strain specific (FAO/WHO, 2006). Further 
characterization of strains is important especially for safety assessment, in fact in order to 
guarantee fermented products and food supplements that are safe for consumption, some 
characteristics of the novel lactobacilli and bifidobacteria strains must be studied to ensure 
their safety. 
Within the “Conventional screening” several in vitro tests are conducted for a further 
characterization of strains to ensure that the bacteria are able to reach the intestine alive and 
vital, an important requirement to ensure their effectiveness. In Figure 1 are represented the 
main phases of the “conventional screening”.  
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Figure 1: Main phases for identification and characterization of probiotics (Joint FAO/WHO Working Group Report 
on Drafting Guidelines for the Evaluation of Probiotics in Food London, Ontario, Canada, 30 April – 1 May 2002) 
 
It is well accepted that an effective human probiotic should be of human origin and this is due 
to the fact that human intestine is different from those of animals, so strains isolated from 
animal intestine may not be suitable for humans (O’Sullivan, 2001). 
For the isolation of new strains, classical cultivation techniques must be employed, particularly 
selective media and specific culture conditions are used for the isolation of strains from human 
fecal samples (Delgado et al., 2006). 
 
Identification and typing 
In the last decade molecular methods, mainly based on the analysis of nucleic acids by using 
polymerase chain reaction (PCR) amplification, have been developed for identifying probiotics 
(Ben-Amor et al., 2007). 
The study of ribosomal RNA genes  is the most common method for the identification of 
bifidobacteria and lactobacilli. Bacterial ribosomes are composed by proteins and three 
13 
 
ribonucleic acids: 5S RNA, 16S RNA, and 23S RNA. The analysis of the 16S rDNA allows to 
discriminate all Bifidobacterium and Lactobacillus species and their respective subspecies and 
biotypes (Germond et al., 2002; Matsuki et al., 2003; Ventura et al., 2006) by sequencing 
fragments of DNA previously amplified by “universal” or group-specific primers. In addition to 
provide a precise identification, comparison of the 16S rRNA gene sequences allows to 
understand the evolutionary relationships among the distinct species. The analysis of 16S rDNA 
sequences has shown that the classification of lactobacilli in three metabolic groups (obliged 
homofermentative, facultative heterofermentative, obliged heterofermentative) is not in 
accordance with their evolutionary relationships. In fact Lactobacillus species can be grouped 
into several groups and don’t form a coherent phylogenetic unit (Felis and Dellaglio, 2007; 
Satokari et al., 2003). 
Methods based on the PCR are widely used and allow the differentiation between strains of the 
same species, by examining patterns generated by amplification of DNA fragments these 
methods offer a potential for probiotic strain typing. Particularly, REP (repetitive extrogenic 
palindromic) PCR examine specific patterns of repetitive DNA elements. REP sequences are 
short DNA fragments detected in the extragenic space, and they are dispersed in the bacterial 
genomes (Ventura et al., 2003; Tobes and Ramos, 2005). 
Recently, more robust typing methods have been applied to species and strains of Lactobacillus 
and Bifidobacterium such as the multilocus sequence typing (MLST) scheme. This method made 
use of an automated DNA sequencing procedure to characterize the alleles present at different 
housekeeping gene loci. As it is based on nucleotide sequences, it is highly discriminatory and it 
provides unambiguous results. This powerful technique has been applied for phylogenetic 
studies of strains of Lactobacillus and a variant of MLST, called multilocus variable-number 
tandem repeats analysis (MLVA) was used for the subtyping of L. casei / L. paracasei. 
Also the genome sequence analysis is nowadays used as a new taxonomic technical approach 
and it provides insights on bacterial evolution thus influencing bacterial taxonomy. Genomic 
sequence information has in fact been proposed for defining a new genomic-phylogenetic 
species concept for prokaryotes. For example, comparative genomics has supported the idea 
that the lactobacilli don’t form a coherent phylogenetic group but it seems that some species 
(L. salivarius, L. plantarum) are more closely related to Enterococcus faecalis than to other 
lactobacilli. An example of genomic techniques is the comparative genome hybridization (CGH) 
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that can be used to determine the genome content of a bacterial strain for which is not known 
the genome sequence. 
 
Antibiotic sensitivity  
Lactic acid bacteria are naturally resistant to many antibiotics, but in most cases the resistance 
is not transferable by horizontal gene transfer (HGT). However when the antibiotic resistance is 
plasmid-associated it can be transferred to other species and genera, so it is important to select 
strains lacking the potential to transfer genetic determinants of antibiotic resistance. About 
that, Mathur and Singh observed that LAB used in probiotics may be a source antibiotic-
resistant genes which could be potentially transferred to pathogenic bacteria (Mathur and 
Singh, 2005). Therefore they suggested  systematic screening for antibiotic resistance in 
probiotic strains: In the case of presence of antibiotic resistance the approach to follow is 
suggested by Courvalin, 2006, consisting in the identification of the resistance gene, evaluation 
of the ability to transfer the resistance, characterization of the biochemical mechanism of 
resistance and elucidation of the genetic basis for resistance. If the resistance feature is not 
associated with a mobile genetic element, the risk of transfer of resistance would be assessed 
as low. 
The experimental methods used to test the sensitivity to antibiotics are described in Chapter 2. 
 
Survival to GIT stressing conditions 
The ability to survive to stressful gastrointestinal tract (GIT) conditions (low pH and high bile 
salts concentrations) is an important criteria used for the selection of probiotics strains. The 
transit of probiotics present in food through the GIT takes variable times and is submitted to 
different stressful conditions. After mastication, the first barrier that bacteria must overcome is 
the low pH of the stomach with values ranging from 1 to 3. Into the duodenum the pH value 
rises to 6-6.5 but bile salts reach concentrations ranging from 1.5 to 2% during the first hour of 
the digestion (Noriega et al., 2004). For the screening of probiotics so it’s important to simulate 
in vitro these GIT conditions: a low pH value and a high bile concentration are tested for 
variable times in order to determinate the survival of the strains under test. 
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Targeted screening focused on the application 
“Conventional” screening described above consists of in vitro experiments that are mainly 
important to assess the safety of probiotic strains. However, it is realized that these tests, 
including identification of strains, safety assessment and characterization of some activities 
(ability to grow in conditions of low pH and in the presence of bile acids) are not accurate to 
predict the potential use and the functionality of probiotic strains. So, it’s necessary to expand 
the knowledge of specific properties of tested strains. 
Knowledge about intestinal microbiota, nutrition, immunity, and genetics in health and disease 
has increased in the past years. This information helps to develop new probiotic strains with 
disease-specific functions. Probiotics are not a uniform group of microorganisms with health 
benefits: the efficacy and the properties of each specific strain should be assessed individually 
rather than as a group of probiotics mainly because different strains exert different effects. 
Then, “conventional” screening must necessarily be followed by a screening depending on the 
application based on the development of platforms for functional characterization, adopting 
screening criteria for assess if the potential new probiotic is suitable for use in certain areas of 
consumer health (oncological diseases, cardio-vascular, metabolic, etc.). 
Until few years ago, there was the idea that the same strain could be used for different 
applications, this is not plausible in fact a strain with specific features is usually employed for a 
specific application. Nowadays in fact is widely supported the thesis that, for the same strain, 
you can not have an effective use for different applications but, for each application, you must 
choose the most suitable strain. 
 
This targeted screening is closely related to the benefits of probiotics on human health. 
An increasing number of studies have shown that probiotic bacteria are in fact able to positively 
influence the state of health, thanks to the numerous activities that they carry out, in 
particular: maintaining a balance in the intestinal microflora, protection against intestinal 
pathogens and modulation immune response leading to an improvement in allergies food and 
autoimmune disorders (Figure 2).  
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Figure 2: Mechanisms of action of probiotics  
 
Prevention of pathogen adherence 
The adhesion of pathogens to the intestinal mucosa appears to be crucial for the beginning of 
the infection process. 
Pathogenic bacteria are in fact able to adhere to the intestinal epithelium, colonize with 
detrimental effects to epithelial cells. 
The microbiota present in the intestine provides a barrier to the adherence of pathogenic 
bacteria and various mechanisms have been proposed to explain this defensive action of 
probiotics. Some authors have suggested that the production of organic acids, such as acid 
lactic and acetic acid by probiotics, especially by some lactobacilli strains, lowers the intestinal 
pH and inhibits the growth of pathogens. Moreover, the same authors have seen that 
probiotics stimulate peristalsis that, indirectly, removes pathogens, accelerating the speed of 
transit in the intestine. 
Another mechanism supported by various studies is the ability of probiotics to compete with 
pathogens in adhering to the intestinal mucosa (Arquès et al., 2015). Some probiotics can 
inhibit the adhesion of pathogens to their binding sites on the surface of the intestinal 
membrane by competing for binding. 
A study of Gopal et al., 2001, has confirmed that some lactobacilli, like L. rhamnosus DR20, L. 
acidophilus HN017 and B. lactis DR10, are able to adhere to intestinal cell lines in vitro and to 
decrease the colonization and the entry of pathogens into the intestinal mucosa. 
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Prevention of diarrhea and intestinal infections 
It’s well known that various strains of lactobacilli can be used to prevent or treat acute diarrhea 
caused by Escherichia coli, Salmonella or Shigella and this effect is mainly due to the production 
of bacteriocins by different strains of probiotics used. A study of Davoodabadi et al., 2015 has 
shown the ability of strains of L. fermentum, L. plantarum and L. paracasei to inhibit the growth 
of enteropathogenic bacteria including strains of Shigella flexneri, Shigella sonnei, Salmonella 
enteritidis and Yersinia enterocolitica. 
Some authors have used L. rhamnosus GG added to yogurt, to treat diarrhea associated with 
the treatment by antibiotics as demonstrated by a recent study that evaluated the efficacy of L. 
rhamnosus GG in the prevention of antibiotic-associated diarrhea both in children and in adults 
(Szajewska and Kołodziej, 2015). The administration of antibiotics can lead to an imbalance in 
the microbiota and a net reduction of the intestinal "beneficial" microflora, the main 
responsible of the resistance to the colonization of pathogens. The results of this study showed 
that humans volunteers that received probiotics with the antibiotic showed lower diarrhea 
compared to individuals that consumed only pasteurized yogurt as control (Siitonen et al., 
1990). 
Efficacy against diarrheal disease is well documented also with other probiotics strains, such as 
L. reuteri, L. casei and Saccharomyces boulardii (Huang et al., 2002; Van Niel et al., 2002). 
Probiotics are widely used for prevention and treatment of diarrhea more in children than in 
adults (Guarino et al., 2015): the administration of probiotics, such as B. bifidum, Streptococcus 
thermophilus and L. rhamnosus, has proved very useful also as prophylaxis to prevent 
nosocomial diarrhea in children (Szajewska et al., 2001). 
The incidence of Crohn's disease and ulcerative colitis collectively called syndrome IBD 
(inflammatory bowel disease), is constantly increase in industrialized countries. The changes in 
lifestyle, including a better hygiene and a reduction in the consumption of foods containing 
bacterial enzymes, may alter the correct microbial balance necessary for the development of a 
correct intestinal immune system (Shanahan, 2004). This can lead to immune reactions towards 
the intestinal bacterial flora, and this could be the first step leading to the development of IBD 
and other disorders related to wrong immune response. Several experimental evidence in fact 
suggest that both Crohn's disease and ulcerative colitis are caused by hyperactivation of the 
immune system against intestinal flora, leading to a chronic inflammatory state and a 
consequent mucosal damage (Shanahan, 2002). 
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The balance between pathogenic and beneficial bacteria in the intestine represents a 
protection against abnormal immune responses that lead to inflammation. 
For this reason a good therapeutic strategy against IBD is a modification of the microflora in 
favor of probiotics (Fedorak and Madsen, 2004). 
Experimental studies carried out ex vivo on intestinal mucosa of patients suffering from Crohn's 
disease have shown that certain Lactobacillus strains, including L. casei, can induce a decrease 
of the release of TNF-α (anti-inflammatory signal) by the inflamed mucosa. 
Moreover experiments conducted on rats which spontaneously develop colitis, have shown 
that oral administration of L. reuteri or L. plantarum 299v did significantly decrease the 
symptoms of the disease (Schultz et al., 2002). Also Torres-Maravilla et al., 2015 demonstrate 
the potential of a strain of L. sanfranciscensis to treat IBD. Often the symptoms of IBD were 
treated by using a mixture of probiotics as demonstrated by a study of Yoon et al., 2015 that 
evaluated the effect of a probiotic mixture composed by L. acidophilus, L. rhamnosus, B. breve, 
B. lactis, B. longum, and S. thermophilus on the changes in fecal microbiota and IBD symptoms. 
They demonstrated that after 4 weeks of administration of this multi-species probiotic mixture 
the fecal concentration of most probiotic strains increased and the diarrhea-symptoms in IBD 
patients improved. 
Overall, these results show that probiotics act by modulating immune response in IBD thanks to 
regulatory cytokines, and this suggest an important role for these bacteria for the treatment of 
IBD. 
 
Stimulation of the immune system and beneficial effects on allergic reactions 
Among the various beneficial effects exerted by probiotics very important is their capacity of 
interaction with the immune system (Jespersen et al., 2015). For this reason it is essential that 
the immune system recognizes the parts of the microbiota as self and express a tolerance 
towards them, this tolerance is also possible thanks to the fact that the bacteria of the 
microbiota do not express virulence factors (Aureli et al., 2011). 
The thesis that probiotics may influence immunity thus exerting a beneficial role in the 
treatment of human diseases is nowadays a topic of great interest. 
There are in fact extensive evidence that suggest that lactic acid bacteria are able to stimulate 
both innate and acquired immune response, the lymphocyte function and the production of 
antibodies and cytokines (Gill et al., 2000; Pessi et al., 2000). 
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First of all, the ability of probiotics to modulate lymphocyte populations has been 
demonstrated by some authors who observed an increase in the population of T-helper 
lymphocytes in rats treated with L. casei (Perdigon et al., 1999). 
Furthermore it was seen that some strains of probiotics are able to increase the number of 
populations of neutrophils and macrophages, as well as to stimulate the activity of the cells 
natural killer (Gill et al., 2000; Matsuzaki and Chin 2000) which are the first line of defense 
thanks to their cytotoxic activity exercising against antigens (Ley et al., 2008). Moreover, some 
strains of lactobacilli induce dendritic cells (DC) maturation that pass through epithelial cells 
and capture antigens from the lumen.  
About the effect of probiotics on the production of antibodies, numerous studies have shown 
that the treatment with some strains of probiotics is able of enhancing the immune response 
antigen-specific against natural infections and immunizations, in particular probiotics act by 
increasing the production at mucosal level of immunoglobulin A (IgA), the first line of defense 
against pathogenic bacteria and viruses that daily are inhaled and ingested. A more recent 
study investigated the IgA increase induced by a strain of L. plantarum and demonstrated that 
this strain increased the IgA level of Peyer's patch (PP) cells, although its mechanism of action is 
not clear yet. They demonstrated that taking concentrations of 0.03% or 0.3% of L. plantarum 
powder for 4 weeks, caused an increase of IgA in the small intestine of the mice (Kikuchi et al., 
2015). Despite these results indicate the ability of this strain to maintain mucosal immunity, it is 
necessary to better understand its mechanism of action in order to use this strain in functional 
food. Another study of Sakai et al., 2014 demonstrated that a strain of L. gasseri stimulates 
dendritic cells to promote the production of TGF-β, IL-6, and IL-10, all critical for IgA production 
from B cells activating in this way the signal to produce IgA in the mouse small intestine. 
 
For many years the production of cytokines was associated only with the response against 
infections and it has been given little attention to the fact that lactic acid bacteria could induce 
the production of cytokines even in conditions of perfect health. The effect most studied on the 
immunomodulatory activity of probiotics regards precisely the expression of cytokines, both 
pro- and anti-inflammatory, at both intestinal and systemic level. Several in vitro studies show 
an increase in pro-inflammatory cytokines such as IL-12 and tumour necrosis factor-alpha (TNF-
α) in the presence of probiotics as evidenced by a study of Nishibayashi et al., 2015 where it 
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was investigated the role of three LAB strains in inducing the production of interleukin-12 from 
human monocytic cells. Particularly the study was conducted by using a strain of E. faecalis, a 
strain of L. gasseri and one of B. breve and it was demonstrated that a treatment with RNase A 
of heat-killed LAB significantly decreased the IL-12 production of human cells demonstrating 
that the single stranded RNA (ssRNA) of LAB is a strong inducer of IL-12 production from human 
monocytes. Other authors confirmed the trend of lactobacilli in increasing the production of 
inflammatory cytokines, finding an increase of IFN-γ and IL-12 in human peripheral blood 
mononuclear cells treated with L. johnsonii and L. sakei, while the level of IL-10 is not seemed 
to increase (Haller et al., 2000). 
It was also reported an activity of probiotics in inducing the expression of anti-inflammatory 
cytokines. About that, an in vivo study of Wang et al., 2015 on patients in dialysis evaluated the 
effect of probiotics on inflammatory markers such as interleukin IL-6 and TNF-α that are 
elevated in patients with this disease and the impact of the same bacteria on the anti-
inflammatory cytokine IL-10. They found that a treatment with a strain of B. bifidum, B. 
catenulatum, B. longum and L. plantarum caused a decrease in the levels of serum of pro-
inflammatory cytokines TNF-α, IL-5 and IL-6 while levels of serum of IL-10 significantly 
increased. 
These studies confirm the role of the probiotics in the modulation of gene expression 
associated with the immune system and inflammation. Specific strains of Bifidobacteria and 
Lactobacilli influence the gene expression of mucins, nuclear factor and interleukins leading to 
an anti-inflammatory response in the presence of enterocytes in culture (Plaza-Diaz et al., 
2014). Moreover, probiotics interact with the surface of antigen-presenting cells in vitro causing 
the downregulation of pro-inflammatory genes that are linked to inflammatory signaling 
pathways, while other anti-inflammatory genes are upregulated. These effects of probiotics are 
widely studied in animal models while information about the impact of probiotics on gene 
expression in human intestinal cells are very scarce. There is the need of further clinical studies 
to elucidate the mechanism of action of probiotics both in healthy humans and in patients with 
chronic diseases. These types of clinical studies are necessary for addressing the influence of 
these microorganisms in gene expression associated with the immune response to finally better 
understand the role of probiotics in the prevention and treatment of disease. 
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Then accumulating evidence suggests that probiotic bacteria play an important role in 
modulating various aspects of immunity and the ability to regulate this type of responses is very 
useful from the clinical point of view, for example for immunoprophylaxis or, more generally, to 
increase immunity against pathogens of different nature. 
There are several studies that demonstrate a role of probiotics also in autoimmune and allergic 
disorders. 
Food allergies are chronic disorders of growing importance in countries more developed, and 
they are mainly due to an uncontrolled immune response against specific antigenic 
determinants present in the environment or in the food. 
Considering the anti-inflammatory and immunomodulatory effects exerted by probiotics, it was 
suggested the use of probiotics as a new strategy for the control of inflammation and allergic 
reactions, because they are able to favorably alter the microflora of the host and modulate the 
intestinal immune response. 
It is well known that an adequate colonization of the intestine by the bacterial flora in the first 
years of life is responsible of the proper balance between the Th1 cells and Th2 ones, which 
provides protection against allergies (Kalliomaki and Isolauri, 2003; Bischoff and Crowe, 2004). 
The intestinal microflora can potentially promote anti-allergenic processes, it can in fact 
stimulates the production of TGF-β and IL-10, resulting in promotion of the oral tolerance 
(Christensen et al., 2002; McGuirk and Mills, 2002). It was in fact observed a decrease in the 
inflammatory immune response to food antigens in allergic individuals following treatment 
with probiotics (Cosenza et al., 2015). 
 
Gut-brain axis 
The term probiotic is always associated with the intestinal environment and with the 
maintenance of its eubiosis. However in recent years has arisen the idea that probiotics can 
also affect brain functions by helping to improve or prevent disorders such as depression and 
anxiety. The ability of the microbiota to communicate with the brain is demonstrated by the 
fact that a decrease in beneficial flora leads to a deterioration of the gastrointestinal and 
neuroendocrine relationships causing diseases. The collaboration between the brain and the 
gastrointestinal tract is fundamental for maintaining homeostasis and it is regulated at the level 
of central and enteric nervous systems (Cryan and O’Mahony, 2011). Perturbation of these 
22 
 
systems has as a consequence an alteration in the stress-response and behavior (Rhee et al., 
2009). So the enteric microbiome has an impact both on the gut that on the brain and for this 
reason it was coined the phrase “gut-brain axis”.  
 
It is certain that bacteria in the human gut have the ability to produce molecules with 
neuroactive functions which could affect the brain. Some typical bacteria of the human GIT are 
in fact able to produce many neurotransmitters and neuromodulators and, among them, 
Lactobacillus spp. and Bifidobacterium spp. have been reported to produce γ-aminobutyric acid 
(GABA) and, especially bacteria of the genus Lactobacillus, have been reported to produce 
acetylcholine and histamine. These secreted neurotransmitters from bacteria in the intestinal 
lumen may induce epithelial cells to release molecules that modulate neural signal in the 
enteric nervous system and consequently the functioning of the brain and the behavior of the 
host (Wall et al., 2014). It was demonstrated that different strains of Lactobacillus and 
Bifidobacterium are able to produce GABA when growing in the presence of monosodium 
glutamate. GABA is a neurotransmitter that in the brain is involved in states of anxiety and 
depression through the regulation of different physiological processes (Schousboe and 
Waagepetersen, 2007). Another study of Messaoudi et al., 2011 assessed the effect of the 
combination of L. helveticus and B. longum on rats and demonstrated that these probiotics 
reduced anxiety in animals. Although the mechanism of action is not known it has been shown 
that different probiotic strains are able to modulate the level of inflammatory cytokines 
(Brenner and Chey, 2009) and to decrease oxidative stress thereby reducing depression and 
anxiety. A bacterial species able of modulating the state of depression by inhibiting the 
production of pro-inflammatory cytokines is the B. infantis (Desbonnet et al., 2008).  
 
Several studies have also shown that the use of a combination of probiotics obtained by 
combining different bacterial genera or different species of the same genera may be more 
effective than a mono-species supplements (Chapman et al., 2011). However, some strains can 
compete with others in the execution of their functions so the use of a mixture of strains to 
obtain a greater effect requires careful verification in the preparation of the mixture itself. 
Moreover, these evaluations were usually carried out using animal models, in particular were 
used germ-free mice or rats. These animals do not have any bacterial contamination, and thus 
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offer the opportunity to study the effect of the complete absence of the intestinal microbiota 
on behavior. Although these animals are useful for research in the field of neuro-
gastroenterology, the results obtained from animal studies can not be extended to human 
individuals since they are not representative of the real situation of the human population. 
Probiotics studies in human are still scarce but available data look promising. For example a 
study of Benton et al., 2007 found that a treatment of three weeks with a drink based on milk 
containing L. casei Shirota improved mood scores in individuals with symptoms of depression. 
 So these data suggest an ability of probiotic strains to modulate some aspects related to brain 
and behavior, but these results obtained in animal models have to be confirmed in human and 
there is also the need to understand the molecular and cellular basis of this gut-brain 
communication mediated by microbiota. 
 
Market of probiotics 
The worldwide interest in the field of probiotics is very high, thanks to the many new products 
launched every year on the market, the interest of researchers in demonstrating the real 
property and consumers, more and more attentive to health products. The growing awareness 
of consumers and their attention to new concepts of health and well-being in recent years, 
favored a significant growth of the global market for probiotics, thereby increasing the level of 
interest and investment of industries, researchers and producers. Over 500 new probiotics 
products were introduced in the last decade, although, not everyone receives the same level of 
success in the market. 
Estimates of Euromonitor International at the end of 2014 confirm the positive trend of the 
markets for vitamins and food supplements in the main countries of Western Europe, with the 
only exception represented by Germany. For all the other markets, the medium annual growth 
rate varies from 2.7% in Italy to 3.9% in the UK. Regarding the expenditure per capita, the 
highest level is reached in Italy with 29,50 €. Italian consumer is followed by the Belgian one 
with 27,20 €. In addition, in Italy the trend of the category is driven by probiotics and minerals. 
Concluding given the rapid evolution of the probiotic market in recent years, companies 
operating in this field have the main objectives of identify new applications for their products 
and differentiate the end use to try to further expand and to support the market. 
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Aim of the thesis 
In recent years, the European market for probiotics has evolved rapidly, thanks mainly to the 
more interest that consumers give to those food that are marketed primarily for their health 
benefits ("functional" products). Although there are many potential benefits of some probiotics 
on human health, there are few bacterial strains for which there is a scientific evidence that 
demonstrates the beneficial effect of the same. For this reason it is necessary an intensive 
research aimed at discovering new bacterial strains and to investigate the mechanisms of 
action and their health properties. 
During these three years I have done an higher education and research apprenticeship, a 
contract for the acquisition of the title of PhD, which includes both practical training in a 
company that a secondary university education. This type of contract introduced with the 
Legislative Decree n. 167/2011 is addressed at young people under the age of 30 years, lasts 
three years and allows young people to enter into the job market with regular employment, 
gaining professional experience and achieving, at the same time, the title of PhD. This contract 
has allowed AAT to personalize my research plan taking into account working specific needs 
and skills requirements and especially considering the needs of the market. 
AAT has for years been engaged in screening new potential probiotic strains owning a large 
collection of bacteria; the objective of my doctoral research is to contribute to the evolution of 
screening criteria by combining conventional approach to newly designed platforms especially 
targeted towards health-promoting applications. The specific objective of the work was to 
isolate one or more bacterial strains able to survive in the acidic environment of the stomach, 
able to survive and multiply in the intestine even in the presence of bile salts and able to 
produce during fermentation a high bacterial mass, with a good capacity of resistance to the 
treatments of freezing and lyophilisation and a significant stability in powdered form. 
Bacterial strains found to possess these features were then subjected to a more specific 
screening, depending on the application to which they will be destined. They will therefore be 
intended to a process of "selection funnel" aimed at the realization of a series of in vitro tests to 
assess their applicability as probiotics for the promotion of human health. 
The isolation of a bacterial strain with these features represents an important goal because 
products that contain this organism could be used not only in adults but also in those persons 
belonging to the age-group typically characterized by a compromised immune system; the 
intestinal flora of children and elderly is often subject to attack by pathogenic bacteria, for this 
reason there is the need to ingest a food enriched with the most suitable bacterial strain (which 
may be different depending on the subject) in order to contribute to the normal function of the 
immune system and to restore the situation of eubiosis. 
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Introduction 
 
Among the microorganisms involved in the preparation of fermented foods, lactic acid bacteria 
are widely used in the production of a great variety of fermented foods, such as yogurt 
(Adolfsson et al., 2004), meat, vegetables, bakery products, silage and other, contributing in 
various ways in determining their characteristics and their stability. 
The increased use of LAB in food production as probiotics has raised safety issues: one of them 
is the nature of acquiring and distribution of antimicrobial resistance (Ammor et al., 2007). 
Overuse of antibiotics have contributed to the emergence of resistant bacteria. Antibiotic 
resistance is the phenomenon by which a bacterium is resistant to the activity of an 
antimicrobial drug. Over the years this phenomenon has become increasingly important, 
especially for those bacteria whose sensitivity to certain drugs seemed undisputed. This 
phenomenon has already been studied extensively in foodborne pathogenic bacteria (Rahimi et 
al., 2010; Gousia et al., 2011), but in recent years also fermented products have received 
particular attention as potential vehicles of the spread of antibiotic resistance determinants, 
which could be transferred to pathogenic bacteria by horizontal via (Perreten et al., 1997; Franz 
et al., 1999; Klein et al., 2000). In particular, this role of diffusion of the antibiotic resistance, 
which consequently favors the selection of resistant bacterial species, is carried out by 
commensal bacteria (Snary et al., 2004) commonly present in food. Recent work had focused 
on strains of L. paracasei, one of the species mainly present in fermented products that, despite 
its probiotic properties (Andriulli et al., 2008; Chouraqui et al., 2008), appears to play a 
pathogenic role (Cannon et al., 2005). Determinants responsible of antibiotic resistance are in 
fact been identified in this species (Huys et al., 2008; Kyriacou et al., 2008; Devirgiliis et al., 
2008; Zonenschain et al., 2009), which can act as a vehicle for the spread of these genes to 
pathogenic bacteria (Teuber and Perreten, 2000). 
As L. paracasei, other commensal bacteria can exchange genes for antibiotic resistance (Teuber 
et al., 1999; Salyers et al., 2004; Ammor et al., 2007); this explains the importance of 
systematically test the strains for the presence of these genes before using them as probiotics 
or as starter cultures in food. 
In 1998 the participants involved in The Lactic Acid Bacteria Industrial Platform (LABIP) 
workshop on probiotics supported criteria for the selection and assessment of probiotic lactic 
acid bacteria (Guarner and Schaafsma, 1998), two of them are the evaluation of resistance to 
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gastric acidity and bile toxicity. Then, bacterial strains considered safe for use in humans, were 
evaluated also for these parameters under laboratory conditions. Particularly resistance to 
gastric acidity is important because probiotic bacteria, before reaching the intestinal tract, must 
first survive through the stomach (Henriksson et al., 1999). The survival of the bacteria in the 
presence of gastric juice depends on their ability to tolerate low pH. Several LAB isolated from 
sausages, e.g., L. sakei, L. plantarum, L. pentosus, can tolerate such acidic conditions (Erkkilä 
and Petäjä, 2000; Klingberg et al., 2006; Pennacchia et al., 2004). Therefore, some authors 
propose that strains intended for probiotic purposes should be screened for tolerance to pH 2.0 
in a culture medium acidified (Klingberg et al., 2006). 
For using lactic acid bacteria as effective probiotics it’s also necessary to evaluate their ability to 
resist the effects of bile acid (Lee and Salminen, 1995), compounds that are synthesized in the 
liver from cholesterol and are secreted into the duodenum in the conjugated form (Hoffman et 
al., 1983). These acids then undergo chemical modifications (for example deconjugation) in the 
colon as a result of microbial activity (Hill and Draser, 1968). It has been shown that both forms 
(conjugated and deconjugated bile acids) exhibit antibacterial activity inhibiting the growth of 
pathogenic bacteria such as Escherichia coli, Klebsiella and Enterococcus (Stewart et al., 1986). 
However, Gram-positive bacteria are found to be more sensitive than Gram-negative bacteria 
(Floch et al., 1972). 
However microorganisms can reduce the emulsifying effect of the bile salts by hydrolyzing 
them with bile salt hydrolase enzymes (Erkkilä and Petäjä, 2000). This enzymatic activity has 
been described in some lactobacilli isolated from intestinal environment such as L. acidophilus, 
L. casei, and L. plantarum (Gilliland and Speck, 1977). Moreover in recent years, other LAB 
strains such as L. sakei, L. pentosus, have been shown to resist bile salts (0.3% (w/v) oxgall) 
(Klingberg et al., 2006). 
 
The aim of this work was to study the occurrence of antimicrobial resistance among newly 
isolated strains of Lactobacillus and Bifidobacterium from healthy subjects. Some other strains 
considered in the course of this PhD thesis had already been previously isolated and 
characterized for their susceptibility to antibiotics and the relative data were confirmed during 
the thesis. New probiotic candidates evaluated as safe for the use in humans have been 
subjected to further in vitro tests aimed to evaluate their probiotic properties. Given the fact 
that probiotic strains are intended for human consumption, the most relevant determinations 
 33 
 
are the ability of the strains to grow in the presence of gastric juice and bile salts. Finally we 
detect the genetic identity of the new strains isolated by an amplification of repeating elements 
of genome DNA. 
 
Materials and methods 
 
Isolation of LAB 
One hundred and fifty strains of LAB were isolated from fecal samples or vaginal swabs. All 
adults and infants were healthy by the moment of the study, without a history of 
gastrointestinal or vaginal infections. Feces were collected with a sterile spatula into a 
container and transported to the laboratory. Serial dilutions were prepared from the material. 
Aliquots of 0,1 ml from 10^7 and 10^9 dilutions of the studied material were inoculated in Petri 
dishes with MRS (De Man, Rogosa and Sharpe) agar medium (BD Difco, USA), complex medium 
suitable for the growth and isolation of bacteria belonging to the genus Lactobacillus. For the 
isolation of bacteria belonging to the genus Bifidobacterium was added, to the MRS medium, L-
cysteine hydrochloride (Sigma-Aldrich, Germany) at a concentration of 0,5 g/l. The dishes with 
cultures were incubated in jar using Anaerocult A (Merck, Germany) for the production of an 
anaerobic environment. It is in fact composed by kieselguhr, iron powder, citron acid and 
sodium carbonate and, when it is put into the jar, the chemical mixture chemically binds 
oxygen, creating an oxygen-free environment and a CO2  atmosphere. 
The purification step was performed using the technique of streak on the same culture media. 
Primary screening of Lactobacillus and Bifidobacterium strains was carried out by evaluating the 
morphology of the colonies. All types of colonies suspected to belong to Lactobacillus or 
Bifidobacterium genus were  isolated in order to obtain pure cultures: first in solid nutrient 
medium, then in liquid nutrient medium for subsequent preparation of frozen bacterial 
cultures. 
 
DNA extraction 
For use in Polymerase Chain Reaction (PCR) DNA from bacteria was extracted using Whatman
TM
 
FTA
TM
 CloneSaver
TM
 Cards (GE Healthcare Life Sciences, UK). CloneSaver Cards are designed for 
the long-term, room temperature storage of DNA from bacterial cultures, resuspended colonies 
or glycerol stocks. DNA stored on CloneSaver Cards is ready for PCR amplification. The area is 
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formatted in a 96-well configuration and its pink color changes to white upon application of 
samples. 5 µl of an overnight bacterial culture (OD600=1,8) were pipetted into the center of one 
of the 96 printed circles; when the sample is applied, the pink color of the spot turned white. 
Samples were let air-dry for one hour prior to process, then a 2,0 mm punch was removed from 
the target sample using a Harris Micro-Punch
TM
 and transferred to a microcentrifuge tube 
suitable for PCR. The punch was washed by adding three times 200 µl of sterile FTA Purification 
Reagent (GE Healthcare, UK) and by adding twice 200 µl of TE buffer (10 mM Tris, 0,1 mM 
EDTA, pH 8,0) to the tube. All traces of TE buffer were removed and the punch is left to dry. 
PCR amplification is made directly from the punch. 
 
Identification of isolated strains 
The putative LAB isolated were further identified by PCR-based 16S rDNA sequencing using a 
pair of universal primers P0 (5’-GAGAGTTTGATCCTGGCTCAG-3’) (Invitrogen, USA) and P6 (5’- 
CTACGGCTACCTTGTTACGA-3’) (Invitrogen, USA) (Di Cello and Fani, 1996). 
The PCR products were separated by electrophoresis on a 1,0% (wt/vol) agarose gel (Segenetic, 
Germany) in 1x Tris/acetate/EDTA (TAE) buffer. The gel was visualised after staining with 
ethidium bromide (Sigma-Aldrich, Germany) under ultraviolet light. PCR products were 
sequenced at BMR Genomics and then, comparing the sequences obtained with the sequences 
present in the database (BLAST RDP..), it has been possible to characterize the bacteria at the 
species level. 
 
Typing by rep-PCR 
To ensure that lactobacilli isolates are different from each other and different from other 
strains already present on the market or in bacterial collections, it was made a rep-PCR 
(repetitive extragenic palindromic-PCR) amplification using the primer (GTG)5 (5'-GTG GTG GTG 
GTG GTG-3') (Invitrogen, USA) or, alternatively, the pair of primers REP1R-Dt (5'-
IIINCGNCGNCATCNGGC-3') (Invitrogen, USA) and rep2-Dt (5'-NCGNCTTATCNGGCCTAC-3') 
(Invitrogen , USA), as proposed by Versalovic et al., 1994. In order to discriminate bacteria that 
belong to the genus Bifidobaterium, rep-PCR was conducted using the primer BOXA1R (5'-
CTACGGCAAGGCGACGCTGACG-3') (Invitrogen, USA) as proposed by Masco et al., 2003. These 
primers were tested for their ability to discriminate between strains of LAB and for their 
reproducibility. 
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Polymerase chain reaction was conducted using the MegaMix (Microzone, UK) that contains 
Taq polymerase (recombinant) in 1,1x reaction buffer (2,75 mM MgCl2) with 220 µM dNTPs and 
stabiliser. The total volume of the reaction is 25 µl: the desired volume of the MegaMix is 
added into the PCR tube, they have been added also two opposing oligonucleotide primers 50 
µM and 1 µl of extracted DNA. In particular, a mixture containing all components of the 
reaction except DNA is made and aliquoted to individual tubes. At room temperature, the 
template DNA is added in each tube and PCR amplification is performed in an automated 
SimpliAmp thermal cycler (Life Technologies, USA) with an initial denaturation step (95°C, 7 
min) followed by 35 cycles of denaturation (90°C, 30 s), annealing (40°C, 1 min) and extension 
(65°C, 8 min), and a single final extension step (65°C, 16 min). Polymerase chain reaction 
conducted using primer BOXA1R differs from the cycle described above and it was conducted 
with the following parameters: 7 min initial denaturation at 95°C, 30 cycles of 94°C for 1 min, 
52°C for 1 min and 65°C for 8 min, followed by a single final extension step (65°C, 16 min).   
For the screening of DNA fingerprint patterns, 15 µl of each PCR reaction is electrophoresed at 
a 80 V constant voltage in 2,2% agarose gel in 1x TAE and then DNA was visualised under 
ultraviolet light, followed by digital capturing of the image using a Kodak Gel Logic 200 imaging 
system (Kodak, USA). 
 
Evaluation of resistance to gastric juice 
New isolated bacterial strains were subjected to an in vitro test aimed to assess their ability to 
resist to the gastric juice. The test was conducted by counting on agar medium at different 
times of contact the liquid culture of the strain previously placed in contact with a solution of 
pepsin (Sigma-Aldrich, Germany) at a concentration of 3 g/l and pH 2,0 (Charteris et al., 1998). 
As a positive control it was used L. rhamnosus GG. 
Particularly, cultures of bacterial strains were grown overnight in 10 ml of MRS broth (BD Difco, 
USA) (with L-cysteine hydrochloride 0,5 g/l if the bacterium belongs to the genus 
Bifidobacterium) and subcultured by using 1% (vol/vol) of the inoculum. The cultures were 
subsequently centrifuged at 7,000 g for 15 min, washed once in an equal volume of 0.25x 
ringer’s solution (Sigma-Aldrich, Germany), and subsequently centrifuged 7,000 g for 15 min as 
proposed by Corcoran et al., 2005. 0,2 ml of washed cell suspension were admixed with 1,0 ml 
of simulated gastric juice and incubated at 37°C for 90 min. Samples were taken at 1, 90 and 
180 min, serially diluted in maximum-recovery diluent (MRD) (BD Difco, USA), plated on MRS 
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medium or MRS medium added of L-cysteine hydrochloride 0,5 g/l, and incubated at 37°C in 
anaerobic conditions for 72 h to determine the viable cells that are therefore able to survive in 
an acid environment such as the stomach. 
 
Evaluation of resistance to bile salts 
The bile tolerance of the respective isolates was examined by slightly modifying the method 
proposed by Gilliland et al., 1984. The liquid culture of each strain was used to inoculate (1% 
v/v) 10 ml of MRS broth medium (with L-cysteine hydrochloride 0,5 g/l if the bacterium belongs 
to the genus Bifidobacterium) and, in parallel, the same volume of the medium containing bile 
salts (Sigma-Aldrich, Germany) at a concentration of 0.3%. The growth of the strain in the two 
culture media was estimated by recording absorbance at 600 nm, because optical density (OD) 
is a parameter directly proportional to the growth of the microorganism. In particular, the OD 
was measured at zero time, after 16 hours of incubation at 37°C and after 24 hours of 
incubation at the same temperature. In the case of bifidobacteria absorbance was recorded 
also at 48 and 72 hours of growth. L. rhamnosus GG, strain resistant to bile salts, was used as 
control. 
 
Antibiotic susceptibility evaluation 
The antimicrobial resistance of a strain to each antibiotic testing was determined as the MIC, 
defined as the minimum concentration of antibiotic that is required to inhibit the growth of a 
microorganism. The MIC was determined through the use of the method of microdilution, 
according to the indications of the method ISO 10932: 2010 IDF 223: 2010 "Milk and milk 
products -Determination of the minimal inhibitory concentration (MIC) of antibiotics applicable 
to bifidobacteria and non-enterococcal lactic acid bacteria (LAB) ". The bacterial sensitivity was 
tested for 9 antibiotics to which the European Food Safety Authority (EFSA) has indicated 
breakpoints (Guidance on the assessment of bacterial susceptibility to antimicrobials of human 
and veterinary Importance. EFSA Journal. 2012; 10(6):2740), reference values to assess the 
sensitivity / resistance of a microorganism to a given molecule having an antibiotic action. 
The document ISO 10932 (version 2010) indicates the scale of concentrations to be used for 
each antibiotic. It is based on a series of dilutions obtained by doubling each time the 
concentration and this concentration depends on the antibiotic in question. The stock solutions 
of antibiotics are diluted in sterile water and, for having in the microplate the same final 
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concentrations reported in the document ISO 10932, it is necessary to prepare dilute solutions 
at a double concentration; these solutions are in fact further diluted 1:1 (obtaining the desired 
final concentration) when the microplate is inoculated with the bacterial cultures. Bacterial 
inocula are prepared streaking on appropriate agar medium strains to be tested and diluting 
some of the colonies grown in liquid medium in order to reach the optical density value 
indicated in the above mentioned document. Finally, microplate was prepared. It has 96 wells 
arranged in 8 rows and 12 columns. All wells of the first column are inoculated with the 
medium inoculated with the strain to be tested (the medium inoculated with the strain 
represents the positive control). While all wells of the last column are filled with only the 
medium (the culture medium sterile without inoculum represents the negative control), the 
remaining wells are filled with the antibiotic to be tested at the concentration 2× previously 
prepared and inoculated with the bacterial strain under study. The microplate is arranged so 
that each row presents only one antibiotic, from its lower concentration to the higher one. 
The document ISO 10932 (version 2010) indicates also strains whose MICs values are known, so 
for this test I used as reference strains L. paracasei ATCC 334 and the B. longum DSM 20219. 
 
Results 
 
Identification of isolated strains 
A total of one hundred and fifty strains were isolated from healthy adults and infants. Each 
strain was identified by partial sequencing of 16S rDNA. Among lactobacilli from fecal samples 
were isolated especially L. plantarum, L. rhamnosus, L. paracasei and L. fermentum while in 
vaginal swabs  the species that predominate are L. crispatus, L. jensenii, L. mucosae, L. vaginalis, 
L. acidophilus and L. gasseri. Regarding bifidobacteria, the most incidence were B. bifidum, B. 
longum and B. animalis lactis while B. adolescentis, B. thermoacidophilum, B. breve and B. 
pseudocatenulatum were more rare. Species identification of isolated strains showed that, in 
some cases from the same patient, can be isolated two or more strains of the same species. 
 
To ensure that the strains isolate are different from each other and different from other strains 
already present on the market or in bacterial collections, it was made a rep-PCR, a rapid 
method for strain differentiation. When rep-PCR profiles of the studied bacteria had 100% 
identity by electrophoretic band number and weights, these strains were considered the same 
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bacterial strain, and vice versa, when rep-PCR produced products with different profiles of the 
bands, the isolated strains were considered as different strains that belong to the same 
Lactobacillus or Bifidobacterium species. 
The fig. 1, 2, 3, 4 show the rep-PCR profiles of different strains of L. paracasei (Fig. 1), L. 
plantarum, L. fermentum (Fig. 2), L. mucosae, L. rhamnosus (Fig. 3) and L . gasseri (Fig. 4). 
 
1         2       3      4      5       6      7      8       9     10     11     12    13    14     15    16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: rep-PCR profiles of L. paracasei strains 
obtained with primer (GTG) (in bold strains 
isolated in this study)  
1 Molecular weight marker 200 bp 
2 L. paracasei LMG S-27487 
3 L. paracasei CBA-L101 
4 L. paracasei CBA-L144 
5 L. paracasei CBA-L145 
6 L. paracasei ATCC 27216 
7 L. paracasei ATCC 334 
8 L. paracasei B21060 
9 L. paracasei TH0034 
10 L. paracasei DN114001 
11 L. paracasei F19 
12 L. paracasei ST11 
13 L. paracasei shirota 
14 L. paracasei CLV1 
15 L. paracasei CV1 
16 L. paracasei LAFTIL26 
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1 Molecular weight marker 200 bp 
2 L. plantarum CBA-L150 
3 L. plantarum CBA-L137 
4 L. plantarum CBA-L138 
5 L. plantarum LMG 6907 
6 L. plantarum LMG 21685 
7 L. plantarum 3319 
8 L. plantarum C21 
9 L. plantarum P1730 
10 L. plantarum F19 
11 L. plantarum 69 
12 L. plantarum P21021 
13 L. plantarum 299V 
14 L. plantarum LMG 17552 
15 L. fermentum CBA-L147 
16 L. fermentum CBA-L146 
17 L. fermentum DSM20052 
18 L. fermentum 1156 
 
Fig. 2: rep-PCR profiles of L. plantarum and L. 
fermentum  strains obtained with primer (GTG)5 (in 
bold strains isolated in this study) 
          1         2        3         4         5        6         7          8         9         10       11      12       13       14        15       16       17       18      
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Fig. 3: rep-PCR profiles of L. mucosae and L. 
rhamnosus strains obtained with primer (GTG)5 (in 
bold strains isolated in this study) 
1 Molecular weight marker 200 bp 
2 L. mucosae CBA-L149 
3 L. mucosae CBA-L148 
4 L. mucosae LMG 19534 
5 L. rhamnosus CBA-L140 
6 L. rhamnosus CBA-L142 
7 L. rhamnosus CBA-L92 
8 L. rhamnosus CBA-L143 
9 L. rhamnosus C48 
10 L. rhamnosus ATCC 10863 
11 L. rhamnosus DSM 20021 
12 L. rhamnosus 1123 
13 L. rhamnosus T12 
14 L. rhamnosus GR-1 
15 L. rhamnosus GG 
16 L. rhamnosus commercial strain 
17 L. rhamnosus ATCC 14957 
18 L. rhamnosus R011 
19 L. rhamnosus ATCC 53103 
20 L. rhamnosus 5/5 
 
    1         2        3        4        5        6        7        8        9       10      11      12      13      14      15      16      17      18     19      20 
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The Fig. 2 shows as the strains L. plantarum CBA-L150, L. plantarum CBA-L138 and L. plantarum 
299V seem to share the same profile. The same situation, as shown in Fig. 3, occurs for strains 
of L. rhamnosus (L. rhamnosus CBA-L140 and L. rhamnosus CBA-L143 seem to have the same 
profile, as well as L. rhamnosus CBA-L142 and L. rhamnosus CBA-L92). 
To ensure that these isolated are different strains it was set up a rep-PCR using the primers 
REP1R-Dt and REP2-Dt maintaining the same conditions described above. In Fig. 5 are shown 
Fig. 4: rep-PCR profiles of L. gasseri obtained with 
primer (GTG)5 (in bold the strain isolated in this 
study) 
1 Molecular weight marker 200 bp 
2 L. gasseri CBA-L72 
3 L. gasseri CNBL 1403 
4 L. gasseri DSM 20243 
5 L. gasseri DSM 20077 
6 L. gasseri DSM 20604 
7 L. gasseri ATCC 19992 
 
       1                2               3             4            5            6             7        
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the rep-PCR profiles of lactobacilli for which it was made this further amplification because they 
were difficult to distinguish. 
     1        2        3        4       5       6       7       8       
 
 
 
 
 
 
 
 
 
   
  
Fig. 5: rep-PCR profiles of L. plantarum and L. rhamnosus  
obtained with primers REP1R-Dt e REP2-Dt (in bold strains 
isolated in this study)  
1 Molecular weight marker 200 bp 
2 L. plantarum CBA-L150 
3 L. plantarum CBA-L138 
4 L. plantarum 299V 
5 L. rhamnosus CBA-L140 
6 L. rhamnosus CBA-L142 
7 L. rhamnosus CBA-L143 
8 L. rhamnosus CBA-L92 
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As shown in Fig. 5 the strains L. plantarum CBA-L150 and L. plantarum CBA-L138 have the same 
profile (the rep-PCR set using primers REP1R-Dt e REP2-Dt confirms the result of the 
amplification with primer (GTG)5), most likely it is the same strain of L. plantarum. The final PCR 
reaction instead confirms that strains of L. rhamnosus isolated are different, in fact, they have a 
different rep-PCR profile (Fig. 5). 
For all other lactobacilli isolated it has not been necessary repeat the rep-PCR because they 
were well discriminated and especially different from each other and from other strains of the 
same species already present on the market or in the bacterial collections (Fig. 1, 2, 3, 4 ). 
For identification of bifidobacteria we decided that rep-PCR using the BOXA1R primer was the 
best method because, as described by Masco et al., 2003, this primer has the highest 
discriminatory power. 
The Fig. 6 and 7 show rep-PCR profiles of strains of B. pseudocatenulatum, B. bifidum, B. 
thermoacidophilum, B. lactis (Fig. 6) and strains of B. breve, B. adolescentis, B. longum (Fig. 7). 
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1       2      3       4       5      6       7      8      9     10     11    12     13     14    15    16    17    18    19    20 
Fig. 6: rep-PCR profiles of B. pseudocatenulatum, B. 
bifidum, B. thermoacidophilum and B. lactis obtained 
with primer BOXA1R (in bold strains isolated in this 
study)  
1 Molecular weight marker 200 bp 
2 B. pseudocatenulatum CBA-B152 
3 B. pseudocatenulatum CBA-B149 
4 B. pseudocatenulatum LMG 10505 
5 B. bifidum CBA-B98 
6 B. bifidum CBA-B150 
7 B. bifidum CBA-B151 
8 B. bifidum LMG 11041 
9 B. bifidum commercial strain 
10 B. bifidum 1070 
11 B. thermoacidophilum CBA-B86 
12 B. thermoacidophilum CBA-B106 
13 B. thermoacidophilum CBA-B85 
14 B. thermoacidophilum CBA-B84 
15 B. lactis CBA-B122 
16 B. lactis CBA-B132 
17 B. lactis BL04 
18 B. lactis BB-12 
19 B. lactis W11 
20 B. lactis commercial strain 
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Fig. 7: rep-PCR profiles of B. breve, B. adolescentis, B. 
longum obtained with primer BOXA1R (in bold strains 
isolated in this study) 
1 Molecular weight marker 200 bp 
2 B. breve CBA-B104 
3 B. breve CBA-B171 
4 B. breve LMG 13208 
5 B. breve DSM 16604 
6 B. adolescentis CBA-B83 
7 B. adolescentis CBA-B81 
8 B. adolescentis 1146 
9 B. adolescentis DSM 20083 
10 B. longum CBA-B128 
11 B. longum CBA-B170 
12 B. longum LMG 13197 
13 B. longum LMG 21814 
14 B. longum DSM 20088 
15 B. longum W11 
16 B. longum DSM 16603 
17 B. longum BL 999 
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As shown in Fig. 6, B. pseudocatenulatum CBA-B152 and B. pseudocatenulatum CBA-B149 have 
the same rep-PCR profile, the same situation also occurs for strains CBA-B86, CBA-B106, CBA-
B84 of B. thermoacidophilum. Moreover B. lactis CBA-B122 and CBA-B132 have the same rep-
PCR profile and equal to that of the commercial strain B. lactis BL04. 
So it has been repeated rep-PCR amplification of B. lactis CBA-B122, CBA-B132 and B. lactis 
BL04 using the primer (GTG)5 (Figure 8). 
 
 
 
Fig. 8: rep-PCR profiles of B. lactis strains obtained with primer (GTG)5 (in bold strains isolated 
in this study) 
 
The latter figure shows that the commercial strain B. lactis BL04 is different from the two 
strains of B. lactis isolated in this work that, however, are resulted equal to each other even 
after this amplification reaction. 
 
Effects of bile salts on viability 
The effect of bile salts on the viability of selected Lactobacillus and Bifidobacterium is 
presented respectively in Table 1 and 2. Comparison of the ability of the strains to grow in 
liquid medium with and without bile salts revealed some variation among strains. 
1 Molecular weight marker 200 bp 
2 B. lactis CBA-B122 
3 B. lactis CBA-B132 
4 B. lactis BL04 
 
  1          2     3    4 
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Tables 1 and 2 show, for each bacterial strain, the OD values reached  in presence and absence 
of bile salts in the culture medium. Particularly, T0: represents the OD values obtained at time 
zero, T16 is the OD carried out after 16 hours of incubation of the culture medium inoculated at 
37°C and T24 is the OD value after 24 hours incubation of the same culture medium inoculated 
at 37°C. 
  T0 T16 T24 
  MRS MRS + Bile salts MRS MRS + Bile salts MRS MRS + Bile salts 
L. paracasei LMG S-27487  0,089 0,107 1,808 1,089 1,376 1,282 
L. paracasei CBA-L101  0,068 0,081 1,232 0,497 1,703 0,740 
L. paracasei CBA-L145 0,087 0,101 1,897 0,995 1,969 1,186 
L. paracasei CBA-L144 0,058 0,054 2,012 0,961 2,096 1,086 
L. plantarum CBA-L137 0,094 0,108 1,955 1,119 2,035 1,395 
L. plantarum CBA-L138  0,100 0,118 2,014 1,550 2,095 1,641 
L. plantarum CBA-L150 0,072 0,070 2,045 1,787 2,108 1,840 
L. rhamnosus CBA-L92  0,091 0,109 1,867 0,800 1,952 1,233 
L. rhamnosus CBA-L142 0,101 0,116 2,050 1,386 2,124 1,522 
L. rhamnosus CBA-L143 0,041 0,042 1,836 0,778 1,855 0,874 
L. rhamnosus CBA-L140  0,097 0,113 1,918 1,051 1,962 1,121 
L. acidophilus CBA-L63 0,076 0,091 1,664 1,330 1,695 1,620 
L. rhamnosus GG 0,108 0,102 2,064 1,332 2,139 1,629 
L. gasseri CBA-L72  0,034 0,029 1,835 0,972 1,875 1,129 
L. gasseri CBA-L100  0,026 0,023 1,715 0,215 1,760 0,186 
L. crispatus CBA-L154 0,021 0,022 1,129 0,070 1,525 0,075 
L. crispatus CBA-L157 0,031 0,028 1,180 0,122 1,514 0,126 
L. crispatus CBA-L158 0,028 0,021 1,061 0,267 1,472 0,271 
L. jensenii CBA-L160 0,034 0,024 1,976 0,074 2,069 0,051 
L. fermentum CBA-L146 0,027 0,028 2,046 1,622 2,011 1,713 
L. fermentum CBA-L147 0,048 0,050 1,951 1,682 1,957 1,768 
L. mucosae CBA-L148 0,013 0,010 1,117 1,342 1,539 1,282 
L. mucosae CBA-L149 0,015 0,008 1,191 0,909 1,457 0,931 
L. vaginalis CBA-L88  0,014 0,037 1,427 1,185 1,595 1,247 
 
Table 1: ability of the lactobacilli to grow in the presence of bile salts evaluated by mean of OD 
measurements  
 
As shown in Table 1, strains L. gasseri CBA-L100, L. crispatus CBA-L154, L. crispatus CBA-L157, L. 
crispatus CBA-L158 and L. jensenii CBA-L160 are not able to grow in presence of bile salts; in 
fact the value of optical density of the culture medium inoculated and containing the salts of 
bile after 24 hours of incubation at 37°C appears to be not significantly different from that read 
at time zero, testimony of a non-bacterial growth. Potentially a strain could survive to the bile 
salts even if it is not able to grow and therefore, in this case, the optical density would still 
remain unchanged. For this reason, for the bacterial strains for which the optical density is not 
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changed it was determined bacterial viability and I have shown that the latter was decreased 
despite the optical density has remained the same. 
The other lactobacilli showed however a capacity of growth in the presence of bile salts, this 
means that 0,3% of bile salts exerted only a small inhibitory effect on these strains and that 
these strains studied showed relatively a good resistance to bile salts. L. acidophilus CBA-L63 is 
the most resistant strain with about the same OD values in presence and absence of bile salts. 
Given the fact that the growth of bifidobacteria is more slow, for them, the absorbance was 
also measured after 48 and 72 hours of incubation of culture medium inoculated at 37°C in 
anaerobic conditions. 
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  T0 T16 T24 T48 T72 
  
MRS 
CYS 
MRS CYS + Bile salts MRS CYS MRS CYS + Bile salts MRS CYS MRS CYS + Bile salts MRS CYS 
MRS CYS + Bile 
salts 
MRS CYS 
MRS CYS + Bile 
salts 
B. longum CBA-B170 0,017 0,021 0,022 0,029 0,021 0,025 0,016 0,619 0,655 0,621 
B. bifidum CBA-B151 0,041 0,033 0,040 0,032 0,045 0,006 0,056 0,101 1,535 0,272 
B. thermoacidophilum CBA-B85 0,075 0,085 1,662 0,197 1,972 0,211 2,100 0,263     
B. thermoacidophilum CBA-B86 0,024 0,028 0,025 0,033 1,544 0,078 2,029 0,545     
B. thermoacidophilum CBA-B106 0,008 0,000 0,017 0,002 0,025 0,059 1,829 0,076     
B. breve CBA-B104 0,022 0,028 0,070 0,044 0,133 0,044 0,959 0,050 1,335 0,061 
B. breve CBA-B171 0,014 0,011 0,014 0,014 0,120 0,130 1,463 0,296 1,402 0,377 
B. lactis CBA-B122 0,030 0,007 0,083 0,040 0,110 0,126 1,274 0,280 1,492 0,267 
B. lactis CBA-B132 0,024 0,035 0,072 0,101 0,065 0,118 0,491 0,499 1,467 0,537 
 
Table 2: ability of bifidobacteria to grow in the presence of bile salts 
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Table 2 shows that all bifidobacteria tested have a poor ability to grow in the presence of bile 
salts; in fact the value of optical density of the culture medium inoculated and containing bile 
salts even after 72 hours of incubation at 37°C appears to be not significantly different from 
that read at time zero (OD always less than one), evidence of a poor bacterial growth. In the 
case of the strains of B. thermoacidophilum we have not been carried out the reading of the 
optical density at T72 hours because they are able to reach the "peak" of growth already after 
48 hours of incubation. 
 
Effects of gastric acidity on viability 
Preliminary experiments were conducted to determine the degree of acid resistance exhibited 
by Lactobacillus and Bifidobacterium strains isolated because the ability of the strains to survive 
in the presence of pepsin is an accurate indicator of the ability of the strains to survive in the 
stomach. The results were compared with the resistance of L. rhamnosus GG, strain resistant to 
the acidity (data presented in the section “supplementary material”). Analysis of the results 
showed that many of the lactobacilli isolated had a good degree of resistance to acidity and this 
suggest the possibility of using these strains as probiotics because they are able to pass through 
the stomach and reach the intestine to exert their beneficial effects. Bifidobacteria, however, 
were less acid resistance than lactobacilli especially if put in contact for a long time with the 
solution of pepsin. 
 
Antibiotic Susceptibility Testing 
Micro-dilution method was used to assess the susceptibility of the LAB strains isolated to 9 
antibiotics, ampicillin (Sigma-Aldrich, Germany), vancomycin (Sigma-Aldrich, Germany), 
streptomycin (Sigma-Aldrich, Germany), gentamicin (Sigma-Aldrich, Germany), kanamycin 
(Sigma-Aldrich, Germany), erythromycin (Sigma-Aldrich, Germany), clindamycin (Sigma-Aldrich, 
Germany), tetracycline (Sigma-Aldrich, Germany)  and chloramphenicol (Sigma-Aldrich, 
Germany). The MIC values obtained are presented in Tables 3 (lactobacilli) and 4 
(bifidobacteria). The strains were classified as resistant or sensitive to a specific antibiotic 
according to the cut-off values proposed by EFSA and listed in Tables 3 and 4. 
 51 
 
 
 
 
Table 3: MIC distributions for 9 antibiotics 
of lactobacilli isolates (in bold cut-off 
values defined by EFSA, 2012 for 
lactobacilli) 
AMP = ampicillin, VAN = vancomycin, GEN 
= gentamicin, KAN = kanamycin, STR = 
streptomycin, ERY = erythromycin, CLI = 
clindamycin, TET = tetracycline, CHL = 
chloramphenicol
  AMP VAN GEN KAN STR ERY CLI TET CHL 
L. paracasei LMG S-27487  2   16 128 64 0,25 0,25 1 4 
L. paracasei CBA-L101  0,5   <4 <8 16 <0,25 1 <2 8 
L. paracasei CBA-L145 8   8 128 32 0,25 0,25 2 4 
L. paracasei CBA-L144 4   8 64 32 0,5 0,125 1 8 
B.P. EFSA (L. casei/paracasei) 4 n.r. 32 64 64 1 1 4 4 
  AMP VAN GEN KAN STR ERY CLI TET CHL 
L. reuteri CBA-L167 16   4 128 32 0,5 0,064 >64 64 
L. reuteri CBA-L168 4   2 64 32 >8 >16 >64 >64 
B.P. EFSA (L. reuteri) 2 n.r. 8 64 64 1 1 16 4 
  AMP VAN GEN KAN STR ERY CLI TET CHL 
L. plantarum CBA-L137  1   1 16 8 0,25 0,032 16 2 
L. plantarum CBA-L138  1   1 32 8 0,5 0,064 8 4 
L. plantarum CBA-L150 1   2 32 16 1 0,25 32 4 
B.P. EFSA (L. plantarum/pentosus) 2 n.r. 16 64 n.r. 1 2 32 8 
  AMP VAN GEN KAN STR ERY CLI TET CHL 
L. rhamnosus CBA-L92  <0,5   8 64 16 <0,25 0,5 <2 2 
L. rhamnosus CBA-L142 4   8 64 16 0,25 0,5 2 8 
L. rhamnosus CBA-L140 4   16 128 32 0,5 0,5 1 8 
L. rhamnosus CBA-L143 2   2 64 4 0,5 0,5 2 8 
B.P. EFSA (L. rhamnosus) 4 n.r. 16 64 32 1 1 8 4 
  AMP VAN GEN KAN STR ERY CLI TET CHL 
L. acidophilus CBA-L63 <0,5 <0,5 <4 <8 16 <0,25 1 <2 2 
L. gasseri CBA-L72 <0,5 1 4 16 8 <0,25 4 4 8 
L. gasseri CBA-L100  <0,5 1 8 128 32 <0,25 4 4 4 
L. crispatus CBA-L154 4 1 4 64 2 0,125 0,032 1 2 
L. crispatus CBA-L155 8 1 16 128 32 0,25 0,032 1 4 
L. crispatus CBA-L156 4 1 16 256 16 0,125 0,25 1 2 
L. crispatus CBA-L157 8 1 16 128 16 0,125 0,032 1 2 
L. crispatus CBA-L158 8 1 8 32 16 0,125 0,032 1 2 
L. crispatus CBA-L159 8 1 32 256 16 0,25 0,064 1 2 
L. jensenii CBA-L160 0,5 2 4 16 2 0,125 0,25 1 1 
L. amylovorus CBA-L164 4 >128 16 128 32 0,5 0,5 1 8 
B.P. EFSA (L. acidophilus group) 1 2 16 64 16 1 1 4 4 
  AMP VAN GEN KAN STR ERY CLI TET CHL 
L. fermentum CBA-L90 1   8 >128 128 <0,25 4 32 8 
L. fermentum CBA-L146 2   1 32 16 0,25 0,032 4 4 
L. fermentum CBA-L147 2   2 64 32 1 0,032 4 4 
L. fermentum CBA-L163 2   2 32 32 0,5 0,032 8 8 
L. fermentum CBA-L161 1   32 128 64 0,5 0,064 4 16 
L. fermentum CBA-L162 2   4 128 64 0,5 0,032 4 4 
L. mucosae CBA-L148 1   1 4 16 0,125 0,032 4 8 
L. mucosae CBA-L149 1   2 16 16 0,25 0,032 16 8 
L. vaginalis CBA-L88 <0,5   <4 16 64 <0,25 <0,25 >32 2 
B.P. EFSA (Lactobacillus obligate 
heterofermentative) 
2 n.r. 16 32 64 1 1 8 4 
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Table 4: MIC distributions for 9 antibiotics of bifidobacteria isolates (in bold cut-off values defined by EFSA, 2012 for bifidobacteria) 
 
 
 
 
 
  AMP VAN GEN KAN STR ERY CLI TET CHL 
B. pseudocatenulatum CBA-B149 0,125 0,5 128 512 128 0,25 0,064 1 2 
B. bifidum CBA-B150 0,25 0,5 16 64 4 0,125 0,032 0,25 1 
B. lactis CBA-B122 0,5 0,5 256 1024 128 0,25 0,064 16 2 
B. pseudocatenulatum CBA-B152 0,125 0,5 64 256 64 0,25 0,064 1 2 
B. adolescentis CBA-B81 0,5 0,5 128 512 128 0,125 0,032 0,5 4 
B bifidum CBA-B98 0,25 0,5 64 64 >256 0,125 0,125 0,5 1 
B. lactis CBA-B132 0,5 0,5 >256 1024 256 0,25 0,064 16 2 
B. bifidum CBA-B151 0,125 0,5 64 256 16 0,125 0,125 0,5 1 
B. breve CBA-B104 2 1 64 512 32 0,25 0,032 0,5 2 
B. adolescentis CBA-B83 0,5 0,5 128 512 32 0,125 0,032 1 1 
B. breve CBA-B171 1 0,5 32 128 >256 0,125 0,032 2 0,5 
B. longum CBA-B170 2 1 64 1024 >256 0,25 0,064 16 1 
B. thermoacidophilum CBA-B84 0,125 0,5 16 64 32 0,125 0,125 64 2 
B. longum CBA-B128 1 0,5 16 16 32 0,125 0,032 0,5 0,5 
B. thermoacidophilum CBA-B86 0,25 0,5 64 256 32 0,125 0,125 64 2 
B. thermoacidophilum CBA-B106 0,25 0,5 16 512 16 0,125 0,064 32 2 
B. thermoacidophilum CBA-B85 0,064 0,5 16 64 16 0,125 0,032 32 2 
B.P. EFSA (Bifidobacterium) 2 2 64 n.r. 128 1 1 8 4 
 53 
 
All of the lactobacilli isolates were found to be susceptible to erythromycin, except L. reuteri 
CBA-L168 that had a very high value of MIC for this antibiotic. Another antibiotic to which all 
lactobacilli isolates were sensitive is gentamicin: only two strains in fact have, for this antibiotic, 
a MIC twice the breakpoint. High level of resistance to ampicillin were observed among L. 
reuteri and lactobacilli that belong to the L. acidophilus group, while almost half of lactobacilli 
isolates tend to be resistant to kanamycin. Another antibiotic to which about 50% of lactobacilli 
were resulted resistant is chloramphenicol, with the exclusion of bacteria of the L. acidophilus 
group for which the incidence of resistance is low and the strains of L. plantarum that were 
resulted sensitive to chloramphenicol. Low levels of resistance to streptomycin, clindamycin 
and tetracycline were observed among all lactobacilli (12,1% for streptomycin and clindamycin 
and 15,2% for tetracycline). 
Among bifidobacteria, the antibiotic resistance to tetracycline is resulted very common and 
affects 41.2% of the isolates. Other antibiotics for which occurred resistances are gentamicin 
and streptomycin, affecting respectively 29.4% and 23.5% of isolates. All bifidobacteria isolates 
were found to be sensitive to ampicillin, vancomycin, kanamycin, erythromycin, clindamycin 
and chloramphenicol. 
 
Conclusions 
In the last few years interest in the physiology and genetics of LAB species has increased 
greatly, and this is mainly due to the fact that these bacteria are increasingly used as starters 
and they are a key in the market of probiotics. LAB possess a lot of desirable properties and this 
represents an important value in the production of fermented products and food supplements. 
However, the beneficial effects of probiotics must be demonstrated primarily through in vitro 
tests; in this work we have done a careful screening of LAB taking into consideration some 
criteria generally used to select and assess potential gut probiotic bacteria. More precisely, we 
focused our attention on the topic of safety of the bacterial strain, a fundamental requirement 
for use in humans and on the ability of the strains to live in conditions similar to those of the 
human gastrointestinal tract that is in the presence of low values of pH and bile salts. The 
criteria used in our study to identify and characterize new potential gut probiotic bacteria 
resulted in the identification of a small number of lactobacilli and bifidobacteria that do not 
show antibiotic resistance and that are capable of resisting the effects of bile and low pH in 
vitro. 
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So, in this study we showed that the adoption of these criteria for in vitro selection of gut 
probiotic bacteria allows the isolation of strains that are certainly safe for use in humans and 
potentially capable to exert their effect in the gastrointestinal tract through the introduction of 
these probiotic strains in food supplements. 
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Ice-cream is generally considered as a nutritive food, representing an interesting vehicle for 
delivering beneficial microorganisms to consumers. Many ice-cream makers use industrial dry 
bases for its preparation. The aim of this study was to investigate the possibility of producing 
spray-dried probiotic formulations to be used together with commercial ice-cream bases. 
A commercial cream base was selected for the study and, according to its composition and 
literature, two different formulations were investigated. Formulation A (FA) consisted in 46 % 
commercial skim milk powder, 24 % anhydrous glucose, 28 % maltodextrin (Maltrin® 40) and 2 
% sodium alginate. Formulation B (FB) contained prebiotic inulin fiber (Fibruline® instant) 
instead of Maltrin®. Powders were obtained with a lab-scale spray dryer dissolving each 
formulation in water at a 10 % w/v, with a 6 mL/min flow rate, 150 °C inlet temperature and 
increasing feed volume (100, 200, 300, 400 mL). The process gave a total dry solids yield 
ranging from 62.07 % (with 100 mL feed volume) to 58.14 % (with 400 ml) for FA, and from 
65.55 % to 59.46 % for FB. Powder aw was always < 0.3.  
The formulations were used for encapsulation of a strain of Lactobacillus paracasei.  
Considering a recommended probiotics minimum daily intake of 10
9
 CFU, a 100 g ice-cream 
serving , a 5 % substitution of the commercial base with the probiotic-enriched base and 
supposing no vital loss during the process, the cellular feed concentration for the spray-drying 
trials was calculated. However, in the presence of probiotics, FA could not be spray dried, while 
probiotic-FB was obtained with a 50.89 % yield, 0.42 aw and 82  % cell mortality. Ice-cream was 
finally prepared in a domestic ice-cream maker using the probiotic-enriched FB after the 
pasteurization step and before the 12 h maturation step which caused limited additional 
mortality. 
Introduction 
Dairy products with incorporated probiotic bacteria are gaining popularity and the probiotics 
comprise approximately 65 % of the world functional food market (Akalin and Erişir, 2008). 
Although the application of probiotics in cheeses and especially in fermented milks has been 
widely explored in the literature, ice-cream is a relatively innovative and apparently suitable 
matrix for delivering probiotics in human diet because of its pleasant taste and attractive 
texture. Furthermore, ice-cream is highly accepted product by children, adolescents, and 
adults, as well as by the elderly public and even though it is more consumed in the summer due 
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to its rather refreshing features, some people have the habit of consuming it throughout the 
year (Cruz et al., 2009). 
Probiotics are live microorganisms that, if administered in adequate amounts, confer health 
benefits on the host. Therefore, probiotic food can be considered as functional food containing 
viable probiotic microorganisms which must be able to survive in the gastrointestinal tract. 
International guide lines, such as the Italian Health Ministry Guide lines on probiotics and 
prebiotics (2013), indicate a recommended daily intake of 10
9
 vital cells (as colony forming 
units, CFU), even though the exact dosage depends on the selected probiotic, probiotic blend 
and desired clinical outcome.  
Many “hand-made” ice-cream makers use industrial dry bases for product preparation. The aim 
of this study was, then, to investigate the possibility of producing dried probiotic formulations 
to be easily used together with commercial ice-cream bases.  
Encapsulation  is the envelopment of small solid particles, liquid droplets or gases in a coating. 
It can be successfully applied to entrap natural compounds, like essential oils or vegetal extracts 
containing antioxidant polyphenols (Spigno et al., 2013) or pigments (De Marco et al., 2013). 
Microencapsulation (final particle size 1–1000 mm) can also be used to preserve lactic acid 
bacteria, both starters and probiotics, in food and during the passage through the 
gastrointestinal tract, contributing to the development of new functional foods (Nazzaro et al., 
2012). Probiotic cell concentrates often need to be stored over longer periods prior to food 
manufacture and ingestion, therefore sometimes they are dried after production. The most 
common procedure is to produce hydrogel-based microcapsules by extrusion or emulsification 
processes and, then, freeze dry them. An alternative method to achieve capsule-building and 
drying in a single step is spray-drying, which is a routine process in the food industry to convert 
liquids (Heidebach et al., 2012), including also particulate fluids (Oi et al., 2013), into dry 
powders. A variety of materials can be used as carrier for probiotics encapsulation, such as 
arabic gum, alginates, maltodextrins, pectins, milk proteins, starch and chitosan among the 
others. In particular, reconstituted skim milk (RSM) has shown a positive effect on the cellular 
survival after spray-drying in combination with prebiotics, such as inulin (Fritzen-Freire et al., 
2012). Also glucose addition has reduced spray-drying mortality of probiotics (Ying et al., 2012). 
Considering the above reviewed literature and having in mind a concept of tailor made 
encapsulation process, according to which the encapsulating materials should be selected 
based on the composition of the target food application, this work investigated the possibility 
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of encapsulating probiotic cultures in a formulation with a composition the closest possible to 
that of the ice-cream base. First, the influence of the use of maltodextrins rather than inulin in 
combination with RSM, glucose and alginate, and of the feeding volume on the process solids 
yield and final powder water activity was evaluated.  Then, the two tested formulations (with 
maltodextrins or inulin) were applied for probiotics encapsulation to assess process feasibility 
and cellular survival. Finally, spray-dried cultures were employed for ice-cream preparation. 
Materials and Methods 
Preparation of modified ice-cream base formulations 
A commercial base for full cream ice-cream preparation (Base Tuttapanna 100, Pernigotti, Italy) 
was used as reference encapsulating material and for ice-cream preparation. Base ingredients, 
in decreasing order, are: powder skim milk, powder full cream, dextrose, emulsifiers (E472, 
E471, E473), anhydrous glucose syrup, maltodextrins, concentrated milk proteins, stabilizers 
(E401, E410, E412), vanillin, natural flavour. 
The commercial base and two different formulations were tested for spray-drying: 
Formulation A (FA): 46 % commercial skim milk powder (Regilait), 24 % anhydrous 
glucose (Carlo Erba, Italy), 28 % maltodextrin (Maltrin® 40, Grain Processing Corporation 
GPC, kindly supplied by LEHVOSS Italia S.R.L.) and 2 % sodium alginate (Carlo Erba, Italy).  
Formulation B (FB): as FA but with 28 % of  prebiotic inulin fiber (Fibruline® instant, 
kindly provided by COSUCRA, VICTA Food & Trade, Italy) instead of Maltrin®.  
All the used materials were characterised for moisture content (by drying at 105 °C until 
constant weight). 
Powders were obtained with a lab-scale spray dryer (Büchi Mini Spray dryer B-290) dissolving 
each formulation at a 10 % w/v in water, with a 6 mL/min flow rate, 150 °C inlet temperature 
and increasing feed volume (100, 200, 300, 400 mL). Trials were carried out in triplicate. For 
each test, outlet temperature was recorded and the collected powder was weighted and 
analysed for moisture content (by drying at 105 °C until constant weight) and aw (AquaLab Dew 
Point Water Activity Meter 4TE).  
The total percent dry solids yield was calculated as the ratio of outlet dry matter to the inlet dry 
matter content. 
62 
 
Preparation of probiotics enriched formulations 
For the preparation of the probiotic functionalised ice-cream the commercial base was 
substituted with a 5 % of a modified base (as FA or FB) enriched with probiotics (Figure 1). The 
required cellular concentration for the solutions to be spray-dried was calculated based on the 
following data or hypotheses: 
No vitality loss occurs during spray-drying; 
A final ice-cream with a 10
8
 CFU/g is desired so that a 100 g serving would guarantee the 
recommended minimum 10
9
 CFU daily intake; 
The ice-cream yield is 1350 g / 100 g of base (as evaluated in preliminary trials); 
Spray–drying feeding solution  has a 10 % w/v solids of formulation ingredients. 
Considering the process yields obtained with FA and FB and the required powder amounts for 
analysis and ice-cream preparation, it was established to spray-dry 600 mL of solution (Figure 
1). Trials were carried out in duplicate and process evaluated as reported in section 2.1.  
Probiotic strain Lactobacillus paracasei LMG S-27487  was cultured  in broth of De Man, Rogosa 
& Sharp (MRS) medium (Difco, US) at 37 °C in microaerophilic conditions for 18 h. A 
concentrated culture pellet from 1500 mL MRS was harvested by centrifugation at 8.000 rpm 
for 15 min, washed twice with sterile distilled saline and finally resuspended in 200 mL of water 
containing the base. The CFU concentration was evaluated and the suspension was stored at 4 
°C until being diluted to 600 mL for spray-drying. 
Viable probiotic cells in the suspension and powder were enumerated by decimal dilutions into 
maximum recovery diluent (MRD) (Difco, US) and plated onto agar MRS medium. Plates were 
anaerobically incubated at 37 °C for 72 h. The number of colonies for two parallel plates was 
counted from a dilution yielding 30 to 300 CFU/plate and the average was recorded. 
Ice-cream preparation 
Ice-cream was prepared with a domestic ice-cream maker (Il Gelataio ICK 5000, De Longhi, 
Italy), according to the process of Figure 1. Commercial fresh whole milk and sugars were used. 
The commercial base has to be used with a “warm process”, which means that it has to be 
mixed with the other ingredients and pasteurized. Literature (BahramParvar et al., 2012) 
indicates a flash treatment at 80 °C for 25 sec, followed by high pressure homogenization and 
maturation at 4 °C for a few hours. The process had to be adapted to laboratory facilities. Milk 
was pre-heated to 40-45 °C in in a water bath set at 90 °C. Sugar was added and mixed with a 
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domestic beater (Ariete, Mixy210, 210 W). The mixture was left in the water bath until reaching 
a 80 °C temperature for 25 sec, rapidly cooled in water-ice bath until 10-12 °C and kept at 4 °C 
overnight (12 h). The final mixture was used for ice-cream making with a 30 min 
beating/freezing time, after which it was frozen, stored for 2 days at -18 °C and then analysed 
for CFU count as reported in section 2.2. 
 
 
Figure 1: Process scheme for the preparation of probiotics enriched ice-cream. 
Statistics 
The values are reported as means ± SD, except for  aw which was measured on one sample for 
each spray-drying trial set. IBM SPSS® 20.0 (SPSS, Chicago, IL, USA) software for Windows was 
used to perform statistical analysis of variance (ANOVA) followed by Tukey’s post hoc test (for 
means discrimination) to assess the significance of variation among the different spray-drying 
trials. Variance homogeneity was confirmed according to Levene’s test. All significance tests 
were conducted at P≤0.01. 
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Results and Discussion 
Preparation of modified ice-cream base formulations 
The idea behind this research is the development of encapsulation formulations for delivery of 
functional ingredients, such as probiotics, into food matrixes using materials that are already 
components of the final product. A commercial base for full cream ice-cream was selected for 
the study, since a milk-based ice-cream could represent a nutritional complete lunch substitute.  
Direct spray-drying of the base, even at an inlet concentration below 10 % w/v, was not 
possible since no powder could be recovered, probably due to the excessive content of 
emulsifiers and stabilizers. It was then decided to select only some of the base components 
taking into account the literature about probiotics encapsulation, as reported in section 1. The 
specific types of maltodextrins and inulin (Maltrin® 40 and Fibruline®) were suggested by the 
relative suppliers as the most suitable for ice-cream application. The spray-drying results are 
reported in Table 1. 
 Table 1: Results of spray-drying trials. The values followed by different superscript letters in the 
same column were statistically different according to ANOVA and Tukey’s post-hoc test. FA: 
formulation with Maltrin® 40; FB: formulation with Fibruline®; FBP: FB with probiotics. 
Feed volume 
(mL) Formulation Total Solids Yield (%) 
Powder Dry matter 
(%) aw Toutlet 
100  FA 62.07 ± 4.42a 96.23 ± 0.21a 0.2774 65.00 ± 1.73ab 
200 FA 59.92 ± 2.43ab 95.97 ± 0.07a 0.2509 64.50 ± 1.50ab 
300 FA 60.80 ± 0.34a 96.38 ± 0.54a 0.2413 65.67 ± 0.58a 
400 FA 58.14 ± 0.46ab 94.34 ± 0.13b 0.2744 65.50 ± 1.50a 
100  FB 65.55 ± 5.71a 96.12 ± 0.14a 0.2609 62.00 ± 0.00b 
200  FB 60.16 ± 2.14ab 96.22 ± 0.27a 0.2482 67.50 ± 0.50a 
300  FB 59.15 ± 1.11ab 96.04 ± 0.13a 0.2425 65.50 ± 0.50a 
400 FB 59.46 ± 0.42ab 93.56 ± 0.27b 0.2952 64.50 ± 0.50ab 
600 FBP 50.89 ± 1.60b 88.72 ± 0.63c 0.4230 61.80 ± 1.50b 
 
Experimental data showed the possibility of obtaining spray-dried powders from both the 
investigated formulations. The carrier composition did not substantially influence the total 
solids yield, while a slight decrease with increasing feed volume was observed. This is due to a 
progressive fouling of the equipment atomizer, which will of course limit the operation time of 
an hypothetic industrial scale process. The yield values are in the range of literature results, 
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even though higher yields are reported for different process conditions and carrier composition 
(Fontes et al., 2014). Outlet temperature was almost the same in all the trials and below 70 °C. 
Residual moisture was not influenced by the formulation, but it was statistically lower when 
400 mL were spray-dried. Water activity of all the samples was below 0.3, which is very positive 
for powder stability since it represents less free water available for biochemical reactions and 
hence longer shelf-life (Fritzen-Freire et al., 2012).  
Visually the two modified bases were similar but slightly different than the original base which 
is more yellow and fine (Figure 2). The latter difference can be easily overcome with a milling 
step, while the colour depends on the composition (the original base contains full cream and 
concentrated milk proteins).  
Both the formulations were then tested for probiotics incorporation. 
Preparation of probiotics enriched formulations 
The microorganism used in this study is a strain of L. paracasei, a species widely employed for 
probiotic aims in the market of the nutritional integrators. The strain was isolated by AAT from 
faeces of healthy child and studied for both the safety of use in humans and for its probiotic in 
vitro and in vivo efficiency. In particular, according to the EFSA guidance (2012), the strain was 
tested for antibiotics sensitivity showing to be sensible to the 8 antibiotics indicated by EFSA, 
which assures its safety for human consumption. Furthermore, the strain revealed to be able to 
survive after the transit through the gastro-intestinal barrier, and to stimulate dendritic cells 
(which represents an anti-inflammatory profile). 
 
 
Figure 2: Original commercial ice-cream base (on the left); modified base with formulation A (in 
the middle); modified base with formulation B (on the right).  
Interestingly, when FA was used, no powder could be collected, indicating interactions between 
the microbial cells and Maltrin® 40. This might be due to the type of maltodextrin, to the 
66 
 
microorganism species or to the specific encapsulating material composition, since other 
authors have succeeded in  spray-drying probiotic cultures with maltodextrins. Ying et al. (2012) 
encapsulated L. rhamnosus GG using whey protein isolates, inulin, glucose and our same 
Maltrin® 40. Sohail et al. (2012) spray-dried L. rhamnosus GG in co-culture with L. acidophilus 
NCFM using sodium alginate and maltodextrin (Fieldose 10C). Even though maltodextrins have 
been used as a carrier material in many studies, they have a potency to penetrate the cell 
membrane which is largely dependent on their molecular weight (Semyonov et al., 2010). 
The total solids yield in the presence of probiotics was lower (Table 1). This might have been 
caused by the higher volume of feed solution, and by a slightly higher inlet solid concentration 
due to the pellet contribution. More probably, other components of the pellet, such as cell wall 
polysaccharides, may have increased stickiness of the powder during the process.  The most 
negative result was the higher moisture content of the powder, and the water activity above 
0.4 which can seriously compromise powder stability and cell vitality during storage. 
Compared to the required cell concentration in the feed (Figure 1), the actual measured value 
was slightly higher (5.7∙10
9
 CFU/mL). Considering the actual feed load, supposing that the 
product lost in the plant has the same composition of the recovered product  and assuming no 
vitality loss during the process, a  theoretical value of 5.2⋅10
10
 CFU/g in the final powder was 
calculated, The measured value was 9.5⋅10
9
 CFU/g revealing a 82 % viability reduction during 
drying.  The result is in agreement with literature, where Sohail et al. (2012) reported cell death 
ranging from 73 to 92 %.  Even though spray drying is a well-established process characterized 
by high production rates and relatively low operational costs, the typical high working 
temperature can cause cell death due to simultaneous dehydration and thermal inactivation. 
The drying temperature of this study (150 °C) was selected based on  literature works on spray-
drying microencapsulation of probiotics (De Castro et al., 2012; Fritzen-Freire et al., 2012). 
Lower temperature have also been used, such as 140 °C by Malmo et al. (2012) for L. reuteri, or 
120 °C by Sohail et al. (2012) for L. rhamnosus and L. acidophilus, and could be tested to 
improve process survival.  
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Ice-cream preparation 
Ice-cream was prepared substituting only a 5 % of the commercial base with the modified base 
(formulation B enriched with probiotics). This low substitution level should reduce the influence 
of base modification on technological performances of final product (such as color, melting 
rate, overrun and melting destabilization) but, especially, it allows the addition of the probiotic 
ingredient after the pasteurization. Considering the dosages reported in Figure 1, the probiotic 
concentration in the ice-cream mixture before beating and freezing was calculated in 3.5∙10
7
 
CFU/g. The viable cells enumeration of the matured mix after 3 days storage at 4 °C gave 
4.3∙10
7
 CFU/ml, corresponding to 3.79 ∙10
7
 CFU/g (taking into account the mixture density of 
1.135 g/ml). This shows that the encapsulated cells remained vital after rehydration. Analysis of 
the final ice-cream after 2 days storage at -18 °C, gave  3.1∙10
7
 CFU/g count corresponding to a 
limited additional 18 % mortality of. Stability during longer storage period has, anyway, to be 
further evaluated. 
Conclusions 
This study showed the possibility of producing spray-drying carrier materials suitable for 
functionalization of commercial ice-cream bases, since containing the same bases ingredients. 
Two formulations were developed, one with maltodextrins, widely used in the food industry 
and spray-drying processes, and one with inulin, a prebiotic fibre with both beneficial effects 
for humans and probiotics preservation. Process yield (58-66 %) and powder aw (< 0.3) were not 
influenced by the formulation type. However, the maltodextrins formulation could not be used 
for probiotics encapsulation (null process yield), while inulin formulation gave a lower yield (51 
%) and higher aw (> 0.4). A 82 % death cell occurred during drying, but the cells survived in the 
ice-cream making process. The results represent an important starting point for the 
development of encapsulated multiple bioactive ingredients containing probiotics, prebiotics 
and other functional compounds such as polyphenols. 
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The regulatory pressure introduced in recent years in Europe led to a practical limitation of the 
communication of beneficial effects of probiotics to consumers and a theoretical detrimental 
impact on probiotic market. Almost nine years after the enter into force of the Regulation (EU) 
1924/2006 on health claims made on food the market of probiotics looks still viable and 
dynamic since the big pool of information sorting out from the omics approach to the study of 
the microbiota is producing a renewed interest about the health improving potential of 
beneficial microbes. Legislative framework seems to be not ready to cope with the innovation 
associated to the development of new analytical approaches. In fact of the about 300 requests 
of health claims presented to EFSA concerning the food area none has been accepted, except 
that referred to the use of yoghurt for lactose intolerance (Papadimitriou et al. 2015). The 
development of new and exhaustive models, taking advantage of the newest omics technology 
will contribute to the understanding of the mechanism of action of probiotics and the 
assessment of a cause-effect relationship between the administration of probiotics and a 
quantifiable beneficial impact on health. 
Traditional in-vitro and ex-vivo screening methods of new probiotic candidates are now 
coupled with omics techniques in order to speed up the selection process, to better understand 
mechanisms underlying their functionality and to explore the opportunity to use cell fractions 
instead that viable probiotics in finished products. 
 
The widely accepted approach to the selection of probiotics includes first the assessment of the 
absence of pathological and virulence traits in order to assure the safe use for human 
consumption, and then the evaluation of the functionality of the strain in terms of prophylactic, 
therapeutic or as a reduction of the risk to develop a certain condition. The significance of this 
validation results directly proportional to the availability of measurable biomarkers associated 
to a certain health or disease condition.  
 
Conventional in-vitro approaches to the selection of new probiotics 
Guidelines focused on the evaluation of probiotics in food have been published already several 
years ago (Joint FAO/WHO Working Group, 2002) focusing on some key aspects for the 
characterization of bacterial strain as probiotics in food and designing a scheme of selection 
that represents the basis for the conventional assessment of probiotic properties. The utility of 
in-vitro assays relies mainly on their presumptive predictive value in order to predetermine, in 
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possibly reliable, fast and easy mode of action, the possible association between the probiotic 
candidate strain and a certain health claim, targeting a general or a specific application. Despite 
the efforts made by regulatory and international bodies in order to suggest a certain degree of 
standardization of in-vitro tests, they still show high variability in terms of reproducibility. These 
assays should be followed and /or partially replaced by in-vivo tests that anyway are often 
time-consuming, expensive and not feasible for ethical reasons.  
 
Persistence and survival in the human gut 
Probiotics are required to survive the passage through the GIT remaining in viable state with 
the sufficient number of cells facing the stressful conditions of the human gastrointestinal tract. 
Simulated gastric and pancreatic juices have been extensively used (Charteris Et al., 1998; 
Lavermicocca et al., 2008; Gorbach & Goldin, 1992) as well as bovine and porcine bile to check 
the ability of probiotics candidate to face the stressful gut environment, mainly due to the fact 
that these assays are easy to perform and cheap compared to other more recent approaches 
such as GIT simulators. Many biases have been associated to this in-vitro approach 
(Papadimitriou et al., 2015) since the unrealistic conditions applied during in-vitro assays that 
expose probiotic candidates to very harsh environmental parameters that do not mimic in 
efficient and realistic way the acidity of the stomach and lower intestine during food 
consumption.  
 
Safety for the use in human nutrition 
The relevance of some safety issues for the use of probiotics in food has been underlined by the 
Joint Working Group FAO/WHO in 2002 that still represents the reference guidelines for the 
assessment of the safety status of probiotics. The determination of the minimal inhibitory 
concentrations (MICs) towards some antibiotics is suggested by EFSA (EFSA Guidance on the 
assessment of bacterial susceptibility to antimicrobials of human and veterinary importance, 
2012) that also defined the microbiological cut-off values to evaluate a new probiotic candidate 
as susceptible or resistant to a pool of 9 antibiotics as well as the reference methodology to 
assess the sensitivity.  
Other safety aspects include hemolytic activity, aggregation to platelets, to fibronectin and to 
fibrinogen, the synthesis of certain enzymes and the production of biogenic amines that are 
usually assessed by in-vitro tests. Nevertheless, some doubts exists about the reliability of these 
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assays based on the fact that the level of expression of these traits in-vivo could be significantly 
different from the in-vitro conditions leading to an under- or an over-estimation of some 
potentially worrisome features of probiotics (Papadimitriou et al., 2015). 
 
Colonization ability 
The investigation of this aspect is usually based on the ability of probiotic cells to interact with 
the host. Several in-vitro assays have been developed in order to evaluate the adhesion of 
bacteria to mucus and or epithelial cells despite the fact that this trait could have positive 
connotations associated to the competition with pathogens for the adherence sites as well as 
negative implications such as the increasing risk of translocation. Moreover, adhesion to 
epithelial cells, such as Caco-2, HT-29, etc, produce partially reliable results due to the low 
reproducibility level of the tested conditions. Other solutions have been proposed taking into 
consideration resected gut tissue or whole tissue models including the mucus layer but still 
presenting reliability bias (Vesterlund et al., 2005; tassel and Miller, 2011). Some physical 
features of probiotic cells have also been taken into consideration to evaluate the ability of a 
strain to interact with the host such as the hydrophobicity of the cell surface whose scientific 
significance is considered rather limited because of the lack of specificity of this feature. Even 
the expression of some enzymatic activity such as GADP (glyceraldeyde-3-phosphate 
dehydrogenase) mediating the attachment to the mucus has been considered as screening 
parameter with scarce representativeness. 
All of the possible adhesion assays are performed on single and purified strains and therefore 
the assay conditions cannot reproduce the real bacterial community structure and the 
interactions among its inhabitants, leading to doubts about the significance of the results and 
their transposition to the gut microbiome. 
 
Antimicrobial potential 
Probiotics are able to exert a competitive inhibition towards pathogens by several mechanisms 
including the production of metabolites with antimicrobial activity. This action has been proven 
to be at large spectrum against other bacteria, fungi and viruses and is based on different 
compounds like organic acids, bacteriocins, etc. Different in-vitro models have been developed, 
from the simplest ones based on diffusion in agar to more advanced systems to reveal the 
release of antimicrobials by the use of indicator strains. Besides the excretion of metabolites, 
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probiotics can also act by co-aggregating with pathogens and/or enhancing the integrity and 
functions of the intestinal barrier. In the first case, probiotic cells bind pathogenic cells 
determining a clumping effect that limits the interaction of pathogens with the surfaces of the 
host and facilitates the excretion of pathogens by biological fluids (saliva, feces, etc). The gut 
barrier function relies on tight junctions whose integrity represents a key issue to limit the 
translocation of bacteria, pathogens included. Probiotics have been recognized to improve the 
integrity of the barrier as measured by the quantification of specific enzymatic activities.  
Similarly to what has been observed for the other described in-vitro models, also the evaluation 
of antimicrobial potential of probiotics is characterized by some biases since the laboratory 
conditions cannot reproduce the in-vivo situation at the level of expression of the real 
antimicrobial potential of the tested probiotic strain is not assured as well as for the complex 
interactions that characterize the microbial natural community of the GIT. 
 
Immunomodulatory actions 
This effect has been associated to the ability of probiotics to stimulate the secretion of 
antibodies by host cells as well as to trigger cell-mediated immune responses. These effects are 
mediated by dendritic cells (DCs) or M cells from the Payer’s patches whose response to the 
presence of bacterial cells is evaluated by models based on co-culture of probiotics and 
immune cells and by detecting and quantifying of cytokines. These models are usually applied 
to the selection of probiotics with anti-inflammatory potential useful for chronic inflammatory 
diseases such as IBD or to be applied in the management of allergic symptoms  due to their pro-
inflammatory profile. Nevertheless, a strong debate exists about the modality of action of 
probiotics in-vivo and on how to translate in-vitro findings to the evaluation of the efficacy of 
probiotics in the modulation of the gut and systemic immunity. 
 
In-vitro models of cardiovascular diseases 
Probiotic candidates are usually screened for the expression of the bile salt hydrolase activity 
(BSH) that allows the deconjugation of bile acids and that can be evaluated qualitatively and 
quantitatively in relatively easy and quick ways (Cani and Van Hul, 2015; Dashkevicz and 
Feighner, 1989; Zheng et al., 2013; Tomaro-Duchesneau et al., 2014). These models are anyway 
considered by some authors largely insufficient to measure the contribution of probiotics to 
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reduce the risks associated to cardiovascular diseases (Papadimitriou et al., 2015), even if the 
beneficial action seems to be supported by scientific evidences (Ebel et al., 2014).  
 
In-vitro anti-cancer models 
Probiotics have been proven to strengthen the protection functions of the body of the host by 
improving metabolic and immunologic parameters. Beneficial bacteria can in fact exert 
antimutagenic and antigenotoxic activities as well as to degrade nitrosamines and heterocyclic 
amines whose accumulation in the gut could lead to potential detrimental effects. Apart from 
sequestering dangerous metabolites, probiotics are also recognized to release in the lumen 
short chain fatty acids (SCFA) with proven anticarcinogenic effects in-vivo (Burns and Rowland, 
2004; Pool-Zobel, 1996; Duangjitcharoen et al., 2014; Castro et al., 2010; Faridnia et al., 2010). 
It is common opinion of reasearchers that these in-vitro tests are not sufficient to provide 
information about the anticancer activity of probiotics since the in-vivo validation is believed to 
be necessary, despite a very promising background is already available (Chong, 2014). 
 
Other in-vitro models have been developed to evaluate reliably and fastly the probiotic profile 
of beneficial candidates such as measurement of B-galactosidase activity to improve the 
symptoms of lactose intolerance, the production of vitamins, the ability to degrade oxalate as 
well as to inhibit oral strains responsible for the production of volatile sulfur compounds (VSCs). 
 
Development of innovative screening platforms 
The requirement for standardized in-vitro assays to evaluate and validate probiotic 
effectiveness is underlined in many cases in order to draw experimental protocols with 
improved reproducibility and therefore decreasing the percentage of false negative and 
positive responders. 
In-vivo models can integrate in-vitro ones in order to drive the choice of the right probiotic for a 
certain application.  
Insect, worm and animal models, mainly rodents, dogs, monkeys and swine, have been 
considered despite the fact that they seem to lack predictivity for the situation in humans and 
therefore a certain degree of criticism should be applied when transferring speculations from 
animals to humans. Despite a general doubtful position emerging especially in the latest years 
about the conventional screening pipeline for probiotics (in-vitro assays – animal model – 
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clinical trial) including mice or rats models and the tendency to check directly in small number 
of humans the findings from in-vitro evidences, animal models will inevitably be continued to 
be used especially to mimic some specific diseases, induced by chemicals or in genetically 
predisposed animals, or infection conditions with specific pathogens. Such models are 
successfully applied to the study of probiotic efficacy in modulating intestinal inflammation 
(chemically-induced gut diseases such as DSS and TNBS, Citrobacter rodentium, Clostriium 
difficile, Salmonella thiphymurium, listeriosis), in preventing carcinogenesis, in restrainting 
metabolic disorders, in contributing to limit the side effects of therapies for auto-immune 
diseases. Moreover, models of the so-called humanized mice or rats, consisting of immune-
deficient animals carrying human tissue or genes, are used more to test new drugs than for 
probiotic validation (Papadimitriou et al., 2015). 
The frontier, represented by in-vitro coupled with in-vivo test models, has been crossed by in-
silico models developed in EU to take into consideration in a mathematical model the 
interaction between host gut, nutrients, epithelial cells and microbes of the gut community 
(Teusink et al., 2005; Tan and Liong, 2014) in order to simulate the high level processes taking 
place in the complex gut environment with predictive function regarding the interaction of 
probiotics with these multiple factors. 
Omics approaches gave in recent years a significant contribution to the comprehension of the 
efficacy of probiotic towards their host, mainly quantifying by molecular methods the 
increased/decreased expression of certain housekeeping genes of the probiotic cell in answer 
to different environmental conditions. Some area on interest have been particularly 
investigated with special reference to those related to resistance to stressful conditions, 
adhesion to host tissues, modulation of the immune system, production of antimicrobial 
substances and nutrient compounds, degradation of prebiotics and quorum sensing.  
Omics technology will surely contribute to elucidate the ongoing communication dynamics 
inside microbiome and between it and host tissues and the impact of an exogenous probiotic 
strain entering this homeostatic situation. 
 
As reported in this manuscript, the number of available assays to validate in-vitro and in-vivo 
the efficacy of probiotics is huge. They are variably explanatory and not always reproducible, 
and in some cases indications about the efficacy of a new probiotic candidates can be retrieved 
only by a combination of several assays.  
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Nobody has defined a clear workflow to select probiotics carrying to reliable and 
unquestionable proof of efficacy, apart from in-vivo testing on humans by appropriately 
designed clinical trials. Due to the very significant costs associated to human studies, probiotics 
are still screened by in-vitro tests with special reference to the application of the simplest and 
cheapest ones to screen huge numbers of bacterial candidates and of the more expensive and 
appropriate ones to the validation of a more limited number of strains coming from the 
previous screening process.. This flow of activities is known as “funnel-like” approach that has 
been applied to this PhD thesis research work to perform the reasoned screening of a pool of 
lactobacilli and bifidobacteria newly isolated from biological samples in a relatively quick and 
easy way, to move then to their characterization by more complex models, developed in 
collaboration with research and clinical bodies, working in specific fields of human health and 
nutrition. Aim of the first screening process was to identify strains responding to basic criteria 
of reliable taxonomical allocation to a defined species as well as of assessment of the safety 
profile of bacterial candidates to be used in humans. Conventional models have also been 
applied to the selection of strains, univocally and safely identified, able to survive the passage 
through  the GIT in viable form and therefore resistant to gastric and pancreatic juices and to 
bile salts, despite the recognized bias of this approach, neglecting sometimes promising 
probiotic candidates or carrying to the discarding of false negative survivors. 
Strains evaluated as responding to the basic conventional criteria of selection were then moved 
to more expensive and time-consuming in-vitro and animal models in order to screen them 
following the efficacy for a certain predefined application on human health.  
 
The validation of the efficacy of some strains to a certain area of human health would lead to 
the development of screening platforms, carrying from a large pool of probiotic candidate 
strains to a restricted group of probiotics specifically and univocally selected for a specific 
human district requiring a certain therapeutic and/or prophylactic action.  
This manuscript focused on a survey of the current knowledge about models of screening and 
validation of new probiotics and to the description of some platforms developed as paradigm of 
a rationale selection process conducing from a huge amount of strains to a univocal association 
one strain-one function. 
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Figure 1. Scheme of a screening approach to new probiotic candidates by conventional in-vitro 
assays 
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Abstract 
 
Probiotics are viable non-pathogenic bacteria able to modify metabolism and induce 
immunomodulatory activity. They can modulate dendritic cell maturation, modify T helper cell 
balance and induce regulatory response and immunological tolerance, representing a 
therapeutic strategy in autoimmune diseases.  
We selected newly identified live strains of probiotics, Lactobacillus crispatus (LMG P-9437) and 
Bifidobacterium breve (LMG S-28195), and tested their properties in immune-modulating 
dendritic cells and inhibiting auto-reactive effector Tcells, via TGFb production. Innovative 
combinations of probiotics were tested in vivo in the animal models of Myasthenia Gravis and 
Multiple Sclerosis, showing immune-modulatory effects both locally in Peyer’s Patches, and 
systemically, inhibiting auto-immune inflammation in the target organs and ameliorating 
clinical symptoms. 
Here we showed preclinical data, highlighting the therapeutic efficacy of the newly selected 
probiotic strains, as potential translational approach for human autoimmune diseases. 
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Introduction 
 
Probiotics are live non-pathogenic bacteria known to have beneficial effects on the host 
organism mostly associated with modulation of immune responses (Perdigon,G. 1995). The 
gastrointestinal tract is the primary site of interactions between the host and the microbiota. 
How bacterial colonization of the gut might influence the development and functions of the 
immune system has become a major focus of interest (Surana,N.K. 2014; Erickson,K.L. 2000). 
The microbiota has a positive impact on immune regulatory functions of the gut, and interest 
has emerged to address the potential role of probiotics in the induction (or restoration) of 
regulatory-type immune responses; moreover, intestinal colonization with commensal bacteria 
is critical for the establishment of oral tolerance (Weiner,H.L. 1997). Recent studies suggest 
that an impaired intestinal barrier function might cause an imbalance between Th1/Th2 
responses, thus triggering autoimmune processes (Fasano 2005; Fasano,A. 2012). Auto-reactive 
Tcells are normally present in all individuals, but mechanisms for peripheral self-tolerance exist 
to control potentially pathogenic Tcells (Piccirillo 2004). Peripheral tolerance is a continuous 
process, occurring when mature lymphocytes, escaped from negative selection during 
ontogeny, encounter self-antigens in secondary lymphoid organs. The mechanisms that control 
peripheral tolerance include ignorance, deletion by apoptosis, the induction of anergy, and 
active suppression, which is mainly realized by specific cell subsets of regulatory Tcells (Treg) 
(Bacchetta 2005).  
In this context, the immune-modulatory properties of probiotics have raised great interest. 
Reviews of several clinical studies support that probiotics may represent a capable preventive 
and therapeutic strategy for allergic and chronic inflammatory diseases (Boyle,R.J. 2006). Even 
if it is reported that they can mediate a control of the balance between pro- and anti-
inflammatory cytokines (Di Giacinto,C. 2005; Amati,L. 2010) the mechanisms underlying these 
beneficial effects are not completely understood but have been associated with immune-
modulatory properties of specific probiotic strains (Erickson,K.L. 2000). Among the complex 
human microbiota, lactobacilli, more predominant in the gastric region and upper gastro-
intestinal tract (GIT) and bifidobacteria, mostly present in the lower intestinal tract, showed 
therapeutic effects in rheumatoid arthritis (So,J.S. 2008; So,J.S. 2008), inflammatory bowel 
disease (Kim,N. 2007; Castagliuolo 2005) and atopic dermatitis (Viljanen,M. 2005). These 
therapeutic effects are achieved through regulation of cytokine expression and modulation of 
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DC function associated with an enhanced generation of regulatory DCs expressing high levels of 
IL10, TGFβ and COX2, and an enrichment of CD4
+
CD25
+
 Treg cells in the inflamed regions (Braat 
2004; Braat 2004; Kwon 2010; Christensen 2002). Single strains (Lavasani,S. 2010) or 
combinations of probiotics (Chae,C.S. 2012) have emerged as promising candidates for 
treatment of inflammatory and autoimmune disorders. Amongst these, Myasthenia Gravis 
(MG) and Multiple Sclerosis (MS), known to be characterized by an imbalance between 
Teffector/Tregulatory cells (Thiruppathi 2012) are of interest due to their highly invalidating 
impact on everyday life. MG is a systemic autoimmune disease leading to muscle weakness and 
fatigability, where the nicotinic acetylcholine receptor (AChR) is the major auto-antigen 
involved at the neuromuscular junction (Conti-Fine 2006). Experimental autoimmune 
myasthenia gravis (EAMG) is a well-established animal model for MG and has been extensively 
studied to elucidate the pathogenic mechanism (Ubiali 2008; Marolda 2013). MS is a chronic, T 
cell-dependent, inflammatory autoimmune disease of the central nervous system (CNS), whose 
animal models, i.e. experimental autoimmune encephalomyelitis (EAE) shares a number of 
clinical, genetic and immunological features with the human disease (Steinman,L. 1999), and 
can be used as prototype-model for new therapies. 
In the present work we identified and investigated strains of lactobacilli and bifidobacteria, 
studying their immune-regulating effects both in vitro and in vivo, combining their action to 
commercially available strains. Treatment of DCs with probiotic combinations led to strong 
immune modulation, able to inhibit auto-reactive effector Tcell activation. Oral administration 
provided regulatory effects with an up-regulation of TGFβ transcript and protein on local gut 
lymphoid tissue, showing therapeutic properties, thus ameliorating clinical symptoms in both 
EAMG and EAE models. 
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Results 
 
Combinations of novel probiotics efficiently immune-modulate gut lymphoid tissue. 
Different strains of live probiotics were tested among a selection of newly identified strains of 
lactobacillus and bifidobacteria. We focused on specific strains of bifidobacteria, known to 
produce anti-oxidant and anti-inflammatory molecules, such as conjugated Linoleic Acid (CLA). 
In particular, Bifidobacterium breve (LMG S-28195; BB), a new identified strain, was able to 
produce this molecule in higher percentages (42.2% of converted CLA) as compared to the 
commercially available strain Bifidobacterium animalis subsp. Lactis, BB12® (BL; 27.1% of 
converted CLA) or to species of lactobacilli, among which the probiotic strain of Lactobacillus 
crispatus (LMG P-9437; LC) and a commercially available strain of Lactobacillus rhamnosus 
(ATCC 530103; LR). LC was chosen for its anti-inflammatory properties as previously reported 
(Voltan 2008; Voltan 2007; Castagliuolo 2005). To strengthen the genus-specific effect of either 
lactobacilli or bifidobacteria, we decided to use probiotic combinations of LC+LR and BB+BL. In 
order to test the in vivo gut colonization after treatment with LC+LR or BB+BL, rat fecal samples 
were collected at different time points (Suppl. Figure 1A). Following the exogenous 
administration of probiotics to rats, lactobacilli were found to persist and were retrieved from 
feces during the administration period as well as during the wash-out (Suppl. Figure 1A). 
Conversely, bifidobacteria increased in feces following 2-wk administration while in the 
subsequent time points total bifidobacteria returned to lower levels (Suppl. Figure 1A). Since 
bifidobacteria are not usually present in significant amount in rodent gut, while lactobacilli are 
natural inhabitants of the GIT, the observed persistence dynamic is in line with previously 
published studies (Elli 2006; Bartosch 2005), showing that it is difficult to increase the 
population of lactobacilli and bifidobacteria in healthy subjects with initial high fecal counts of 
these microbial groups. 
To study the local immune-regulatory effects of probiotic combinations, the gut-associated 
lymphoid tissue of mesenteric lymph nodes (mesLNs) and Peyer’s Patches (PPs) was analyzed, 
together with the systemic compartment of peripheral blood leukocytes (PBL). The percentage 
of CD4
+
CD25
+
 Treg increased following 2-wk treatment with bifidobacteria in PBL, PPs and 
mesLNs (Suppl. Figure 1B). Alongside, the supernatant of ex-vivo cultured mesLN cells derived 
from BB+BL-treated rats showed a significant increase in TGFβ protein level compared to 
mesLNs from vehicle-treated animals (Suppl. Figure 1C). Moreover, we analyzed the gene 
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expression levels of immune-regulatory markers in mesLNs and PPs, after 4-wk treatment 
showing higher expression of FoxP3, CTLA4, CCR7 and TGFβ, only in PPs (Suppl. Figure 1D). 
Interestingly, bifidobacteria induced a persisting immune-regulation in PPs even after wash out 
(T4), despite the observed slight decrease in bacteria counts. 
 
Bifidobacteria ameliorate Experimental Autoimmune Myasthenia Gravis. 
We studied the immune-regulatory effect of the newly identified probiotic strains in the EAMG 
model. Rats immunized with Torpedo californica Acetylcholine receptor (TAChR) were treated 
with combinations of probiotic strains, either lactobacilli or bifidobacteria, following a 
combined preventive-therapeutic schedule (Figure 1A). EAMG clinical manifestations (clinical 
score and body weight, Figure 1B-C respectively) were significantly ameliorated by both LC+LR 
and BB+BL administration with the latter being more efficient, already at an earlier disease 
stage (7 wks p.i.). Interestingly, at the level of primary responses in draining lymph nodes 
(drLNs), BB+BL treatment was able to partially attenuate TAChR specific Tcell proliferation 
(Figure 1D). Nevertheless, the systemic effect of probiotics was characterized by a significant 
decrease in sera anti-AChR Ab titers in BB+BL-treated (15.18 pmol/ml ±4.55) but not in LC+LR-
treated (23.79 pmol/ml ±7.23) animals, compared with vehicle (43.94 pmol/ml ±6.16) (Figure 
1E). Alongside, a clear ameliorating effect of BB+BL combination was observed locally, at the 
level of EAMG target tissue. Indeed, microscopic evaluation using fluorescently-labeled 
Bungarotoxin (BTX) demonstrated increased number of AChR clusters and AChR mean 
fluorescence intensity in gastrocnemius muscle of BB+BL-treated rats (Figure 2A-B). Moreover, 
quantitative RIA analysis demonstrated that BB+BL-treated animals showed a muscle AChR 
content (0.09 pmol/g ±0.01) similar to healthy control animals (0.091 pmol/g ±0.006), much 
higher compared to both vehicle (0.05 pmol/g ±0.006) and LC+LR-treated rats (0.06 pmol/g 
±0.006; Figure 2C). Further, to evaluate the immune-regulatory effect of probiotics in EAMG, 
we quantified the expression levels of selected immune-related mRNA transcripts in the 
myasthenogenic thymic tissue (Cordiglieri 2014) and in immune lymphoid organs, PPs and 
spleen (Figure 2D-E). Indeed, both lactobacilli and bifidobacteria reduced the expression of 
inflammatory mediators, such as IFNγ and IL6, while modulating regulatory markers. In 
particular, bifidobacteria treatment induced an increase of TGFβ in thymus and PPs (Figure 2D). 
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Probiotic-induced amelioration of Experimental Autoimmune Encephalomyelitis. 
Since imbalance between immune-regulatory and auto-aggressive effector Tcells is supposed to 
be a key feature in autoimmune diseases, we decided to corroborate the efficacy of probiotics 
in another autoimmune animal model, EAE of the Lewis rat, in which effector T cells play a 
major role. Animals were daily fed with probiotic combinations (LC+LR; BB+BL) according to a 
prophylactic schedule, prior to EAE induction (Figure 3A), then oral administration continued 
until disease peak, providing a preventive treatment. EAE clinical manifestations (Figure 3B) 
were significantly ameliorated by both LC+LR and BB+BL administration, being BB+BL treatment 
slightly more efficient, compared to vehicle-treated animals. The reduced clinical symptoms 
were accompanied by dampened primary immune responses in drLNs (Figure 3C), suggesting 
ongoing immune-regulation induced by probiotic treatment, in the specific district of auto-
aggressive effector Tcell formation. Indeed, Th1/Th17 inflammatory markers were significantly 
down-regulated in the spinal cord of treated rats (Figure 3D), whilst immune-regulatory genes 
were up-regulated locally at the level of PPs (Figure 3E). Alongside, both CNS immune cell 
infiltration and astrocytosis were significantly reduced following probiotic treatment (Figure 3F-
G), which also prevented EAE- induced demyelination in the spinal cord (Figure 3H-I). To further 
confirm the effect of prophylactic-preventive probiotic treatment in blocking CNS immune 
infiltration during EAE, we performed transfer EAE experiments, via injection of GFP
+
 
encephalitogenic myelin basic protein (MBP)-specific Tcell blasts (Figure 4A) and evaluated Tcell 
migration and accumulation in lymphoid tissues and CNS. Indeed, both lactobacilli and 
bifidobacteria reduced GFP
+
 Tcell infiltration in lumbar spinal cord, whilst retaining 
encephalitogenic blasts in peripheral immune organs (Figure 4B-D). 
 
Probiotic-induced TGFβ production by DCs inhibits effector Tcell activation and 
immunological synapse formation. 
To address the mechanism through which the combinations of newly identified probiotic 
strains exert their functions, we tested in vitro the effects of single and combinated probiotics 
on DCs, derived from rat bone-marrow myeloid precursors (Figure 5) and human peripheral 
blood mononuclear cells (PBMCs) (Suppl. Figure 2). Probiotic treatment induced DC maturation, 
as visualized by the enrichment in activation surface marker expression: CD11c, CD80, MHCII 
and CD103, for rat DCs (Figure 5A,B), CD80, CD86, MHCII and CD83 for human DCs (Suppl. 
Figure 2A). Importantly, probiotic combination-induced DC maturation was accompanied by an 
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immune-modulatory phenotype characterized by higher expression levels of TGFβ, CCR7 and 
IL6 (Figure 5C; Suppl. Figure 2B), compared to control samples. Interestingly, this immune-
modulating phenotype was observed also on DCs treated with combination of heat-inactivated 
probiotic strains (Figure 5D). DCs incubated with heat-inactivated probiotics, especially with 
BB+BL, were characterized by high expression levels of TGFβ and CCR7, accompanied by 
increased Aldh1a and reduced TLR4 (Figure 5D) and high TGFβ protein levels (Figure 5E). These 
data suggest that proteoglycan residues present on the bacteria shell may modulate DCs, even 
when probiotic agents are not alive (Taverniti,V. 2011). 
To address the immune-modulatory effects of probiotics on DCs, we used an in vitro co-culture 
set-up, which mimics the in vivo environment leading to antigen-specific T cell activation. 
Indeed, we studied co-cultures of antigen (Ag)-loaded DCs in presence of Th1/Th17 effector T 
cells (Teff) specific for either MBP or AChR (using the rat immunogenic epitope of the α-subunit 
of AChR; R97-116), similarly to previously published experiments (Cordiglieri 2014). Specifically, 
we analyzed the cellular interactions between MBP- and R97-116- specific Teff and Ag (MBP or 
R97-116)-loaded DCs, treated or not with heat-inactivated probiotic combinations of LC+LR or 
BB+BL (Figure 6A). When co-cultured with Ag-DCs, Teff showed a random movement (Miller 
2004) (Figure 6B; Suppl. Video 1), and then acquired a stationary phenotype when 
encountering the proper MBP-MHC complex, showing a relatively stable low Vmax (4 μm/min), 
and remaining fixed to anchor points (Cordiglieri 2014; Kawakami 2005). After 60 minutes co-
culture, 80% of Teff showed a stationary phenotype with a minimum meandering index and 
Teff/Ag-DC contacts were long lasting, visually resembling immunological synapse formation. 
When DCs were previously treated with lactobacilli (LC+LR/DCs; Figure 6C, Suppl. Video 2) or 
bifidobacteria combination (BB+BL/DCs; Figure 6D, Suppl. Video 3), increased Teff Vmax were 
observed at 60-min co-culture, and only 30% of Teff presented a stationary phenotype. These 
phenomena were very similar to what was observed using DCs, which had been treated with 
the immune-modulating cytokine TGFβ (Figure 6E, Suppl. Video 4), where we observed only 
40% of stationary cells between 30 and 60 minutes of co-culture (see Suppl. Figure 3 for 
statistical comparisons), suggesting that probiotics treatment on DCs leads to a TGFβ-like 
immune-regulatory milieu. Indeed, probiotic modulation of DCs promoted a marked TGFβ 
increase in the co-culture, accompanied by a reduced inflammatory milieu which inhibited 
Th1/Th17 cytokine expression (IFNγ, IL17, IL2, IL2Rα), as quantified by qPCR after 12h co-
culture (Figure 7A). Importantly, the up-regulation of TGFβ mRNA level was accompanied by a 
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significant increase in TGFβ protein level in the co-cultures where DCs had been previously 
incubated with bifidobacteria (Figure 7B). 
 
Discussion 
 
In recent years, probiotic bacteria have been suggested to provide health benefits (Belkaid,Y. 
2014). In particular, the use of specific strains as safe supplements for human consumption has 
been approved to enhance the gut bacterial composition. Probiotics are known for their 
multiple actions, including regulation of intestinal microbial homeostasis, maintenance of the 
gastrointestinal barrier function, interference with pathogen colonization ability, and 
modulation of local and systemic immune responses (Boirivant,M. 2007; Guglielmetti,S. 2011). 
In this context, given the intimate interplay between gut microbiota and the host immune 
system, it is not surprising that some probiota members have been linked to immune-
modulation (Haller,D. 2010). Indeed, only recently, a putative role for probiotics has been 
investigated in animal models of different autoimmune diseases such as rheumatoid arthritis 
(Wu,H.J. 2010), EAE (Lavasani 2010), EAMG (Chae 2012), and type 1 diabetes (Markle,J.G. 
2013). In particular, both single strains and probiotic combinations have been proposed as 
therapeutic approaches for amelioration of ongoing diseases (Lavasani 2010; Chae 2012),.  
Here we focused on EAMG and EAE models and elucidated the immune-modulatory effect of 
probiotic agents, including two newly identified strains: Lactobacillus crispatus (LMG P-9437) 
and Bifidobacterium breve (LMG S-28195). We investigated the effect of specific combinations 
of lactobacilli and bifidobacteria, in order to enhance the genus-specific immune-modulatory 
action, highlighted by the in vitro data (Figure 5), where a genus -specific synergistic effect is 
observed. In the EAMG model, which is characterized by a primary IgM-mediated phase 
followed by a chronic IgG-induced disease (Baggi 2012), we decided to employ a probiotic 
administration schedule comprising both a preventive and a therapeutic treatment. Previous 
studies showed that prophylactic-preventive, but not prophylactic-therapeutic administration 
of commercial probiotic combination resulted in reduced clinical symptoms (Chae 2012). 
Differently, our approach covered both the initial and the progressive phases of the disease and 
resulted in its significant amelioration when the combination of bifidobacteria was 
administered (Figure 1). The clinical data were corroborated by analyses of neuromuscular 
junction morphology, muscle AChR content and anti-AChR Ab titer (Figure 2), showing 
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significant bifidobacteria effect. In contrast, we observed that treatment with lactobacilli was 
not comparably efficient (Figure 1-2), probably due to their differential pattern of gut 
colonization and survival and their local effect on gut-associated lymphoid tissue (Suppl. Figure 
1). Indeed, bifidobacteria are known to preferentially inhabitate the lower intestinal tract (Elli 
2006; Bartosch 2005), where they are easily in contact with immune cells, thus exploiting their 
immune-modulating function. In fact, bifidobacteria induced production of TGFβ in mesLNs and 
up-regulation of several immune-regulatory genes in PPs (Suppl.Figure 1).  
The second autoimmune disease model, in which we decided to test the efficacy of the newly 
identified probiotic combinations, is a monophasic, acute Tcell-mediated disease, different 
from the chronic progressive murine EAE previously published (Lavasani 2010). This model is 
particularly useful in evaluating the effects of novel therapeutic approaches on Tcell activation 
(Flugel,A. 2001; Cordiglieri 2010). Moreover, due to the short duration of the disease, the 
prophylactic-preventive administration timely coordinate bacterial colonization with disease 
onset (Figure 3; Suppl.Figure 1), leading to a decrease in specific effector Tcell responses, and 
consequently diminished clinical symptoms following both probiotic combination treatments. 
In such model, we did not observe statistically significant differences between lactobacilli and 
bifidobacteria (Figure 3). The efficacy of probiotic treatment led to diminished immune cell 
infiltrates in the spinal cord, whilst retaining leukocytes in immune peripheral organs (Figure 4), 
and reduced demyelination, astrocytosis, and neurodegeneration. In order to elucidate the 
mechanisms exploited by the probiotic agents, we took advantage on in vitro set ups, thus 
allowing dissection of the immune-modulatory effects. The four employed strains, even after 
heat inactivation, showed DCs modulation towards a tolerant phenotype, characterized by high 
levels of TGFβ, thus implying a major role for bacterial shell proteoglycan residues (Figure 5; 
Suppl.Figure 2) (Taverniti,V. 2011). Indeed, the treatment with heat-inactivated probiotic 
combinations on DCs, dampened immunological synapse formation with effector Tcells, in an in 
vitro co-culture model (Cordiglieri 2014), resulting in diminished effector Tcell activation, 
Th1/Th17 inflammatory mediator production, whilst increasing TGFβ (Figure 6-7; Suppl.Figure 
3; Suppl. Videos 1-4). 
Thus, we have shown that probiotic agents, lactobacilli and bifidobacteria, may induce a TGFβ-
mediated immune-modulation on DCs in vitro. Translated in the in vivo context, at the level of 
gut-associated lymphoid tissues (mesLNs and PPs), DCs may be prompted by probiotics to 
induce Treg. In experimental models involving autoimmune reactions, an increased amount of 
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circulating Treg may actively suppress effector Tcell functions, thus inhibiting the ongoing 
autoimmune inflammation.  
Taken together, these preclinical data could represent a promising novel therapeutic approach 
in autoimmune diseases. Importantly, differently from other treatments, probiotics are safe 
food supplements, completely feasible with everyday life, thus implying a very good compliance 
for the patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
Materials and Methods 
 
Probiotic strain cultures 
Strains of lactobacilli were grown in De Man, Rogosa & Sharp (MRS) medium (Difco, US) broth 
at 37° C in microaerophilic conditions for 18 h, while bifidobacteria were cultured in the same 
medium added with 0,05% cysteine at 37°C by anaerobic incubation for 24-48 h. Probiotic 
strains: Lactobacillus crispatus (LMG P-9437; LC), Lactobacillus rhamnosus (ATCC 53103; LR), 
Bifidobacterium breve (LMG S-28195; BB), Bifidobacterium animalis subsp. Lactis, BB12® (BL; 
from CHR Hansen, Denmark). 
Strains used are considered safe, particularly L. crispatus LMG P-9437 and B. breve LMG S-
28195 had already been previously isolated and characterized for their susceptibility to 
antibiotics and the relative data were confirmed during the thesis. L. rhamnosus ATCC 53103 
has not antibiotic resistances while B. animalis subsp. Lactis, BB12 shows a resistance to 
tetracycline due to the presence of the tetW gene but this resistance is not transmissible so the 
strain does not present safety problems. More precisely, upstream of tetW is a transposase 
gene, which is cotranscribed in tandem. Transposases are involved in the horizontal gene 
transfer of genetic elements among bacteria, but to date there is no evidence that tetW in B. 
animalis subsp. lactis is transmissible. 
 
Preparation of probiotic cultures administered to animals 
Lactobacilli and bifidobacteria were grown in MRS broth as previously stated. At the end of the 
incubation period, cells were harvested by centrifugation at 8000 rpm for 5 minutes, washed 
twice with sterile distilled saline and finally resuspended in a solution of 20% glucose + 10% 
glycerol to obtain a final concentration of 10^9 colony-forming units (CFU) per 100 µl of 
bacterial suspension. Concentrated cultures was then divided in single doses and aliquotes 
were stored at -80°C until administration to animals. Enumeration of viable bacterial cells was 
performed on agarized selective media (MRS for lactobacilli and Transoligosaccharide 
propionate agar medium TOS added with 50 µg/ml mupirocin for bifidobacteria) (Merck 
Millipore, US) by decimal counts just after preparation as well as along the storage in frozen 
conditions in order to ascertain their stability over time.  
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Fecal samples collection and analysis 
Fecal samples were collected immediately before the first administration (T0), after every 
treatment week (T1, T2, T3) and after 1-week wash-out, following treatment termination (T4). 
Samples were immediately stored at -20°C and processed within 24 h. Fresh fecal samples were 
decimally diluted into sterile saline solution and plated onto selective media in order to 
enumerate total lactobacilli and bifidobacteria, as described above. Plates were anaerobically 
incubated at 37° C for 72 h. The number of colonies for two parallel plates was counted from a 
dilution yielding 30 to 300 CFU/plate and the average was recorded. 
 
Animals and experimental models 
Animals were purchased from Charles River Breeding Laboratories (Calco, Italy) and kept at the 
animal facility of the Institute. A total of 100 animals were used for all experiments and 
sacrificed after deep anesthesia via carbon dioxide; for immunization and treatments, animals 
were anesthetized with 2% isofluorane (60:40 N2O:O2, flow rate 0.8 L/min). EAMG and EAE 
were induced in female Lewis rats, aged 6-8 wks, by immunization in the hind limbs s.c., with 50 
µg of TAChR (extracted from Torpedo electric organ; Aquatic Research Consultants) or 200 µg 
of MBP (Sigma) emulsified in CFA in a total volume of 200 µl/rat. 
 
EAMG and EAE clinical evaluation 
Evaluation of disease manifestations in EAMG rats was performed by testing muscular 
weakness as reported (Ubiali 2008; Marolda 2013). Clinical scoring was assessed after exercise 
for 30 seconds, using the grip strength test. Disease severity was graded as follows: grade 0, 
normal strength and no abnormalities; grade 1, mildly decreased activity and weak grip or cry; 
grade 2, clinical signs present before exercise (tremor, head down, hunched posture, weak 
grip); grade 3, severe clinical signs at rest, no grip, moribund; and grade 4, dead. Each animal 
was weighed and scored at the beginning of each experiment and twice weekly until the end of 
the experiment; EAMG was confirmed by Prostigmine test (i.p. injection). Evaluation of disease 
manifestations in EAE rats was performed as reported (Cordiglieri 2010). Animals were assessed 
daily for neurologic signs of EAE according to the following five-point scale: 0, healthy; 1, tail 
weakness or paralysis; 2, paraparesis (incomplete paralysis of one or two hind limbs/plegia of 
one hind limb); 3, paraplegia extending to the thoracic level; 4, forelimb weakness or paralysis 
with hind limbs paraparesis or paraplegia; and 5, moribund or dead animal. 
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Treatment protocols 
For in vivo gut colonization, oral administrations (2.5x10
9
 CFU/ml; 3wks; 5d/wk) with lactobacilli 
(LC+LR) and bifidobacteria combinations (BB+BL) have been performed in healthy female Lewis 
rats (8 wk-old, n=20). Fecal samples for biological analysis were collected at different time 
points: before treatment (T0), after 1, 2 or 3 wks of treatment (T1, T2, T3) and 1 wk after 
removal of probiotic treatment (T4). Animals were sacrificed at T2 and T4 time point. For EAMG 
model (6 wk-old, 2 indipendent experiments, total 15 rats/treatment), oral probiotic 
administration started from the disease induction for 2 wks (preventive treatment) and from 4 
wk post immunization (p.i.) (therapeutic protocol) with strain combinations (LC+LR and BB+BL). 
EAMG animals were sacrificed at 10 wks p.i.. For EAE model, oral probiotic administration 
started one wk before immunization (prophylactic treatment) until 14 days after disease 
induction (preventive protocol) with LC+LR and BB+BL. EAE animals (8 wk-old, 3 indipendent 
experiments, total 18 rats/treatment) were sacrificed at the disease peak (d 21 p.i.). For EAE 
transfer, after prophylactic and preventive treatments, MBP-specific GFP
+
 Tcells were injected 
at d 14 and rats were sacrificed at d 18 to perform infiltration analysis. 
 
Immunobiological analysis 
LNs were isolated from EAMG and EAE rats and processed into single cell suspensions. 2×10
5
 
cells/well were cultured with 0.25 µg/ml TAChR or 5-10 µg/ml MBP (specific Ag for EAMG and 
EAE, respectively) and 2 µg/ml Concanavalin A (ConA; Sigma; positive control) in 96-well flat 
plates in 200 μl RPMI medium (Euroclone) supplemented with 10% FCS, 1% Na-pyruvate, 1% 
non-essential aa, 1% L-glutamine, 1% penicillin-streptomycin (Euroclone), 50 μM 2-
mercaptoethanol (Sigma), plus 1% normal rat serum. After 72h of incubation at 37°C with 5% 
CO2, cultures were pulsed with 0.5 μCi [
3
H]-thymidine per well for 18h, and proliferation was 
measured from quadruplicates cultures on a beta counter (PerkinElmer). 
 
Muscle AChR content 
AChR content in muscles was assayed as previously described (Baggi 2004). Briefly, AChR was 
solubilized from muscle membranes overnight at 4°C in a buffer of Tris-HCl (pH 7,5), NaCl, 
PMSF, EDTA, plus 2% Triton X-100, after a centrifugation at 17000×g for 1h. Solutions 
containing solubilized AChR were clarified by centrifugation at 100,000×g for 30min. AChR 
crude extracts (100 μl, duplicates) were incubated with [
125
I]-αBTX (PerkinElmer) 4h at room 
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temperature, transferred on DE-81 DEAE disks (Whatman International) and washed with Tris-
HCl buffer 0.5% Triton X-100. Radioactivity was determined by gamma counting. The aspecific 
binding was subtracted from each sample by parallel tubes pre-incubated with cold αBTX 
(Sigma). The results were expressed as picomole of αBTX binding sites per gram of muscle. 
 
Anti-AChR Ab titer  
Anti-rat AChR Abs were assayed in individual sera by RIA (Baggi 2004). Rat AChR was extracted 
from rat muscle and labeled with 2 nM [
125
I]-αBTX. Sera were incubated over-night with [
125
I]-
αBTX labeled rat AChR (0.5 pmol). Ab-AChR complexes were precipitated by adding an excess of 
rabbit anti-rat IgG (Sigma). Pellet were washed twice with cold PBS plus 0.5% Triton X-100 
(Carlo Erba) and [
125
I]-αBTX labeling was evaluated via a γ-counter (PerkinElmer). Serum 
samples incubated with rat AChR pre-incubated in excess of cold αBTX (Life Technologies; 
aspecific binding) were subtracted from test samples. The anti-AChR Ab titers were expressed 
as picomole of [
125
I]-αBTX binding sites precipitated per milliliter of serum.  
 
Histological analysis  
Ten, fifteen or twenty-µm thick serial sections from 4% PFA-fixed and cryo-protected frozen 
spinal cord, spleen, gastrocnemius muscle were cut in transversal slices, using a Leica CM1950 
cryostat. For AChR fluorescence labeling αBTX-Tetramethylrhodamine (Life Technologies) was 
employed. Images were captured via fluorescence-confocal laser-scanning microscopy (EZ-C1 
scan-head equipped with Eclipse TE2000-E microscope; Nikon). Maximum projections of 15-µm 
thick sections were acquired using a 20x (NA 0.85) objective and used for evaluation of AChR 
cluster numbers and mean fluorescence intensity (MFI) (Cole,R.N. 2008). All image settings 
were determined at the beginning of the imaging session and were not changed. All sections 
were collected in the same session permitting comparison of fluorescence intensity as a 
measure of relative AChR density. To avoid biased sampling, we examined for each section 
every adjacent field, collecting images of all fluorescently labeled AChR cluster. Single z-scan 
acquired using a 60x (NA 1.40) objective were employed for morphological characterization of 
neuromuscular junction. Histological myelin staining, performed on 20 µm spinal cord slices 
using Black Gold II (BGII, Histo-Chem Inc. Jefferson), and H&E staining were performed on 6 
slices per animal (n=4 for each treatment group) and captured with Aperio digital scanner 
equipped with 20x objective (ScanScope, Aperio Technologies). Single and double 
96 
 
immunofluorescence staining were performed on 6 serially cut 10-µm thick spinal cord slices 
per animal (n=4 for each treatment group) with primary Abs specific for: CD3 (eBioscience), 
βTubulin (Covance), GFAP (Dako), MBP (Chemicon), Desmin (Thermo-Fisher); non-immune IgG 
(Sigma) staining was used as isotype control. Secondary labeling was performed with Alexa 
Fluor 488- or 546-conjugated goat anti-mouse and anti-rabbit IgGs, and DAPI (all from Life 
Technologies) staining. Images were captured via fluorescence-confocal laser-scanning 
microscopy (EZ-C1 scan-head equipped with Eclipse TE2000-E microscope; Nikon). Maximum 
projections of 6-µm thick z-stacks were acquired using a 60x (NA 1.40) objective and used for 
evaluation of CD3, MBP, GFAP and βTubulin MFI values, as elsewhere reported (Colombo,E. 
2012). Image analysis was performed with Image J (Version 1.43u) and FIJI (Schindelin,J. 2012): 
color density (for BGII), MFI and single/double-positive cells were measured on at least 3 
adjacent field areas per section. 
 
cDNA synthesis and qPCR  
Total RNA was extracted using Trizol reagent, cDNA was synthesized from RNA using random 
hexamers, and reverse transcriptase. Real-time quantitative PCR for IFNγ, CCR7, CTLA4, FoxP3, 
TGFβ, IL2, IL2rα, IL6, IL17, TNFα, TLR4, Aldh1a2, GAPDH and βActin was performed using Assay-
on Demand Gene Expression Products. βActin and GAPDH were used as housekeeping 
endogenous genes. mRNA levels of target genes were expressed as relative values (2
-Δct
x100) 
normalized towards the chosen housekeeping genes, in which ΔCt represents the difference 
between Ct of the target gene and Ct of the housekeeping gene. Real-time PCR reactions were 
performed in duplicates using an ABI Prism 7500 FAST Real-Time PCR System (all reagents and 
molecular probes were from Life Technologies). 
 
Rat and human DC cultures 
Single cell suspensions of myeloid precursor cells (MPCs) were derived from bone marrows of 
naïve Lewis rats and cultured in complete RPMI medium, containing 1% Na-pyruvate, 1% non-
essential aa, 1% L-glutamine, 1% penicillin-streptomycin, 50 μM 2-mercaptoethanol, 10% FCS, 
in presence of GM-CSF and IL4 (both 20 ng/ml; Peprotech) for 10 days to differentiate into 
immature DCs (Marolda 2013). DCs were then seeded either in live imaging glass-inserted 
plates (3x10
5 
DCs/dish) or 24-well culture plates (1x10
5
 wt DCs/well; 2.5x10
5 
human DCs/well) 
and treated with viable or heat-inactivated (5min at 90°C) probiotics, for 4-8h in a ratio 1:100 
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(1-3x10
7
 CFU/ sample), according to the specific assay, as specified in the respective figure 
legend. DCs were derived from healthy PBMCs as reported (Nava 2012), by culturing cells in 
complete RPMI medium in presence of GM-CSF and IL4 for 7 days. 
 
FACS analysis  
Rat and human DCs were cultured in 24-well plates (1x10
5
 DCs/well) in presence of 1x10
6
 
CFU/well of single probiotic strains or probiotic combinations and incubated for 4h. DCs were 
then extensively washed and collected for cytofluorimetric analysis using specific mouse anti-
human and mouse anti-rat FITC-, PE- and PerCP-labeled Abs against specific DC surface markers 
(MHCII, CD80, CD86, CD103, CD11c, CD83; all from eBioscience). PBL purified via percol 
gradient (Lymphoprep, Nycomed), together with PPs and mesLN cell suspensions obtained 
from 2-wk treated rats with probiotics or vehicle, were stained for FITC- and PE- labeled 
regulatory Tcell markers (CD4, CD25, both from eBioscience). As negative control, FITC-, PE- and 
PerCP-labeled mouse IgGs were used. Samples were acquired using a FACS vantage (BD) or a 
MACSquant (Miltenyi) and gated for Forward Scatter  (FSC) and Side Scatter (SSC) parameters; 
7-AAD marker (BD) was employed to visualize dead cells. Numbers of living and dead cells were 
counted relatively to a known amount of unlabeled beads appropriately gated (BD). 
 
R97-116 and MBP specific effector Tcell lines  
EGFP
+/+
 transgenic Lewis rats were immunized with 200 μg of R97-116 peptide (CASLO lab) or 
200 μg of MBP in CFA as previously described (Cordiglieri 2010; Cordiglieri 2014). At d 10 p.i., 
drLN cell suspensions were cultured in complete RPMI medium, containing 2% rat serum and 
stimulated with R97-116 or MBP (5 μg/ml). Tcells were maintained and expanded as reported 
(Flugel,A. 2001).  
 
Live-imaging assay 
Time-lapse video microscopy was performed using a live-imaging Nikon set-up equipped with 
temperature/CO2 control unit (OKOlab). Naïve or TGFβ (10 ng/ml) or heat-inactivated (5min at 
95°C) probiotic-treated (1x10
7
 CFU/sample) wt DCs (3x10
5
/imaging dish) and R97-116- or MBP-
specific GFP
+ 
Teff (1x10
6
/imaging dish) were co-cultured for 12h on glass-inserted imaging 
collagen-coated dishes. Differential interference contrast (DIC) and green channel images were 
acquired on a 512x512 pixel field of view, with 1.31 μm/pixel conversion. Recordings were 
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performed in 30s time intervals using an inverted microscope (with 20x, 0.5 NA, objective) and 
a Q-imaging Fast Camera (Roper scientific), and processed by NIS Elements AR software v3.1 
(Nikon). ImageJ software was used to evaluate cell trajectories and velocities. Cells were 
defined as stationary if they moved less than 10 µm/10min, motile if they moved more than 10 
µm/10min (Cordiglieri 2014; Kawakami 2005). 
 
TGFβ ELISA 
Supernatants of DCs cultures treated for 4-8h with heat-inactivated probiotics, of DC/Teff co-
cultures plated for 12h, as previously described, and of mesLN cell suspensions obtained from 
2-wk treated animals with probiotics or vehicle and ex vivo cultured for 24h, were tested for 
TGFβ protein levels by ready-to-use sandwich ELISA (eBioscience), following manufacturer’s 
instructions.  
 
Statistical analysis 
All values were expressed as means ± SEM. Statistical analysis was performed according to the 
nature of data. Normally distributed data were analyzed using one- or two-way ANOVA 
followed by appropriate post-hoc comparisons. p<0.05 was considered statistically significant. 
GraphPad Prism v5.0 (GraphPad Prism, CA) was used for data elaboration and statistical 
analysis.  
 
Study approval  
The present studies in animals and humans were reviewed and approved by the Italian Ministry 
of Health (Institutional experimental code: IMP-04-11 and IMP-03-11) and were performed in 
respect to the Italian Principle of Laboratory Animal Care (DDL 116/92), in accordance to 
European Communities Council Directive 86/609/EEC and 2010/63/UE. 
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Figure legends 
Figure 1. Combinations of newly identified probiotic strains lead to EAMG amelioration. 
A) Experimental plan and treatment schedule: 2-wk preventive and 4-wk therapeutic oral 
administration (2.5x10
9
 CFU/day; 5d/wk) in TAChR/CFA immunized Lewis rats. T=0: 
immunization day. B-C) Clinical score (B) and body weight change (C) of EAMG animals treated 
with LC+LR (gray triangle), BB+BL (black square), or vehicle (white circle). Mean ± SEM values of 
1 representative of 2 independent experiments, n=9 rats/group. D) Primary immune responses 
in drLNs of EAMG animals treated with LC+LR, BB+BL, or vehicle, ex-vivo stimulated with ConA 
and TAChR. Mean ± SEM of 2 independent experiments, n=6 rats/group. Data of cpm values 
expressed as stimulation index in arbitrary units, normalized to unstimulated drLN cells. E) Anti-
AChR Ab sera titer of EAMG animals treated with LC+LR (gray bar), BB+BL (black bar), or vehicle 
(white bar). Mean ± SEM of 2 independent experiments. Statistics: 2-way-ANOVA analysis plus 
Bonferroni post-hoc comparisons (B-C) and 1-way ANOVA analysis plus Dunnet post-hoc 
comparisons (D-E) of lactobacilli- and bifidobacteria- Vs vehicle-treated animals. (*)= p<0.05, 
(**) = p<0.01, (***) = p<0.001.  
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Figure 2. Bifidobacteria reduced loss in muscle AChR content and increased regulatory 
environment in EAMG. 
A) Immunofluorescence for muscle (Desmin, green) and AChR (αBTX-Tetramethylrhodamine, 
red) of gastrocnemius muscle of healthy donor and EAMG rats treated with LC+LR, BB+BL or 
vehicle. Magnification: 50 µm. Inserts show zoomed areas for better image of AChR clusters 
(magnification: 10 µm). B-C) Muscle AChR quantification in healthy donor (HD; striped bars) 
and EAMG rats treated with LC+LR (gray bars), BB+BL (black bars) or vehicle (white bars). Mean 
fluorescence intensity of AChR (B, left graph), number of AChR clusters (B, right graph) in 
gastrocnemius muscle and total muscle AChR content (pmol/g of tissue, C). Mean ± SEM of n=2 
rats/group, at least 10 sections/animal analyzed for B and n=18 rats/group for C. D-E) qPCR 
analysis of thymus (D, left part of each graph), PPs (D, right part of each graph) and spleen (E) of 
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EAMG rats treated with LC+LR (gray bars), BB+BL (black bars) or vehicle (white bars). Mean ± 
SEM of 2 independent experiments, n=6 rats/group. mRNA values normalized to βActin 
housekeeping gene and expressed as 2
-Δct
 x100. Statistics: 1-way-ANOVA plus Bonferroni (B-C) 
or Dunnet (D-E) post-hoc comparisons. (*) = p<0.05; (**) = p<0.01; (***) = p<0.001 Vs vehicle, 
(#)= p<0.05, (###) = p<0.001, (BB+BL) Vs (LC+LR) 
 
 
 
 
Figure 3. Combinations of newly identified probiotic strains lead to EAE amelioration. 
A) Experimental plan and treatment schedule: 1-wk prophylactic and 2-wk preventive oral 
administration (2.5x10
9
 CFU/day; 5d/wk) in MBP/CFA immunized rats. T=0: immunization day. 
B) Clinical score of EAE animals treated with LC+LR (gray triangle), BB+BL (black square), or 
vehicle (white circle). Representative of 3 independent experiments, n=9 rats/group. C) Primary 
responses in drLNs of EAE animals treated with LC+LR, BB+BL, or vehicle ex vivo stimulated. 
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Mean ± SEM of 2 independent experiments, n=6 rats/group. D-E) qPCR analysis of lumbar spinal 
cord (D) and PPs (E) of EAE rats treated as specified. Mean ± SEM of 2 independent 
experiments, n=6 rats/group. mRNA values normalized to βActin and expressed as 2-Δct x100. F-
I) Stainings and quantifications of infiltrating Tcells (CD3, red; F, upper row; G, left), reactive 
astrocytes (GFAP, green; F, upper row; G, right),  Hematoxyllin/Eosin stainings (F, lower row), 
oligodendrocytes (MBP, green; H, upper row; I, left), neurons (βTubulin, red; H) and myelin (BG 
II; H, lower row; I, right) of thoracic spinal cord of EAE rats treated with LC+LR (middle images; 
gray bars), BB+BL (right images; black bars) or vehicle (left images; white bars). Magnification: 
50 µm. WM: white matter; GM: gray matter; M: meninges. Black arrow-heads point to immune 
cell infiltrates. Representative images (F, H) of 4 rats/group, 6 sections analyzed/rat (G, I). DAPI: 
nuclei counterstaining. MFI: mean fluorescence intensity. Statistics: 2-way-ANOVA plus 
Bonferroni (B-C) or 1-way-ANOVA plus Dunnet comparisons (D-E; G, I). (*) = p<0.05, (**) = 
p<0.01; (***) = p<0.001 Vs vehicle-treated animals.  
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Figure 4. Probiotics influence CNS immune cell infiltration in EAE. 
A) Experimental scheme: GFP
+
 encephalitogenic MBP-specific Tcell transfer in MBP/CFA-
immunized animals treated with probiotics following prophylactic-preventive schedule. T=0: 
immunization day. B) Cytofluorimetric analysis of GFP
+
 transferred Tcells circulating in blood, 
accumulating in spleen and infiltrating the lumbar spinal cord, in EAE rats treated with LC+LR 
(gray), BB+BL (black) or vehicle (white). Data are expressed as number of cells per total organ or 
ml of blood. Representative data of 2 independent experiments, n=5 rats/group. Statistics: 2-
way-ANOVA plus Bonferroni post-hoc comparisons: (*) = p<0.05; (**) = p<0.01; (***) = p<0.001 
Vs vehicle-treated animals, (#)= p<0.05, (BB+BL) Vs (LC+LR). C) Histological analysis of GFP
+
 
encephalitogenic MBP-specific Tcells accumulating in perivascular cuffs and meningeal areas of 
thoracic spinal cord in EAE rats treated with LC+LR, BB+BL or vehicle. Magnification: 50 µm for 
upper panels, 10 µm for middle and lower panels. Arrow-heads point to GFP+ MBP-specific 
Tcells and Tcell clusters. WM: white matter; M: meninges. D) Histological analysis of GFP+ MBP-
specific Tcells accumulating in the spleen of EAE rats, treated with LC+LR, BB+BL or vehicle, at 
the level of vessels (V), white (WP) and red pulp (RP). Magnification: 50 µm for upper and lower 
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panels, 10 µm for middle panels. Arrow-heads point to GFP+ MBP-specific Tcells,. Hm/Eo: 
Hematoxyllin/Eosin staining. Representative images of 5 rats/group, 6 sections analyzed/rat.  
 
 
 
 
Figure 5. Both viable and heat-inactivated probiotic strains show high immune-modulatory in 
vitro properties on DCs 
A-B) Surface marker cytofluorimetry of rat bone marrow derived DCs incubated with LC (light 
gray), LR (dark gray), and combination of both strains (LC+LR; black) (A), or with BB (light gray), 
BL (dark gray) and combination of both strains (BB+BL; black) (B), compared to untreated DCs 
(NT; white). Mean ± SEM of 2 independent experiments, n=6 rats/group. C) qPCR analysis of rat 
bone marrow derived DCs incubated with LC+LR (gray) and BB+BL (black), compared to 
untreated DCs (NT; white). Mean ± SEM of 2 independent experiments, n=6 rats/group. mRNA 
values normalized to βActin and expressed as 2-Δct x100. D) qPCR analysis of immune-
modulating (TGFβ, CCR7, Aldh1a2) and activatory (TLR4) gene expression in DCs following 4h 
incubation with combinations of  heat-inactivated lactobacilli (LC+LR; gray) or bifidobacteria 
(BB+BL; black), compared to control vehicle-treated DCs (NT; white). Mean ± SEM of 2 
independent experiments, n=6 rats/group. mRNA values normalized to βActin and expressed as 
2
-Δct
 x100. D) TGFβ release in supernatants of DCs following 4h incubation with combinations of 
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heat-inactivated LC+LR (gray) or BB+BL (black), compared to NT DCs (white). Statistics: 1-way-
ANOVA plus Dunnet (A-B) or Bonferroni (C-D) post-hoc comparisons. (*) = p<0.05, (**) = 
p<0.01, (***) = p<0.001 Vs NT; (#) = p<0.05, (##) = p<0.01, (###) = p<0.001 (BB+BL) Vs (LC+LR).  
 
 
 
 
 
Figure 6. Inhibition of Teff activation induced by probiotic-modulated DCs. 
A) Experimental scheme: DCs incubated for 4h with combinations of heat-inactivated probiotics 
(LC+LR; BB+BL) or for 8h with TGFβ (10ng/ml), then seeded on imaging dishes in presence of 
MBP or R97-116, prior to co-culture with GFP
+
 MBP-specific or R97-116 specific Teff for motility 
assay (1h movie) followed by 12h culture and qPCR analysis. B-E) Motility phenotype analysis of 
GFP
+
 Teff in presence of DCs vehicle-treated (B) or previously incubated with combinations of 
heat-inactivated lactobacilli (C) or bifidobacteria (D), or in presence of TGFβ-treated DCs (E). 
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Upper row: displacement of Teff along the image plan at time points 10, 30 and 60 min; second 
row: percentage of motile (blue for TMBP eff; cyan for TR97-116 eff) Vs stationary (red for TMBP eff; 
orange for TR97-116 eff) Teff over the time; third row: mean velocity (µm/min) of analyzed motile 
and stationary cells over the time; lower row: meandering index of motile and stationary cells. 
Motile cells: moving more than 10 µm in 10 min; stationary cells: defined as moving less than 
10 µm in 10 min. Values shown in each graph are mean quantifications ± SEM of triplicate time-
lapse videos for each condition with TMBP and triplicate videos with TR97-116 with at least 225 
TMBP and 225 TR97-116 effector cells analyzed for each time stack (time-lapse: 30 seconds; 121 
time points/video). For TGFβ-treated DC condition, only R97-116 specific Teff were employed 
(triplicate videos with 225 Teff analyzed). No differences were observed between TMBP and TR97-
116 in the motility behavior.  
 
 
Figure 7. Inhibition of Th1/Th17 inflammatory milieu by probiotic-modulated TGFβ-inducing 
DCs 
A) Cytokine qPCR analysis after 12h co-culture of GFP
+
 antigen-specific Teff in presence of 
antigen-pulsed DCs previously incubated with heat-inactivated probiotic combinations (LC+LR, 
gray; BB+BL, black), TGFβ (striped) or vehicle (NT, white), as represented in Figure 6. Mean ± 
SEM of 2 independent experiments, (n=3/group with TMBP; n=3/group with TR97-116). Data show 
mRNA values normalized to βActin and expressed as 2
-Δct
 x100. Statistics: 1-way-ANOVA plus 
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Dunnet post-hoc comparisons: B) TGFβ release in supernatants of 12h co-culture of GFP
+
 
antigen-specific Teff in presence of antigen-pulsed DCs previously incubated with heat-
inactivated probiotic combinations (LC+LR, gray; BB+BL, black), or vehicle (NT, white) Statistics: 
1-way-ANOVA plus Dunnet (A) or Bonferroni (B) post-hoc comparison. (*) = p<0.05, (**) = 
p<0.01, (***) = p<0.001 Vs NT; (#) = p<0.05; (##) = p<0.01; (###) = p<0.001 (BB+BL) Vs (LC+LR).  
Supplementary material 
 
 
 
Supplementary Figure 1. Probiotic immune-modulatory in vitro properties and in vivo gut 
colonization 
A) Amount of total lactobacilli and bifidobacteria in fecal samples, as analyzed via decimal 
counts of viable bacteria in selective culturing media over time of administration and wash out 
(T=4; gray: LC+LR; black: BB+BL). Representative data of 2 independent experiment, n=3/group 
B) Percentages of CD4
+
CD25
+
 Treg at T2 in PBL, PPs and mesLNs of animals treated with LC+LR 
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(gray), BB+BL (black) or vehicle (white). C) TGFβ protein levels in the supernatants of 24h 
cultured mesLN cells from animals following 2-wk treatment with LC+LR (gray), BB+BL (black) or 
vehicle (white). D) qPCR analysis of locally-altered immune-modulating genes in mesLNs (left 
panel) and PPs (right panel) following probiotic treatment at T=4 (gray: LC+LR; black: BB+BL; 
white: vehicle). Mean ± SEM of 2 independent experiments, n=6 rats/group. Data show mRNA 
values normalized to βActin housekeeping gene and expressed as 2
-Δct
 x100. Statistics: 1-way-
ANOVA plus Dunnet (B, C, D) post-hoc comparisons: (**) = p<0.01, (***) = p<0.001 Vs vehicle; 
(#) = p<0.05, (##) = p<0.01, (###) = p<0.001 (BB+BL) Vs (LC+LR). 
 
Supplementary Figure 2. Newly identified probiotic strains induce immune-regulatory 
phenotype on human DCs 
A-B) Human monocyte-derived DCs incubated with LC (light gray) and BB (dark gray), or with 
combinations of LC+LR (steel gray) and BB+BL (black) compared to untreated DCs (NT; white). 
Surface marker cytofluorimetry (A) and qPCR analysis (B). Mean ± SEM of 2 independent 
experiments, n=6/group. Data show mRNA values normalized to GAPDH housekeeping gene 
and expressed as 2
-Δct
 x100. Statistics: 1-way-ANOVA plus Bonferroni post-hoc comparisons: 
(**) = p<0.01; (***) = p<0.001 Vs NT; (#) = p<0.05 (BB+BL) Vs (LC+LR). 
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Supplementary Figure 3. Inhibition of Teff by immune-modulated DCs. 
A-C) Statistical analysis and comparisons among co-cultures of Teff (both MBP- and R97-116 
specific) in presence of DCs treated with combinations of LC+LR (gray), BB+BL (black), TGFβ 
(striped) or untreated DCs (NT, white), as shown in Figure 6. Graphs show percentages (A), 
mean velocity (µm/min, B) and meandering index (C) of motile Teff at time point 10, 30 and 60 
min of imaging analysis. Values shown in each graph are mean quantifications ± SEM of six 
time-lapse videos for each condition with at least 450 Teff analyzed for each time stack (time-
lapse: 30 seconds; 121 time points/video). For TGFβ-treated DC condition, only TR97-116 eff was 
employed (triplicate videos with 225 Teff analyzed). Statistics: 2-way-ANOVA plus Bonferroni 
post-hoc comparisons: (*) = p<0.05; (**) = p<0.01; (***) = p<0.001 Vs co-culture of Teff with 
(NT)DCs. 
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Supplementary Video 1.  
Rat TMBP effs form stable contacts with MBP-presenting DCs and get activated. Time-lapse 
video-microscopy of rat GFP
+/-
 TR97-116 eff (green) in co-culture with rat R97-116-loaded DCs and 
10 μg/ml R97-116 Ag. Overlaid images of green fluorescence and differential interference 
contrast (DIC) channels. Observation time: 60 min. 30-sec intervals. Stack reproduction rate: 5 
frames/sec. Shown is a cropped detail of one representative movie from 4 independent 
recordings of co-culture condition. Magnification: 10 μm. 
 
Supplementary Video 2. 
Pre-incubation with combination of heat-inactivated LC+LR induces immune-modulatory 
phenotype on DCs leading to dampening of Teff/DC R97-116-specific stable contacts. Time-
lapse video-microscopy of rat GFP
+/-
 TR97-116 eff (green) in co-culture with rat R97-116-loaded 
DCs and 10 μg/ml R97-116 Ag. Overlaid images of green fluorescence and DIC channels. 
Observation time: 60 min. 30-sec intervals. Stack reproduction rate: 5 frames/sec. Shown is a 
cropped detail of one representative movie from 4 independent recordings of co-culture 
condition. Magnification: 10 μm. 
 
Supplementary Video 3. 
Pre-incubation with combination of heat-inactivated BB+BL induces immune-modulatory 
phenotype on DCs inhibiting Teff/DC R97-116-specific stable contacts and Teff activation. Time-
lapse video-microscopy of rat GFP
+/-
 TR97-116 eff (green) in co-culture with rat R97-116-loaded 
DCs and 10 μg/ml R97-116 Ag. Overlaid images of green fluorescence and DIC channels. 
Observation time: 60 min. 30-sec intervals. Stack reproduction rate: 5 frames/sec. Shown is a 
cropped detail of one representative movie from 4 independent recordings of co-culture 
condition. Magnification: 10 μm. 
 
Supplementary Video 4. 
Pre-incubation with TGFβ induces immune-modulatory phenotype on DCs inhibiting Teff/DC 
contacts and Teff activation. Time-lapse video-microscopy of rat GFP
+/-
 TR97-116 eff (green) in co-
culture with R97-116-loaded DCs and 10 μg/ml R97-116 Ag. Overlaid images of green 
fluorescence and DIC channels. Observation time: 60 min. 30-sec intervals. Stack reproduction 
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rate: 5 frames/sec. Shown is a cropped detail of one representative movie from 4 independent 
recordings of co-culture condition. Magnification: 10 μm. 
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Introduction 
Biogenic amines (BA), mainly tyramine, histamine, putrescine, cadaverine, are low molecular 
weight organic bases formed by the quick broken down of food proteins in the body by 
enzymes, such as MAO (monoamine oxidase-A), which render them harmless. Toxic effects of 
BA on human body can develop through both increased availability, due to high amounts of 
ingestion by foods, and/or impaired BA degradation, due to increased sensitivity of individuals. 
A pathological deficiency of amine oxidase activities as well as the excessive consumption of 
ethanol and some drugs (Zimatkin and Anichtchik, 1999; Horton et al., 2005) may lead to high 
levels of BA in the organism (Kuefner et al., 2004). Several toxicological problems related to 
high levels of BA were reported (Marinè-Font et al., 1995) such as effects derived from their 
vasoactive properties of histamine and tyramine, as well as palpitations, headaches, vomiting 
and hypertension (Silla Santos, 1996; Lonvaud-Funel, 2001). 
Apart from the reduction of BA accumulation in foods following the choice of the right starter 
culture, envisaged by EFSA in 2011, the control of BA in human body could be realized mainly 
through a reduced exogenous ingestion of BA-rich fermented foods.  Biogenic amines in effect 
occur in different kinds of food, such as cheese, wine, beer, fishery products and other 
fermented foods (Halàsz et al., 1994). The highest mean values for the sum of biogenic amines 
were retrieved in ‘fish sauce’ (582 - 588 mg/kg), fermented vegetables (375 – 390 mg/kg ), 
cheese (177 – 334 mg/kg) and fermented sausages (281 – 283 mg/kg) (EFSA opinion, 2011). The 
active growth of several bacteria and proteolysis during sausage fermentation, makes this 
environment particularly favourable to biogenic amine formation (Bover-Cid et al., 1999). 
Morevoer, the catabolism of amino acids carried by LAB and the resulting high concentration of 
BA can affect the quality of fermented foods and their organoleptic properties (Verges et al., 
1999; Palacios et al., 2005). 
In fermented foods, BA are mainly generated by decarboxylation of the corresponding amino 
acids through specific enzymes of Lactic Acid Bacteria (LAB) and, for this reason, testing amino 
acid decarboxylation activities of LAB, before using them as starter cultures for fermentation, is 
of great relevance.  
LAB are usually able to produce histamine via histidine decarboxylase (Lonvaud-Funel and 
Joyeux, 1994), tyramine via tyrosine decarboxylase (Lucas et al., 2003) and putrescine via 
ornithine decarboxylase (Marcobal et al., 2004).  
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BA are also endogenously produced in the human gut by the microbiota that degrade proteins 
and aminoacids abundantly available in this natural environment (de Palencia et al., 2011). The 
actual relevance for public health of BAs directly produced in the intestine is presently unclear 
and not proven (EFSA opinion, 2011) despite a current strong debate about the impact of high-
protein dietetic regimens on human health and the potential deleterious effects of this diet on 
gut health, with special reference to red and processed meat, and increased risk to develop 
cancer (IARC Monographs, vol. 114, October 2015). 
The production of BA has been associated with some groups of microorganisms. For instance, 
putrescine and cadaverine production is frequently found in enterobacteria, a bacterial group 
for which presence and distribution of amino acid decarboxylase activity has been largely 
studied. Very few information regarding the production of BA are available for LAB. Some 
species of lactobacilli, mainly Lactobacillus buchneri and L. curvatus, have been recognized to 
produce histamine and tyramine. No data are currently available about bifidobacteria. Within 
microbial groups, the capacity to produce BA has been recognised, however, as a strain-specific 
feature (Coton and Coton, 2009; Lucas et al., 2005; Marcobal et al., 2006). 
Different screening methods are available to detect amino acid decarboxylase activity in 
bacteria. Qualitative methods usually involve the use of a precursor amino acid and a medium 
containing a pH indicator (Moeller 1954; Choudhury et al., 1990), its color change indicates the 
production of a more alkaline BA by the cultured bacteria from the precursor amino acids. The 
limit of this method is the possibility to create false positive results, due to the formation of 
alkaline compounds other than  BA and false negatives results due to the fermentation activity 
of many bacteria that leads to the formation of acids compounds. Therefore other methods 
were developed to detect bacteria able to generate BA in the environment. In this context PCR 
has become an important method for the rapid and specific detection of the target genes. 
Marcobal et al. (2005) described a multiplex PCR based on primers targeting genes encoding 
amino acid decarboxylase of LAB as potential BA producers. 
Despite the previous observations, recent reports considered the role of LAB as BA degraders. 
In fact, LAB isolated from fermented foods have been proven to degrade BA through the 
production of amine oxidase enzymes. Garcia-Ruiz et al. (2011) tested 85 LAB strains isolated 
from wine. The greatest BA-degrading ability was exhibited by 9 strains belonging to the 
Lactobacillus and Pediococcus genera, and most of them were able to simultaneously degrade 
at least two of the three studied BA. Capozzi et al. (2012) postulated the use of two strains of L. 
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plantarum for the degradation of BA in wine based on their ability to catabolize tyramine and 
putrescine leading to more than 30% breakdown in culture media. In 2001, Fadda et al. isolated 
from meat some strains of L. casei and L. plantarum which have been proved to be able to 
degrade tyramine. 
The control of BA-producers by the antagonistic effect of BA-degraders in natural environments 
as well in the human body could be of great interest in order to control harmful bacterial 
population in the gut and to limit the overproduction of BA due to the increased ingestion of 
proteins of animal origin. This could open the way to the use of probiotic-based supplements 
with improved activity in BA degradation. 
During the study presented in the manuscript, a pool of newly isolated lactobacilli and 
bifidobacteria, previously characterized for their in-vitro probiotic properties, were screened 
taking into consideration the dualism between production and degradation that lactobacilli 
encounter with respect to BA metabolism. Firstly they were investigated for the undesired 
feature of the ability to synthesise BA (Capozzi et al., 2012; Landete et al., 2007) and then for 
the valuable ability of BA degradation through the activity of specific enzymes.   
 
Materials and methods 
 
Strains and culture conditions 
Strains of lactobacilli and bifidobacteria isolated from fecal samples or vaginal swabs were 
grown at 37°C in MRS broth (BD Difco, USA) supplemented, in the case of bifidobacteria, with L-
cysteine hydrochloride (Sigma-Aldrich, Germany) at a concentration of 0,5 g/l. Cultures were 
incubated for 24-48 hours in anaerobic conditions. Strains were cultured on plates of agar MRS 
and TOS mupirocin 100 µg/ml media for lactobacilli and bifidobacteria, respectively. Plates 
were incubated at 37°C for 48-72 hours in anaerobic conditions. The enzymatic activity of the 
enzymes involved in BA degradation was detected by growing the strains on culturing media 
supplemented with 100 µg/ml of each BA such as histamine, tyramine, etc. Cultures, incubated 
for 16 hours at 37°C in anaerobic conditions, were then centrifuged and submitted to the 
preparation described below. Table 1 lists the screened strains.  
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DNA extraction and PCR primers and procedure 
For use in Polymerase Chain Reaction (PCR) DNA from bacteria was extracted using Whatman
TM
 
FTA
TM
 CloneSaver
TM
 technology (GE Healthcare Life Sciences, UK).  
In order to identify strains able to produce one or more biogenic amines, PCR primers targeting 
amino acid decarboxylase genes were used as described by Coton et al. (2010). Primer 
sequences and their targets are listed in Table 2. 
L. reuteri DSM 20016
T
 was included as positive control for histamine production. PCR was 
conducted in a final volume of 50 µl. Amplification reaction mixture contained 50 ng of 
bacterial DNA, one of the available pairs of primers depending on the gene to be amplified 
(0,12 µM of HDC3/HDC4 for histidine decarboxylase, 0,2 µM of TD2/TD5 for tyrosine 
decarboxylase, 0,8 µM of ODC1/ODC2 for ornithine decarboxylase or 0,8 µM of AgD1/AgD2 for 
agmatine deaminase) and MegaMix (Microzone, UK). 
The reactions were performed in an automated SimpliAmp thermal cycler (Life Technologies, 
USA) using the following cycling parameters: 95°C for 5 minutes followed by 35 cycles of 95°C 
1min, 52°C 1 min, 72°C 1min 30 s with a final extension step of 5 min at 72°C (Coton et al., 
2010). Amplified products were resolved on a 0,8% (wt/vol) agarose gel (Segenetic, Germany) 
and stained with ethidium bromide. The amplicon expected for the reference strain L. reuteri 
DSM 20016
T
 was about 400 bp fragment of hdc gene. 
 
Protein extraction from probiotic cells 
The ability to degrade BA by oxidation of the same was tested according to the method of 
Callejòn et al., 2014 with some modifications. Strains were grown overnight in 50 ml of medium 
supplemented with BA as described in Strains and culture conditions. The cultures grown were 
centrifuged to recover the bacterial pellet and washed twice with 25 ml of phosphate buffer 50 
mM pH 7.4. The pellet was resuspended in 0.5 ml of the same buffer that was previously added 
with 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich, Germany) and transferred 
into eppendorf tubes of 1.5 ml containing glass beads with a diameter of 100 µm. Cells were 
disrupted in FastPrep-24 (MP, USA) by 4 cycles of 45 seconds each, alternated to incubation in 
ice for 5-10 minutes between one cycle and the other. Cell extracts were centrifuged at 13000 
rpm for 15 min to precipitate the pellet and the supernatant was recovered and kept at -20°C 
until use. 
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Quantification of the extracted proteins 
Extracted proteins were quantified using Pierce BCA Protein Assay Kit (Thermo SCIENTIFIC, USA) 
following the instruction of the supplier. A set of serial dilutions of BSA (internal control) and 
the BCA Working Reagent were prepared and use to design a standard line. Test samples 
incubated at 37°C for 30 minutes were submitted to spectrophotometric lecture at O.D. 562 nm 
in order to measure the absorbance. A standard curve was designed by plotting O.D. 
measurement for each BSA standard vs its known concentration in µg/ml. Final protein 
concentration of the tested samples was indirectly calculated based on their O.D. value by using 
the standard curve as reference. 
 
Enzymatic assay for diamine oxidase 
20 µl of each protein extract was mixed with 10 µl of loading buffer (10% glycerol, 50 mM Tris-
HCl pH 6,8, bromophenol blue 0,02%). 20 µl of this mix was loaded on a stacking 4% 
polyacrylamide gel and separated in a 8% polyacrylamide gel using an electrophoretic buffer 
consisting of Tris-glycine (25 mM Tris base, 192 mM glycine), as proposed by Callejòn et al. 
(2014). The purified enzyme Laccase from Trametes Versicolor (Sigma-Aldrich, Germany) was 
used as positive control in the gel. At the end of the electrophoretic run the gel was placed in 
sodium phosphate buffer (50mM, pH 7,4) containing 1 mM of each biogenic amine, for 15 min. 
The solution was then removed and replaced by a new solution consisting of the same buffer 
containing horseradish peroxidase (1000 U/l) and diaminobenzidine 0,25 mM (DAB). The ability 
to degrade BA was revealed by the appearance of a brown color, due to the formation of a 
precipitate as a result of DAB oxidation, on the reference band after 1-2 hours of staining.  
 
Results 
 
BA synthesis by novel probiotic lactobacilli 
The PCR approach proposed by Coton et al. (2010) was applied to the detection of the genes 
coding for amine decarboxylase like tyrosine decarboxylase (tyrdc) for tyramine, ornithine 
decarboxylase or agmatine deaminase (odc and agdi) for putrescine and histidine 
decarboxylase (hdc) for histamine. Almost all the isolated strains were negative for the 
detection of the 4 genes. Only L. vaginalis CBA-L88 showed two amplicons of about 400 bp and 
 123 
600 bp, indicating that this strain putatively possess the genes for the production of histamine 
via histidine decarboxylase (hdc+) and putrescine via agmatine deaminase (agdi+).  
Figures 1 and 2 present the images of the electrophoretic gels carrying the amplicons obtained 
for the control and the tested strains. This strain was therefore excluded from the subsequent 
screening phase since it appears not suitable for safety reasons to be used as probiotic in viable 
form. Sanders et al. (2010) observed that the addition of probiotic organisms to foods should 
take biogenic amine producing capacity into account if opportunity for production and 
substrate availability are conducive to such activity. 
 
BA degradation by novel probiotic lactobacilli 
Proteins extracted from the viable cells of the tested strains were quantified and normalised to 
a final concentration of about 10 mg/ml. These extracts were used in diaminobenzidine (DAB) 
assay in the presence of a mixture of histamine, tyramine and putrescine. Strains positive to the 
detection of the amino oxidase, as well as the control enzyme from Trametes versicolor, 
showed a brown precipitate indicating the link of the chromogen to the substrate. Results 
shown in Figure 3 indicate that one strain L. rhamnosus CBA-L140 possess the enzyme for the 
degradation of BA while for all the other tested strains showed negative reactions. Another L. 
rhamnosus strain, CBA-L140, showed a positive reaction but different in size if compared to 
positive control since it putatively carries a different enzyme responsible for the degradation of 
BA.  
 
Conclusions 
The production of BA represents an issue of great interest due to their detrimental impact on 
human health, proportional to their gut concentration. The problem of the accumulation of BA 
mainly concerns fermented products and food with high protein content because different gut 
bacteria are able to synthesize BA via decarboxylation of the amino acids. Moreover the lack of 
information about the ability of the strains to synthesize BA leads to neglect this issue and to 
the use of BA-forming strains as starter in food fermentation. The investigation of the ability of 
bacterial strains to synthesize BA leads to increased knowledge of the same and so to a more 
conscious use in food preparations. It is necessary to confirm the inability of the strain to 
synthesize BA before considering it as safe and therefore suitable to be used as a starter culture 
as well as a probiotic for which the presence of genes coding for amine decarboxylase is 
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considered a safety concern. PCR method to detect genes involved in the synthesis of the BA 
represents a rapid and specific tool for the selection of strains with decarboxylase activity, 
other than the conventional approach based on metabolic tests on supernatants of bacteria 
cultured on BA.  
On the other hand, the potential for BA breakdown should be considered an important feature 
among starter and probiotic strains, since some LAB show oxidase activities. This aspect should 
represent an additional criterion in the selection of strains for food fermentation and/or food 
supplements. The identification of one or more Lactobacillus and/or Bifidobacterium strain able 
to degrade BA in-vitro as well as its subsequent genetic and functional characterization could 
open the way to the use of a probiotic strain as food supplement in hypocaloric, high protein 
feeding regimens.  
 
Legends 
Table 1: bacterial strains used in the present work. 
Table 2: primers used in the PCR targeting BA-production genes. hdc, histidine decarboxylase; 
tyrdc, tyrosine decarboxylase; odc, ornithine decarboxylase; agdi, agmatine deaminase. 
 
Figure 1: PCR with primers HDC3/HDC4 to detect the hdc gene. A 200 bp marker (Invitrogen, 
USA) was included (lane 1).  
 
Figure 2: PCR with primers AgD1/AgD2 to detect the agdi gene. A 200 bp marker was included 
(lane 1).  
 
Figure 3: amino degradative activity showed by LAB extracts as a result of electrophoresis on 
polyacrylamide gel and staining with DAB.  
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Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bacterial strains screened for BA production Bacterial strains screened for BA degradation 
L. rhamnosus CBA-L142 L. rhamnosus CBA-L92 
L.  rhamnosus CBA-L140 L. rhamnosus CBA-L143 
L.  rhamnosus CBA-L143 L.  fermentum CBA-L147 
L. vaginalis CBA-L88 L. rhamnosus CBA-L142 
B. breve CBA-B104 L. fermentum CBA-L146 
B. breve CBA-B171 L. gasseri CBA-L72 
L. reuteri commercial strain L. rhamnosus CBA-L140 
L. reuteri DSM 17938 L. paracasei CBA-L144 
L. reuteri DSM 20016  L. acidophilus CBA-L63 
 L. paracasei CBA-L101 
 L. paracasei CBA-L145 
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Table 2 
Target gene Primer Sequence Product (bp) Reference 
hdc HDC3 GATGGTATTGTTTCKTATGA 435 Coton et al., 2010 
hdc HDC4 CCAAACACCAGCATCTTC 435 Coton et al., 2010 
tyrdc TD2 ACATAGTCAACCATRTTGAA 1133 Coton et al., 2010 
tyrdc TD5 CAAATGGAAGAAGAAGTAGG 1133 Coton et al., 2010 
odc ODC1 NCAYAARCAACAAGYNGG 900 Coton et al., 2010 
odc ODC2 GRTANGGNTNNGCACCTTC 900 Coton et al., 2010 
agdi AgD1 CAYGTNGAYGGHSAAGG 600 Coton et al., 2010 
agdi AgD2 TGTTGNGTRATRCAGTGAAT 600 Coton et al., 2010 
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Figure 1 
1   2   3    4   5   6   7   8  9  10 
 
 
1. Molecular marker weight 200 bp (Invitrogen, USA) 
2. L. rhamnosus CBA-L142  
3. L. rhamnosus CBA-L140  
4. L. rhamnosus CBA-L143 
5. L. vaginalis CBA-L88 
6. B. breve CBA-B104  
7. B. breve CBA-B171  
8. L. reuteri commercial strain 
9. L. reuteri DSM 17938  
10. L. reuteri DSM 20016  
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Figure 2 
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1. Molecular marker weight 200 bp 
2. L. rhamnosus CBA-L142  
3. L. rhamnosus CBA-L140  
4. L. rhamnosus CBA-L143 
5. L. vaginalis CBA-L88  
6. B. breve CBA-B104 
7. B. breve CBA-B171  
8. L. reuteri commercial strain 
9. L. reuteri DSM 17938  
10. L. reuteri DSM 20016  
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Figure 3 
 
 
       C.   Positive control: Laccase from Trametes versicolor 
1. L. paracasei CBA-L144 
2. L. acidophilus CBA-L63 
3. L. paracasei CBA-L145 
4. L. rhamnosus CBA L-140 
5. L. rhamnosus CBA L-142 
6. L. paracasei CBA-L101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   C                 1       2      3      4       5       6 
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Chapter 7: Summary and concluding 
remarks 
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Nowadays, the market of food supplements is particularly rich and varied. In recent years, the 
spread of probiotics containing Lactobacillus or Bifidobacterium mostly in association with 
other bacteria, is considerably increased. 
The demand for health by the population has undergone a sharp increase in recent years in 
both quantitative and qualitative terms, consumers are becoming in fact more knowledgeable 
and attentive to the issues of health and prevention. 
An increasing number of functional foods are enriched with probiotics and for consumers is 
becoming increasingly important to get the information necessary to know how to make the 
best choices. 
For these reasons it is necessary an intensive research in order to respond to the needs of the 
individuals in term of health and prevention. 
 
During my PhD thesis I was in charge for the screening of new potential probiotic strains by 
combining conventional approach to newly designed platforms especially targeted towards 
health-promoting applications. I initially focused on the so-called "conventional screening” 
aimed to the isolation of new bacterial strains of lactobacilli and bifidobacteria and to assess 
the safety of the same for use in human food (second signs of national and international 
regulatory bodies). This first part of the work, in addition to safety, was aimed to assess the 
efficacy of the bacterial strains: for use in humans is in fact important that the strains are able 
to survive in the acidic environment of the stomach and able to survive and multiply in the 
intestine even in the presence of bile salts. 
Bacterial strains found to possess these features were then subjected to a more specific 
screening, depending on the application to which they will be destined. They will therefore be 
intended to a process of "selection funnel" aimed at the realization of a series of in vitro tests to 
assess their applicability as probiotics for the promotion of human health. 
About that, it is important to emphasize that while some effects of probiotics, such as their 
ability to reduce intestinal disorders, are well documented; for other conditions are not 
available strong evidences that demonstrate the efficacy of the same. Moreover, the effects are 
“strain-specific” and must not be extended to other probiotics of the same genus or species. 
I'm so focused on new areas of application, and I assessed the applicability of the selected 
strains in food or pharmaceutical field. 
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A first activity of functional characterization of new probiotic strains was carried out in 
collaboration with the Department of Food Science of the University of Udine and was aimed to 
evaluate the potential use of new strains in the food supplementation of patients that follow a 
high-protein diets to reduce the risk of intestinal accumulation of biogenic amines (metabolic 
application). This activity has allowed me to identify a strain of Lactobacillus able to synthesize 
biogenic amines and one strain with alleged amino degradative activity that must be confirmed 
soon. I would like in fact to continue the characterization of this best suitable candidate as BA 
degraders, by quantifying BA in culture medium incubated with and without the strain, via high-
performance liquid chromatography (HPLC)-based methods or alternative developed methods 
and therefore ranking the degradative activity expressed by this selected strain. 
Another screening activity is derived from the collaboration between AAT Srl and the 
Neurological Institute "Carlo Besta", which had as its main objective the study of the 
immunoregulatory effects of new strains of lactobacilli and bifidobacteria. Individual strains or 
combinations of probiotics were evaluated and are resulted good promising candidates for the 
treatment of inflammatory and autoimmune diseases. Among these were taken into account 
the myasthenia gravis and multiple sclerosis, diseases of great interest because of their highly 
debilitating impact on daily life. 
The treatment of dendritic cells with different combinations of probiotics led to a strong 
immune modulation and oral administration showed therapeutic properties, thereby improving 
the clinical symptoms in both models used for the study of the two diseases. 
In particular, we focused on two newly identified strains: L. crispatus LMG P-9437 and B. breve 
LMG S-28195 and we studied the effect of specific combinations of these two strains with other 
probiotic strains already available on the market, in order to improve their immunomodulatory 
action. In the case of myasthenia gravis, we obtained a significant improvement of the 
symptoms of the disease when given the combination of bifidobacteria while treatment with 
the lactobacilli was not equally efficient. In the second model of autoimmune disease used we 
have not observed statistically significant differences between lactobacilli and bifidobacteria, 
the clinical manifestations are in fact significantly improved both in the case of administration 
of the lactobacilli which in the case of administration of the strains of bifidobacteria, although 
this second treatment proved slightly more efficient. These data could be a promising new 
therapeutic approach for the treatment of autoimmune diseases, the future development will 
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be in fact the translation of these experiments in the in vivo context, by testing strains in 
patients with these diseases. 
Finally, strains were screened also for a food application. The activity was carried out in 
collaboration with the Institute of Geology and Agro-Food Engineering of the Catholic 
University of Piacenza and it had the aim of investigate the possibility of producing spray-dried 
probiotic formulations to be used together with commercial ice-cream bases. A commercial 
cream base was selected for the study and, according to its composition and literature, two 
different formulations were investigated (one with maltodextrins, widely used in the food 
industry and spray-drying processes and one with inulin, a prebiotic fibre with both beneficial 
effects for humans and probiotics preservation) and used for encapsulation the strain L. 
paracasei LMG S-27487. The results show that the maltodextrins formulation could not be used 
for probiotics encapsulation (null process yield), while inulin formulation gave a lower yield (51 
%). A 82 % death cell occurred during drying, but the cells survived in the ice-cream making 
process. So, these results represent an important starting point for the development of 
encapsulated multiple bioactive ingredients containing probiotics or other functional 
compounds. 
Summarizing, in this study I showed that the adoption of logical criteria for the in vitro selection 
of probiotic bacteria can result in the isolation of strains able to exert different effects mainly 
on human health. However, as reported in the recent literature, it appears unlikely that a single 
probiotic bacteria strain is able to exert the most different functions but, on the contrary, it is 
more likely that these effects are strain specific as observed in my study. 
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Supplementary material 
Table 1 shows, for each bacterial strain, the values of the count (expressed in CFU/ml) obtained 
in the presence of pepsin in the culture medium, respectively, after 0, 1, 90, 180 minutes of 
incubation of the strains at 37 ° C in anaerobic conditions. 
  T0 T1 T90 T180 
L. paracasei LMG S-27487 2,4 X 10^9 4,8 X 10^8 3 X 10^5 < 1 X 10^3 
L. paracasei CBA-L101 3,4 X 10^9 1,0 X 10^9 < 1 X 10^5 < 1 X 10^3 
L. paracasei CBA-L145 6,8 X 10^9 1,2 X 10^9 < 1 X 10^5 < 1 X 10^3 
L. paracasei CBA-L144 1,9 X 10^10 3,0 X 10^9 4,8 X 10^5 2 X 10^2 
L. plantarum CBA L137 2,2 X 10^9 4,7 X 10^8 < 1 X 10^5 < 1 X 10^3 
L. plantarum CBA-L138 1,6 X 10^8 1,5 X 10^7 < 1 X 10^5 < 1 X 10^3 
L. plantarum CBA-L150 7,6 X 10^9 2,2 X 10^9 1,4 X 10^4 2 X 10^2 
L. rhamnosus CBA-L92 2,9 X 10^9 1,1 X 10^9 6 X 10^5 < 1 X 10^3 
L. rhamnosus CBA-L142 5 X 10^9 1,1 X 10^9 1 X 10^5 3 X 10^3 
L. rhamnosus CBA-L140 5,3 X 10^9 1,5 X 10^9 6 X 10^5 < 1 X 10^3 
L. rhamnosus CBA-L143 1,1 X 10^10 3,3 X 10^9 1,9 X 10^7 7 X 10^5 
L. acidophilus CBA-L63 1,2 X 10^9 2,9 X 10^8 4 X 10^5 3,7 X 10^4 
L. rhamnosus GG 7,3 X 10^9 1,3 X 10^9 2 X 10^5 < 1 X 10^3 
L. gasseri CBA-L72 4,1 X 10^9 9,8 X 10^8 8,6 X 10^7 2,3 X 10^4 
L. fermentum CBA-L146 5,4 X 10^9 2 X 10^9 9 X 10^6 2 X 10^3 
L. fermentum CBA-L147 4 X 10^9 4,4 X 10^8 3 X 10^3 < 1 X 10^2 
L. mucosae CBA-L148 1,6 X 10^9 4,1 X 10^8 8 X 10^3 < 1 X 10^2 
L. mucosae CBA-L149 3,7 X 10^9 8,2 X 10^8 9,1 X 10^3 < 1 X 10^2 
L. vaginalis CBA-L88 3,6 X 10^9 8,9 X 10^8 1,3 X 10^5 2,0 X 10^4 
 
Table 1: ability of the bacterial strains to grow in the presence of pepsin in the culture medium 
The results show how the CFU/ml after only one minute of contact of the bacterial culture with 
the solution of pepsin are, at worst, less of a decimal logarithm compared to those obtained at 
time zero; the bacterial vitality was also reduced drastically after 90 minutes and then 
decreased again until reaching a value in the order of 10^2 - 10^3 CFU/ml after 180 minutes. 
Only the strains L. rhamnosus CBA-L143, L. acidophilus CBA-L63, L. gasseri CBA-L72 and L. 
vaginalis CBA-L88 after being exposed for 180 minutes with the pepsin solution still have a 
bacterial vitality in the order of 10^4 - 10^5 CFU/ml. 
This assay despite the fact that it is easy to perform and cheap, it presents some defects 
because it does not reflect the ideal conditions such as the residence time in the 
gastrointestinal tract of the bacterial strains which varies depending on the subject. Just 
because these in-vitro tests as described by Papadimitriou et al., 2015 expose the bacterial 
strain to too strong stress conditions that do not represent what happens in the gastrointestinal 
tract during food consumption, I re tested some bacterial strains with another method 
proposed by Corcoran et al., 2005 that used less restrictive conditions in fact it expected a 
pepsin concentration decrease and a reduction of the contact time of the strains with it. Using 
the latter method, I could prove an increase in the percentage of bifidobacteria and lactobacilli 
able to survive. 
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